window.__IS_SSR__=true
window.__INITIAL_STATE__={
"attachmentsReducer": {
"audio_0": {
"type": "attachments",
"id": "audio_0",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background0.jpg"
}
}
},
"audio_1": {
"type": "attachments",
"id": "audio_1",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background1.jpg"
}
}
},
"audio_2": {
"type": "attachments",
"id": "audio_2",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background2.jpg"
}
}
},
"audio_3": {
"type": "attachments",
"id": "audio_3",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background3.jpg"
}
}
},
"audio_4": {
"type": "attachments",
"id": "audio_4",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background4.jpg"
}
}
},
"placeholder": {
"type": "attachments",
"id": "placeholder",
"imgSizes": {
"thumbnail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-160x107.jpg",
"width": 160,
"height": 107,
"mimeType": "image/jpeg"
},
"medium": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-800x533.jpg",
"width": 800,
"height": 533,
"mimeType": "image/jpeg"
},
"medium_large": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-768x512.jpg",
"width": 768,
"height": 512,
"mimeType": "image/jpeg"
},
"large": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"1536x1536": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1536x1024.jpg",
"width": 1536,
"height": 1024,
"mimeType": "image/jpeg"
},
"fd-lrg": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1536x1024.jpg",
"width": 1536,
"height": 1024,
"mimeType": "image/jpeg"
},
"fd-med": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"fd-sm": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-800x533.jpg",
"width": 800,
"height": 533,
"mimeType": "image/jpeg"
},
"post-thumbnail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"twentyfourteen-full-width": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1038x576.jpg",
"width": 1038,
"height": 576,
"mimeType": "image/jpeg"
},
"xxsmall": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-160x107.jpg",
"width": 160,
"height": 107,
"mimeType": "image/jpeg"
},
"xsmall": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"small": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"xlarge": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"full-width": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1920x1280.jpg",
"width": 1920,
"height": 1280,
"mimeType": "image/jpeg"
},
"guest-author-32": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 32,
"height": 32,
"mimeType": "image/jpeg"
},
"guest-author-50": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 50,
"height": 50,
"mimeType": "image/jpeg"
},
"guest-author-64": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 64,
"height": 64,
"mimeType": "image/jpeg"
},
"guest-author-96": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 96,
"height": 96,
"mimeType": "image/jpeg"
},
"guest-author-128": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 128,
"height": 128,
"mimeType": "image/jpeg"
},
"detail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 160,
"height": 160,
"mimeType": "image/jpeg"
},
"kqedFullSize": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1.jpg",
"width": 2000,
"height": 1333
}
}
},
"futureofyou_103649": {
"type": "attachments",
"id": "futureofyou_103649",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "103649",
"found": true
},
"parent": 103581,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-400x266.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 266
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-960x638.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 638
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-e1453851409558.jpg",
"width": 1920,
"height": 1275
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1180x784.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 784
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-800x531.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 531
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1920x1275.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1275
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1180x784.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 784
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-768x510.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 510
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1453851359,
"modified": 1453851403,
"caption": "Theranos founder and CEO Elizabeth Holmes at the Fortune Global Forum, November 2015.",
"description": null,
"title": "Theranos",
"credit": " Stuart Isett/Fortune Global Forum",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_58611": {
"type": "attachments",
"id": "futureofyou_58611",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "58611",
"found": true
},
"parent": 0,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-400x146.png",
"width": 400,
"mimeType": "image/png",
"height": 146
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915.png",
"width": 598,
"height": 218
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-96x96.png",
"width": 96,
"mimeType": "image/png",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-64x64.png",
"width": 64,
"mimeType": "image/png",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-75x75.png",
"width": 75,
"mimeType": "image/png",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-32x32.png",
"width": 32,
"mimeType": "image/png",
"height": 32
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-128x128.png",
"width": 128,
"mimeType": "image/png",
"height": 128
}
},
"publishDate": 1445975846,
"modified": 1454610976,
"caption": "Theranos and its finger-prick blood-testing technology has come under siege from a Wall Street Journal investigation.",
"description": "Silicon Valley-based Theranos says it can diagnose a variety of diseases with a finger stick that takes just a few drops of blood — as opposed to a blood draw.",
"title": "theranos",
"credit": "Theranos",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_104009": {
"type": "attachments",
"id": "futureofyou_104009",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "104009",
"found": true
},
"parent": 103654,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband-400x268.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 268
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband.jpg",
"width": 750,
"height": 502
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Sweat-Sensor-Wristband-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1453916336,
"modified": 1453916440,
"caption": "A sweat sensor wristband that researchers say can continuously track changes in the chemical composition of sweat.",
"description": null,
"title": "Sweat Sensor-Wristband",
"credit": "UC Berkeley",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_103139": {
"type": "attachments",
"id": "futureofyou_103139",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "103139",
"found": true
},
"parent": 0,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-937x576.jpg",
"width": 937,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-400x233.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 233
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411.jpg",
"width": 936,
"height": 545
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-800x466.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 466
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-768x447.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 447
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/pacemaker-e1453767784411-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1453766638,
"modified": 1453768173,
"caption": "Pacemakers with a wireless function transmit patient data to physicians via the Internet, and that connection isn't always secure.\n",
"description": null,
"title": "pacemaker",
"credit": "University of Rochester Medical Center",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_100997": {
"type": "attachments",
"id": "futureofyou_100997",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "100997",
"found": true
},
"parent": 100995,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-1024x576.jpeg",
"width": 1024,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-400x225.jpeg",
"width": 400,
"mimeType": "image/jpeg",
"height": 225
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-960x540.jpeg",
"width": 960,
"mimeType": "image/jpeg",
"height": 540
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-672x372.jpeg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot.jpeg",
"width": 1024,
"height": 576
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-96x96.jpeg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-800x450.jpeg",
"width": 800,
"mimeType": "image/jpeg",
"height": 450
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-64x64.jpeg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-75x75.jpeg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-32x32.jpeg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-768x432.jpeg",
"width": 768,
"mimeType": "image/jpeg",
"height": 432
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2017/01/Steve-Berkowitz-Headshot-128x128.jpeg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1453409059,
"modified": 1453409109,
"caption": "Lumos Labs CEO Steve Berkowitz, at the helm since November.",
"description": null,
"title": "Steve Berkowitz Headshot",
"credit": "Lumos Labs",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_100173": {
"type": "attachments",
"id": "futureofyou_100173",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "100173",
"found": true
},
"parent": 100084,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-400x372.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 372
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-960x894.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 894
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366.jpg",
"width": 2786,
"height": 2594
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-1180x1099.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 1099
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-644x600.jpg",
"width": 644,
"mimeType": "image/jpeg",
"height": 600
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-1920x1788.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1788
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-1180x1099.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 1099
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-768x715.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 715
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/s69-39961-e1453252783366-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1453252722,
"modified": 1453252817,
"caption": "The launch of Apollo 11, which brought astronauts to the surface of the moon",
"description": "The launch of Apollo 11, which brought astronauts to the surface of the moon",
"title": "Apollo 11",
"credit": "NASA",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_93427": {
"type": "attachments",
"id": "futureofyou_93427",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "93427",
"found": true
},
"parent": 93348,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-400x300.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 300
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-960x720.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 720
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large.jpg",
"width": 2560,
"height": 1920
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-1180x885.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 885
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-800x600.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 600
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-1920x1440.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1440
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-1180x885.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 885
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-768x576.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 576
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/iStock_000060595932_Large-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1452038812,
"modified": 1452038833,
"caption": null,
"description": null,
"title": "futuristic human brain",
"credit": "iStock",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_97441": {
"type": "attachments",
"id": "futureofyou_97441",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "97441",
"found": true
},
"parent": 94302,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image-400x190.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 190
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image-672x332.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 332
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image.jpg",
"width": 700,
"height": 332
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Patent-filing-image-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1452751519,
"modified": 1452790455,
"caption": "Though the Broad Institute and the University of California Berkeley both filed patents for CRISPR-Cas9, the Broad's expedited application was approved while Berkeley's was still pending.",
"description": null,
"title": "Patent filing image",
"credit": "Liebrecht Fick",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_96633": {
"type": "attachments",
"id": "futureofyou_96633",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "96633",
"found": true
},
"parent": 94836,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-400x224.png",
"width": 400,
"mimeType": "image/png",
"height": 224
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-672x372.png",
"width": 672,
"mimeType": "image/png",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit.png",
"width": 821,
"height": 460
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-96x96.png",
"width": 96,
"mimeType": "image/png",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-800x448.png",
"width": 800,
"mimeType": "image/png",
"height": 448
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-64x64.png",
"width": 64,
"mimeType": "image/png",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-75x75.png",
"width": 75,
"mimeType": "image/png",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-32x32.png",
"width": 32,
"mimeType": "image/png",
"height": 32
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-768x430.png",
"width": 768,
"mimeType": "image/png",
"height": 430
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/fitbit-128x128.png",
"width": 128,
"mimeType": "image/png",
"height": 128
}
},
"publishDate": 1452620434,
"modified": 1452620441,
"caption": null,
"description": null,
"title": "fitbit",
"credit": "Fitbit",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_66445": {
"type": "attachments",
"id": "futureofyou_66445",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "66445",
"found": true
},
"parent": 64080,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-400x162.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 162
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-960x389.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 389
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited.jpg",
"width": 1812,
"height": 735
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-1180x479.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 479
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-800x325.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 325
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-1180x479.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 479
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/11/HIV_large_edited-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1447371867,
"modified": 1447372947,
"caption": "HIV, shown in yellow, infecting a human T cell.",
"description": null,
"title": "HIV_large_edited",
"credit": "Seth Pincus, Elizabeth Fischer and Austin Athman/NIH",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
}
},
"audioPlayerReducer": {
"postId": "stream_live",
"isPaused": true,
"isPlaying": false,
"pfsActive": false,
"pledgeModalIsOpen": true,
"playerDrawerIsOpen": false,
"liveAudioPlayStartedAt": 0,
"liveAudioPlayContext": ""
},
"authorsReducer": {
"jbrooks": {
"type": "authors",
"id": "80",
"meta": {
"index": "authors_1716337520",
"id": "80",
"found": true
},
"name": "Jon Brooks",
"firstName": "Jon",
"lastName": "Brooks",
"slug": "jbrooks",
"email": "jbrooks@kqed.org",
"display_author_email": true,
"staff_mastheads": [
"science"
],
"title": "Digital Editor",
"bio": "Jon Brooks is a former Digital Editor for KQED Science. He is the former editor of KQED’s daily news blog, News Fix. In 2014, he won a California Journalism Award for his coverage of ride services like Uber and Lyft and the taxi industry. A veteran blogger, he previously worked for Yahoo! in various news writing and editing roles. Jon is also a playwright whose work has been produced in San Francisco, New York, Italy, and around the U.S. He has written about film for his own blog and studied film at Boston University.",
"avatar": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g",
"twitter": "jbrooksfoy",
"facebook": null,
"instagram": null,
"linkedin": null,
"sites": [
{
"site": "arts",
"roles": [
"Contributor",
"editor"
]
},
{
"site": "news",
"roles": [
"author"
]
},
{
"site": "futureofyou",
"roles": [
"administrator"
]
},
{
"site": "mindshift",
"roles": [
"editor"
]
},
{
"site": "stateofhealth",
"roles": [
"editor"
]
},
{
"site": "science",
"roles": [
"administrator"
]
},
{
"site": "quest",
"roles": [
"editor"
]
}
],
"headData": {
"title": "Jon Brooks | KQED",
"description": "Digital Editor",
"ogImgSrc": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g",
"twImgSrc": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g"
},
"isLoading": false,
"link": "/author/jbrooks"
},
"katsnow": {
"type": "authors",
"id": "235",
"meta": {
"index": "authors_1716337520",
"id": "235",
"found": true
},
"name": "Katrin Snow",
"firstName": "Katrin",
"lastName": "Snow",
"slug": "katsnow",
"email": "ksnow@kqed.org",
"display_author_email": true,
"staff_mastheads": [
"science"
],
"title": "Senior Editor",
"bio": "Kat started in radio in 1985 at KMUN in Astoria, Oregon, where the Columbia River meets the sea. She worked several years protecting monarch butterfly habitat in California with the Xerces Society, an invertebrate conservation organization, before a love for radio news drew her back into journalism. Kat came to KQED in 2002, and before that was a reporter and news director at KUER in Salt Lake City, covering the state legislature, the environment and health. Kat coaches reporters and others in embodied narration and public speaking. She is a certified teacher of Soul Motion®, a conscious dance practice, and can sometimes be found in the Mojave desert or the Eastern Sierra.",
"avatar": "https://secure.gravatar.com/avatar/fa6bf8a74a2692973a5484e64ebd2b52?s=600&d=blank&r=g",
"twitter": "cosmologicalkat",
"facebook": null,
"instagram": null,
"linkedin": null,
"sites": [
{
"site": "arts",
"roles": [
"contributor"
]
},
{
"site": "news",
"roles": [
"editor"
]
},
{
"site": "futureofyou",
"roles": [
"editor"
]
},
{
"site": "science",
"roles": [
"editor"
]
}
],
"headData": {
"title": "Katrin Snow | KQED",
"description": "Senior Editor",
"ogImgSrc": "https://secure.gravatar.com/avatar/fa6bf8a74a2692973a5484e64ebd2b52?s=600&d=blank&r=g",
"twImgSrc": "https://secure.gravatar.com/avatar/fa6bf8a74a2692973a5484e64ebd2b52?s=600&d=blank&r=g"
},
"isLoading": false,
"link": "/author/katsnow"
},
"lindseyhoshaw": {
"type": "authors",
"id": "5432",
"meta": {
"index": "authors_1716337520",
"id": "5432",
"found": true
},
"name": "Lindsey Hoshaw",
"firstName": "Lindsey",
"lastName": "Hoshaw",
"slug": "lindseyhoshaw",
"email": "lhoshaw@kqed.org",
"display_author_email": false,
"staff_mastheads": [],
"title": "KQED Contributor",
"bio": "Lindsey Hoshaw is a former interactive producer for KQED Science. Before joining KQED, Lindsey was a science correspondent for The New York Times, The Boston Globe, Forbes and Scientific American. On Twitter @lindseyhoshaw",
"avatar": "https://secure.gravatar.com/avatar/274b07694c998eaa8f26cfabaa941186?s=600&d=mm&r=g",
"twitter": "lindseyhoshaw",
"facebook": "lindsey.hoshaw.9",
"instagram": null,
"linkedin": null,
"sites": [
{
"site": "arts",
"roles": [
"author"
]
},
{
"site": "news",
"roles": [
"subscriber"
]
},
{
"site": "futureofyou",
"roles": [
"editor"
]
},
{
"site": "bayareabites",
"roles": [
"contributor"
]
},
{
"site": "stateofhealth",
"roles": [
"author"
]
},
{
"site": "science",
"roles": [
"edit_theme_options",
"subscriber"
]
},
{
"site": "quest",
"roles": [
"edit_post_subscriptions",
"edit_usergroups",
"unfiltered_html",
"unfiltered_upload",
"leadcoordinator",
"editor"
]
},
{
"site": "food",
"roles": []
}
],
"headData": {
"title": "Lindsey Hoshaw | KQED",
"description": "KQED Contributor",
"ogImgSrc": "https://secure.gravatar.com/avatar/274b07694c998eaa8f26cfabaa941186?s=600&d=mm&r=g",
"twImgSrc": "https://secure.gravatar.com/avatar/274b07694c998eaa8f26cfabaa941186?s=600&d=mm&r=g"
},
"isLoading": false,
"link": "/author/lindseyhoshaw"
}
},
"pagesReducer": {
"futureofyou_category_kqed-news": {
"type": "terms",
"id": "futureofyou_73",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "73",
"score": 12.672578
},
"featImg": null,
"name": "KQED News",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "KQED News Archives | KQED Arts",
"ogDescription": null
},
"ttid": 73,
"slug": "kqed-news",
"isLoading": false,
"title": "KQED News",
"pageMeta": {
"site": "futureofyou",
"WpPageTemplate": "page-topic-editorial",
"currentPage": 38
},
"blocks": [
{
"blockName": "kqed/post-list",
"attrs": {
"layout": "cardArticle2",
"query": "posts/futureofyou?category=kqed-news",
"seeMore": false,
"paginated": true,
"page": 38
}
},
{
"blockName": "kqed/ad"
}
]
}
},
"pfsSessionReducer": {},
"postsReducer": {
"stream_live": {
"type": "live",
"id": "stream_live",
"audioUrl": "https://hls.kqed.org/hls/kqed_app/playlist.m3u8",
"title": "Live Stream",
"excerpt": "Live Stream information currently unavailable.",
"link": "/radio",
"featImg": "",
"label": {
"name": "KQED Live",
"link": "/"
}
},
"stream_kqedNewscast": {
"type": "posts",
"id": "stream_kqedNewscast",
"audioUrl": "https://www.kqed.org/.stream/anon/radio/RDnews/newscast.mp3?_=1",
"title": "KQED Newscast",
"featImg": "",
"label": {
"name": "88.5 FM",
"link": "/"
}
},
"futureofyou_104578": {
"type": "posts",
"id": "futureofyou_104578",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "104578",
"score": null,
"sort": [
1454054348000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1454054348,
"format": "standard",
"disqusTitle": "Yet Another Partner Pulls Back From Theranos",
"title": "Yet Another Partner Pulls Back From Theranos",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>\u003cstrong>Update Friday, Jan. 29\u003c/strong>: On Thursday, health insurer Capital BlueCross said beleaguered blood-testing company Theranos would stop drawing blood at the insurer's retail store in Enola, Pa., according to \u003ca href=\"http://www.wsj.com/articles/theranos-stops-drawing-blood-from-patients-at-capital-bluecross-pennsylvania-store-1454093470\" target=\"_blank\">The Wall Street Journal\u003c/a> and \u003ca href=\"http://www.pennlive.com/news/2016/01/capital_blue_steps_back_from_e.html\" target=\"_blank\">local reports\u003c/a>.\u003c/p>\n\u003cp>That move came on the same day that Walgreens suspended Theranos services at its Palo Alto, Calif., store and told Theranos to stop sending blood samples taken at any Walgreens to Theranos' Newark lab for testing. That lab was found to be deficient in a way that put patients in \"immediate jeopardy,\" according to the Centers for Medicare & Medicaid Services, which conducted an inspection last fall.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003cbr>\nWalgreens is suspending Theranos Lab services at the drugstore chain's outlet in Palo Alto, Calif. (also known as Theranos' hometown). Early Theranos-adopter Walgreens also told the company to \"\u003ca href=\"http://news.walgreens.com/press-releases/general-news/walgreens-informs-theranos-to-cease-use-of-its-newark-calif-lab-for-blood-test-analysis.htm\" target=\"_blank\">immediately cease\u003c/a>\" sending blood samples collected at Walgreens stores to Theranos' Newark, Calif. lab, which the government found out-of-compliance with standards.\u003c/p>\n\u003cp>The Centers for Medicare & Medicaid Services, the agency that conducted the inspection of the Newark lab last fall, said the facility was deficient in a way that puts patients in \"immediate jeopardy.\"\u003c/p>\n\u003cp>According to the agency, that term is defined as “a situation in which immediate corrective action is necessary because the laboratory’s non-compliance … has already caused, is causing, or is likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.”\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Walgreens had offered Theranos' FDA-approved blood test for herpes at the Palo Alto drugstore. An employee there says, with the suspension, the Palo Alto outlet is currently not offering any blood testing.\u003c/p>\n\u003cp>The drugstore chain also says it will require blood samples collected at other stores to be sent to Theranos' certified Arizona lab, or to an accredited outside lab. Theranos has several dozen facilities located in Walgreens outlets in Arizona.\u003c/p>\n\u003cp>Theranos responded to news of the CMS findings by stating that the agency's inspection took place last year, and that the report doesn't reflect current practices. The Silicon Valley company also said it is taking corrective steps. Theranos Vice President of Communications Brooke Buchanan said in an email statement today that, \"We look forward to continuing to work with Walgreens to provide access to reliable, high quality, and low-cost lab testing services.\"\u003c/p>\n\u003cp>She also said the company would fix \"quickly and completely\" the one issue -- related to hematology -- that resulted in the \"immediate jeopardy\" characterization.\u003c/p>\n\u003cp>We asked Buchanan how Theranos planned to address the CMS mandate that it identify and take \"corrective action\" for patients who have been potentially affected by the problems at the lab.\u003c/p>\n\u003cp>\"We are developing our corrective action plan and that is part of the plan,\" she said.\u003c/p>\n\u003cp>Founded by CEO Elizabeth Holmes, Theranos has raised millions by pitching its technology as a cheaper, faster way to run dozens of blood tests.\u003c/p>\n\u003cp>Deerfield, Illinois-based Walgreens said no patient samples will be sent to the Newark lab until the issues raised by CMS have been resolved.\u003c/p>\n\u003cp>Any pulling back by Walgreens could be a serious blow to Theranos, once a Silicon Valley darling that seemed poise to disrupt the blood-testing industry. Over the past several months, however, the company has suffered the slings and arrows of The Wall Street Journal, which has published a string of negative stories casting doubts on Theranos' proprietary blood-testing technology.\u003c/p>\n\u003cp>\u003ca href=\"http://www.bloomberg.com/news/articles/2016-01-28/walgreens-halts-use-of-theranos-california-lab-after-u-s-report?cmpid=twtr1\" target=\"_blank\">Bloomberg\u003c/a> characterized the partnership between Walgreens and the secretive Theranos as \"the most public evidence of Theranos's promise of providing quicker and cheaper lab testing.\"\u003c/p>\n\u003cp>Bloomberg is also reporting that the Cleveland Clinic and Intermountain Healthcare, both of which Theranos hoped would evaluate its technology, are balking:\u003c/p>\n\u003cblockquote>\u003cp>Theranos had asked the Cleveland Clinic, a prominent research hospital, to run a study comparing Theranos’s technology to traditional blood draw, Holmes has said.\u003c/p>\n\u003cp>The Cleveland Clinic, however, said Wednesday that it had started no such program.\u003c/p>\n\u003cp>“The Cleveland Clinic has not begun any work related to the study at this time,” spokeswoman Eileen Sheil said Wednesday. “We are not consultants, nor do we have any financial investments in the company. ..”\u003c/p>\n\u003cp>Intermountain Healthcare, a 22-hospital system based in Utah, said in October that it was planning to run a pilot program with Theranos technology, to be used alongside traditional blood testing for comparison.\u003c/p>\n\u003cp>Intermountain hasn’t used Theranos’s technology yet, according to spokesman Daron Cowley. “We have not yet scheduled a possible pilot” study, Cowley said Wednesday in an e-mail. “We’ll certainly evaluate this and all information before beginning a pilot.”\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>Associated Press contributed to this report.\u003c/em>\u003c/p>\n\n",
"disqusIdentifier": "104578 http://ww2.kqed.org/futureofyou/?p=104578",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/28/walgreens-suspends-theranos-service-at-palo-alto/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 811,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 24
},
"modified": 1454118919,
"excerpt": "In wake of negative inspection at Theranos lab, health insurer joins Walgreens in suspending Theranos blood draws.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "In wake of negative inspection at Theranos lab, health insurer joins Walgreens in suspending Theranos blood draws.",
"title": "Yet Another Partner Pulls Back From Theranos | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Yet Another Partner Pulls Back From Theranos",
"datePublished": "2016-01-28T23:59:08-08:00",
"dateModified": "2016-01-29T17:55:19-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "walgreens-suspends-theranos-service-at-palo-alto",
"status": "publish",
"path": "/futureofyou/104578/walgreens-suspends-theranos-service-at-palo-alto",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>\u003cstrong>Update Friday, Jan. 29\u003c/strong>: On Thursday, health insurer Capital BlueCross said beleaguered blood-testing company Theranos would stop drawing blood at the insurer's retail store in Enola, Pa., according to \u003ca href=\"http://www.wsj.com/articles/theranos-stops-drawing-blood-from-patients-at-capital-bluecross-pennsylvania-store-1454093470\" target=\"_blank\">The Wall Street Journal\u003c/a> and \u003ca href=\"http://www.pennlive.com/news/2016/01/capital_blue_steps_back_from_e.html\" target=\"_blank\">local reports\u003c/a>.\u003c/p>\n\u003cp>That move came on the same day that Walgreens suspended Theranos services at its Palo Alto, Calif., store and told Theranos to stop sending blood samples taken at any Walgreens to Theranos' Newark lab for testing. That lab was found to be deficient in a way that put patients in \"immediate jeopardy,\" according to the Centers for Medicare & Medicaid Services, which conducted an inspection last fall.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003cbr>\nWalgreens is suspending Theranos Lab services at the drugstore chain's outlet in Palo Alto, Calif. (also known as Theranos' hometown). Early Theranos-adopter Walgreens also told the company to \"\u003ca href=\"http://news.walgreens.com/press-releases/general-news/walgreens-informs-theranos-to-cease-use-of-its-newark-calif-lab-for-blood-test-analysis.htm\" target=\"_blank\">immediately cease\u003c/a>\" sending blood samples collected at Walgreens stores to Theranos' Newark, Calif. lab, which the government found out-of-compliance with standards.\u003c/p>\n\u003cp>The Centers for Medicare & Medicaid Services, the agency that conducted the inspection of the Newark lab last fall, said the facility was deficient in a way that puts patients in \"immediate jeopardy.\"\u003c/p>\n\u003cp>According to the agency, that term is defined as “a situation in which immediate corrective action is necessary because the laboratory’s non-compliance … has already caused, is causing, or is likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.”\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Walgreens had offered Theranos' FDA-approved blood test for herpes at the Palo Alto drugstore. An employee there says, with the suspension, the Palo Alto outlet is currently not offering any blood testing.\u003c/p>\n\u003cp>The drugstore chain also says it will require blood samples collected at other stores to be sent to Theranos' certified Arizona lab, or to an accredited outside lab. Theranos has several dozen facilities located in Walgreens outlets in Arizona.\u003c/p>\n\u003cp>Theranos responded to news of the CMS findings by stating that the agency's inspection took place last year, and that the report doesn't reflect current practices. The Silicon Valley company also said it is taking corrective steps. Theranos Vice President of Communications Brooke Buchanan said in an email statement today that, \"We look forward to continuing to work with Walgreens to provide access to reliable, high quality, and low-cost lab testing services.\"\u003c/p>\n\u003cp>She also said the company would fix \"quickly and completely\" the one issue -- related to hematology -- that resulted in the \"immediate jeopardy\" characterization.\u003c/p>\n\u003cp>We asked Buchanan how Theranos planned to address the CMS mandate that it identify and take \"corrective action\" for patients who have been potentially affected by the problems at the lab.\u003c/p>\n\u003cp>\"We are developing our corrective action plan and that is part of the plan,\" she said.\u003c/p>\n\u003cp>Founded by CEO Elizabeth Holmes, Theranos has raised millions by pitching its technology as a cheaper, faster way to run dozens of blood tests.\u003c/p>\n\u003cp>Deerfield, Illinois-based Walgreens said no patient samples will be sent to the Newark lab until the issues raised by CMS have been resolved.\u003c/p>\n\u003cp>Any pulling back by Walgreens could be a serious blow to Theranos, once a Silicon Valley darling that seemed poise to disrupt the blood-testing industry. Over the past several months, however, the company has suffered the slings and arrows of The Wall Street Journal, which has published a string of negative stories casting doubts on Theranos' proprietary blood-testing technology.\u003c/p>\n\u003cp>\u003ca href=\"http://www.bloomberg.com/news/articles/2016-01-28/walgreens-halts-use-of-theranos-california-lab-after-u-s-report?cmpid=twtr1\" target=\"_blank\">Bloomberg\u003c/a> characterized the partnership between Walgreens and the secretive Theranos as \"the most public evidence of Theranos's promise of providing quicker and cheaper lab testing.\"\u003c/p>\n\u003cp>Bloomberg is also reporting that the Cleveland Clinic and Intermountain Healthcare, both of which Theranos hoped would evaluate its technology, are balking:\u003c/p>\n\u003cblockquote>\u003cp>Theranos had asked the Cleveland Clinic, a prominent research hospital, to run a study comparing Theranos’s technology to traditional blood draw, Holmes has said.\u003c/p>\n\u003cp>The Cleveland Clinic, however, said Wednesday that it had started no such program.\u003c/p>\n\u003cp>“The Cleveland Clinic has not begun any work related to the study at this time,” spokeswoman Eileen Sheil said Wednesday. “We are not consultants, nor do we have any financial investments in the company. ..”\u003c/p>\n\u003cp>Intermountain Healthcare, a 22-hospital system based in Utah, said in October that it was planning to run a pilot program with Theranos technology, to be used alongside traditional blood testing for comparison.\u003c/p>\n\u003cp>Intermountain hasn’t used Theranos’s technology yet, according to spokesman Daron Cowley. “We have not yet scheduled a possible pilot” study, Cowley said Wednesday in an e-mail. “We’ll certainly evaluate this and all information before beginning a pilot.”\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>Associated Press contributed to this report.\u003c/em>\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/104578/walgreens-suspends-theranos-service-at-palo-alto",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_80",
"futureofyou_617",
"futureofyou_245"
],
"featImg": "futureofyou_103649",
"label": "futureofyou_54"
},
"futureofyou_104100": {
"type": "posts",
"id": "futureofyou_104100",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "104100",
"score": null,
"sort": [
1453930414000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1453930414,
"format": "standard",
"disqusTitle": "Theranos Lab Problems Pose 'Immediate Jeopardy' to Patients, Government Says",
"title": "Theranos Lab Problems Pose 'Immediate Jeopardy' to Patients, Government Says",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>A government inspection of blood-testing company Theranos' lab has found deficiencies that \"pose immediate jeopardy to patient health and safety.\"\u003c/p>\n\u003cp>Immediate jeopardy, as defined by CMS, means \"a situation in which immediate corrective action is necessary because the laboratory's non-compliance ... has already caused, is causing, or is likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.\"\u003c/p>\n\u003cp>The \u003ca href=\"https://www.scribd.com/doc/296874497/Letter-from-CMS-to-Theranos\" target=\"_blank\">letter\u003c/a> informing Theranos of the inspection results was sent to the company on Monday by the Centers for Medicare & Medicaid Services, which oversees lab inspections. It cites five different conditions for certification, specified under the \u003ca href=\"http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105.htm\" target=\"_blank\">Clinical Laboratory Improvement Amendments\u003c/a> of 1988 (CLIA), that have not been met by the lab.\u003c/p>\n\u003cp>CMS has given Theranos 10 days to correct the deficiencies. In addition, the company must show evidence of \"corrective action\" for patients who have been found to have been affected by problems at the lab.\u003c/p>\n\u003cp>After the letter's release, the company defended itself in a statement from vice president Brooke Buchanan. Buchanan said the inspection, conducted in November, didn't reflect the current condition of the lab, and that it had already fixed some of the problems cited by inspectors.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\"A full plan of correction will be submitted to CMS within days,\" Buchanan said. (For the full statement, scroll to the bottom.)\u003c/p>\n\u003cp>Read the entire CMS letter here -- more after the jump.\u003c/p>\n\u003cp>[scribd id=296874497 key=key-hOWLaaDMsFe6OQCno57r mode=scroll]\u003c/p>\n\u003cp>The government action underscores negative publicity resulting from a string of articles by The Wall Street Journal alleging \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/26/for-theranos-the-bad-news-keeps-coming/\" target=\"_blank\">serious problems\u003c/a> with the company's patented blood-testing process, which is supposed to require blood that can be collected with just the prick of a finger in order to test for a \u003ca href=\"https://www.theranos.com/test-menu\" target=\"_blank\">host of substances and medical conditions\u003c/a>. But currently, it uses the technology for just one test, to detect herpes.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>Full statement from Theranos\u003c/em>:\u003c/p>\n\u003cblockquote>\u003cp>We received a report from CMS documenting their findings from a scheduled survey in our Newark, CA lab that took place last fall. In line with our commitment to leading the lab industry in transparency, we wanted you to hear directly from us regarding this survey and report:\u003c/p>\n\u003cp>This survey of our Newark, CA lab began months ago and does not reflect the current state of the lab. As the survey took place we were simultaneously conducting a comprehensive review of our laboratory’s systems, processes and procedures to ensure that we have best-in-class quality systems. We value engagement with our regulators, and are committed to ensuring that all our labs operate at the highest standards. We are still reviewing the report, but we addressed many of the observations during the survey and are actively continuing to take corrective action. A full plan of correction will be submitted to CMS within days.\u003c/p>\n\u003cp>CMS’s findings included standard and condition-level deficiencies, and one finding at the “immediate jeopardy” level, based on a condition-level deficiency in one specific area – hematology. To be clear, that finding does not apply to the whole lab, and none of these findings relate to our Arizona lab, where we currently process over 90 percent of our tests.\u003c/p>\n\u003cp>Three of the condition-level deficiencies are related to personnel, such as documentation and oversight; one is related to analytic systems; and the one referenced above to hematology. CMS found that within hematology, certain policies, procedures, and associated events did not meet the relevant standards.\u003c/p>\n\u003cp>We were grateful to have our regulators directly review our alternative proficiency testing processes for our proprietary technologies and related operations. (See more on that at the end of this note below.)\u003c/p>\n\u003cp>As part of our review, we have made policy and personnel changes in our Newark, CA lab, including adding a new CLIA lab director with the conclusion of our lab director search. Our new lab director, Dr. Kingshuk Das, is a board-certified pathologist and M.D. and, among other accomplishments, an Associate Medical Director of UCLA’s Clinical Laboratories. We have also brought on a new clinical consultant, Dr. Waldo Concepcion, the Chief of Clinical Transplantation and Professor of Surgery at Stanford University Medical Center.\u003c/p>\n\u003cp>We value engagement with our regulators, which helps us build best-in-class systems, and are committed to ensuring that all our labs operate at the highest standards.\u003c/p>\n\u003cp>Theranos remains the sole company to call for - and voluntarily submit itself to - stronger regulatory oversight. Theranos has voluntarily committed to FDA review of its laboratory-developed tests and publishing its prices, lab proficiency testing pass rate, customer satisfaction scores, guest visit times, and more, to realize a system in which individuals become more engaged with their health, and early detection and prevention of disease become realities.\u003c/p>\n\u003cp>***\u003c/p>\n\u003cp>CMS issued no findings on the following allegations mentioned in recent media coverage:\u003cbr>\n• An allegation of proficiency testing “cheating”\u003cbr>\n• An allegation that management “instructed lab employees to keep testing patients” despite indications of purported problems\u003cbr>\n• An alleged complaint to CMS in which an R&D employee allegedly “deleted” QC data\u003cbr>\n• An allegation that Theranos improperly hid the existence of its lab holding its proprietary technologies\u003cbr>\n• An allegation that Theranos manipulated data to make its proprietary machines seem more accurate\u003cbr>\n• An allegation of a “dilution” protocol causing inaccurate results\u003cbr>\n• An allegation regarding the handling of a purported “proficiency-testing sample” in February 2014\u003c/p>\u003c/blockquote>\n\n",
"disqusIdentifier": "104100 http://ww2.kqed.org/futureofyou/?p=104100",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/27/government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 929,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 22
},
"modified": 1453946953,
"excerpt": "The Centers for Medicare & Medicaid Services has given Theranos 10 days to correct the deficiences.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The Centers for Medicare & Medicaid Services has given Theranos 10 days to correct the deficiences.",
"title": "Theranos Lab Problems Pose 'Immediate Jeopardy' to Patients, Government Says | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Lab Problems Pose 'Immediate Jeopardy' to Patients, Government Says",
"datePublished": "2016-01-27T13:33:34-08:00",
"dateModified": "2016-01-27T18:09:13-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients",
"status": "publish",
"path": "/futureofyou/104100/government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>A government inspection of blood-testing company Theranos' lab has found deficiencies that \"pose immediate jeopardy to patient health and safety.\"\u003c/p>\n\u003cp>Immediate jeopardy, as defined by CMS, means \"a situation in which immediate corrective action is necessary because the laboratory's non-compliance ... has already caused, is causing, or is likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.\"\u003c/p>\n\u003cp>The \u003ca href=\"https://www.scribd.com/doc/296874497/Letter-from-CMS-to-Theranos\" target=\"_blank\">letter\u003c/a> informing Theranos of the inspection results was sent to the company on Monday by the Centers for Medicare & Medicaid Services, which oversees lab inspections. It cites five different conditions for certification, specified under the \u003ca href=\"http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105.htm\" target=\"_blank\">Clinical Laboratory Improvement Amendments\u003c/a> of 1988 (CLIA), that have not been met by the lab.\u003c/p>\n\u003cp>CMS has given Theranos 10 days to correct the deficiencies. In addition, the company must show evidence of \"corrective action\" for patients who have been found to have been affected by problems at the lab.\u003c/p>\n\u003cp>After the letter's release, the company defended itself in a statement from vice president Brooke Buchanan. Buchanan said the inspection, conducted in November, didn't reflect the current condition of the lab, and that it had already fixed some of the problems cited by inspectors.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"A full plan of correction will be submitted to CMS within days,\" Buchanan said. (For the full statement, scroll to the bottom.)\u003c/p>\n\u003cp>Read the entire CMS letter here -- more after the jump.\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003ciframe\n class=\"scribd_iframe_embed\"\n src=\"//www.scribd.com/embeds/296874497/content?start_page=1&view_mode=&access_key=key-hOWLaaDMsFe6OQCno57r\"\n title=\"http://www.scribd.com/doc/296874497\"\n data-auto-height=\"true\" scrolling=\"no\" id=\"scribd_296874497\"\n width=\"100%\" height=\"500\" frameborder=\"0\">\u003c/iframe>\n \u003ca class=\"utils-parseShortcode-shortcodes-__scribdShortcode__scribd_footer\"\n href=\"http://www.scribd.com/doc/296874497\"\n target=\"_blank\" rel=\"noopener noreferrer\">View this document on Scribd\u003c/a>\u003c/p>\u003cp>\u003c/p>\n\u003cp>The government action underscores negative publicity resulting from a string of articles by The Wall Street Journal alleging \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/26/for-theranos-the-bad-news-keeps-coming/\" target=\"_blank\">serious problems\u003c/a> with the company's patented blood-testing process, which is supposed to require blood that can be collected with just the prick of a finger in order to test for a \u003ca href=\"https://www.theranos.com/test-menu\" target=\"_blank\">host of substances and medical conditions\u003c/a>. But currently, it uses the technology for just one test, to detect herpes.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>Full statement from Theranos\u003c/em>:\u003c/p>\n\u003cblockquote>\u003cp>We received a report from CMS documenting their findings from a scheduled survey in our Newark, CA lab that took place last fall. In line with our commitment to leading the lab industry in transparency, we wanted you to hear directly from us regarding this survey and report:\u003c/p>\n\u003cp>This survey of our Newark, CA lab began months ago and does not reflect the current state of the lab. As the survey took place we were simultaneously conducting a comprehensive review of our laboratory’s systems, processes and procedures to ensure that we have best-in-class quality systems. We value engagement with our regulators, and are committed to ensuring that all our labs operate at the highest standards. We are still reviewing the report, but we addressed many of the observations during the survey and are actively continuing to take corrective action. A full plan of correction will be submitted to CMS within days.\u003c/p>\n\u003cp>CMS’s findings included standard and condition-level deficiencies, and one finding at the “immediate jeopardy” level, based on a condition-level deficiency in one specific area – hematology. To be clear, that finding does not apply to the whole lab, and none of these findings relate to our Arizona lab, where we currently process over 90 percent of our tests.\u003c/p>\n\u003cp>Three of the condition-level deficiencies are related to personnel, such as documentation and oversight; one is related to analytic systems; and the one referenced above to hematology. CMS found that within hematology, certain policies, procedures, and associated events did not meet the relevant standards.\u003c/p>\n\u003cp>We were grateful to have our regulators directly review our alternative proficiency testing processes for our proprietary technologies and related operations. (See more on that at the end of this note below.)\u003c/p>\n\u003cp>As part of our review, we have made policy and personnel changes in our Newark, CA lab, including adding a new CLIA lab director with the conclusion of our lab director search. Our new lab director, Dr. Kingshuk Das, is a board-certified pathologist and M.D. and, among other accomplishments, an Associate Medical Director of UCLA’s Clinical Laboratories. We have also brought on a new clinical consultant, Dr. Waldo Concepcion, the Chief of Clinical Transplantation and Professor of Surgery at Stanford University Medical Center.\u003c/p>\n\u003cp>We value engagement with our regulators, which helps us build best-in-class systems, and are committed to ensuring that all our labs operate at the highest standards.\u003c/p>\n\u003cp>Theranos remains the sole company to call for - and voluntarily submit itself to - stronger regulatory oversight. Theranos has voluntarily committed to FDA review of its laboratory-developed tests and publishing its prices, lab proficiency testing pass rate, customer satisfaction scores, guest visit times, and more, to realize a system in which individuals become more engaged with their health, and early detection and prevention of disease become realities.\u003c/p>\n\u003cp>***\u003c/p>\n\u003cp>CMS issued no findings on the following allegations mentioned in recent media coverage:\u003cbr>\n• An allegation of proficiency testing “cheating”\u003cbr>\n• An allegation that management “instructed lab employees to keep testing patients” despite indications of purported problems\u003cbr>\n• An alleged complaint to CMS in which an R&D employee allegedly “deleted” QC data\u003cbr>\n• An allegation that Theranos improperly hid the existence of its lab holding its proprietary technologies\u003cbr>\n• An allegation that Theranos manipulated data to make its proprietary machines seem more accurate\u003cbr>\n• An allegation of a “dilution” protocol causing inaccurate results\u003cbr>\n• An allegation regarding the handling of a purported “proficiency-testing sample” in February 2014\u003c/p>\u003c/blockquote>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/104100/government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_73"
],
"tags": [
"futureofyou_80",
"futureofyou_617"
],
"featImg": "futureofyou_58611",
"label": "futureofyou_54"
},
"futureofyou_103654": {
"type": "posts",
"id": "futureofyou_103654",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "103654",
"score": null,
"sort": [
1453917659000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1453917659,
"format": "video",
"disqusTitle": "New Wearable Health-Monitoring Device Analyzes Your Sweat",
"title": "New Wearable Health-Monitoring Device Analyzes Your Sweat",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>OK, who \u003cem>wouldn't\u003c/em> want their very own perspiration analysis system?\u003c/p>\n\u003cp>Well, good news, my friends. In a \u003ca href=\"http://www.nature.com/news/wearable-sweat-sensor-paves-way-for-real-time-analysis-of-body-chemistry-1.19254\" target=\"_blank\">paper published Wednesday\u003c/a> in the journal Nature, researchers at Stanford University and UC Berkeley say they have created just such a gadget.\u003c/p>\n\u003cp>And naturally, you can wear it -- as a flexible head or wrist band.\u003c/p>\n\u003cp>The device works by marrying sensors that detect and analyze sodium, potassium, glucose and lactate -- elements found in sweat -- to a wireless circuit board of interconnected chips. The circuit board then beams its analysis to a smartphone or other device.\u003c/p>\n\u003cp>The new system's inventors say the technology could potentially issue alerts for problems like fatigue, dehydration and overheating, as well as open up new fields of research.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>https://www.youtube.com/watch?v=OzZBVOF8u-0&feature=youtu.be\u003c/p>\n\u003cp>\"With continuous, real-time monitoring of populations of people, we’ll be able to mine the collected data for patterns that can guide clinically oriented investigations and deliver personalized medicine,”said Stanford Genome Technology Center Director Ron Davis, who worked on the project with Sam Emaminejad, a postdoctoral scholar at Stanford and UC Berkeley, and Ali Javey, a UCB researcher in electronic materials.\u003c/p>\n\u003cp>The team tested the device by having individuals exercise for different durations and intensity.\u003c/p>\n\u003cp>\"We were able to show how well the device worked,\" said UC Berkeley's George Brooks, a researcher in exercise physiology and metabolism who worked with the inventors. \"A medical technician could get a reading on somebody instantaneously and then follow that, instead of taking a blood sample and then sending that to a laboratory and waiting several hours for a result.\"\u003c/p>\n\u003cp>So when you can buy it? Well, maybe not next Christmas. From \u003ca href=\"http://www.nature.com/news/wearable-sweat-sensor-paves-way-for-real-time-analysis-of-body-chemistry-1.19254\" target=\"_blank\">Nature\u003c/a>:\u003c/p>\n\u003cp>\u003cem>Javey says he has applied for patents on the technology. But there are still many challenges to overcome before you can expect to buy a sweat sensor incorporated into a wearable fitness band. For one thing, scientists aren’t used to working with such tiny quantities of fluid, and people aren’t always sweating. “Many applications will be outside athletics, where wearable bands or patches will have to locally stimulate sweat,” says [wearable technology researcher Jason] Heikenfeld. \u003c/em>\u003c/p>\n\u003cp>Also in the article, Javey cautions that sweat sensors are not as accurate as blood tests.\u003c/p>\n\u003cp>So for now, don't sweat the results. But maybe soon ...\u003c/p>\n\u003cp>\u003c/p>\n\u003cp> \u003c/p>\n\n",
"disqusIdentifier": "103654 http://ww2.kqed.org/futureofyou/?p=103654",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/27/new-wearable-health-monitoring-device-analyzes-your-sweat/",
"stats": {
"hasVideo": true,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 414,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 14
},
"modified": 1453926551,
"excerpt": "Researchers at Stanford and UC Berkeley say they have created a non-invasive health monitoring device that works by tracking changes in sweat.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "Researchers at Stanford and UC Berkeley say they have created a non-invasive health monitoring device that works by tracking changes in sweat.",
"title": "New Wearable Health-Monitoring Device Analyzes Your Sweat | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "New Wearable Health-Monitoring Device Analyzes Your Sweat",
"datePublished": "2016-01-27T10:00:59-08:00",
"dateModified": "2016-01-27T12:29:11-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "new-wearable-health-monitoring-device-analyzes-your-sweat",
"status": "publish",
"path": "/futureofyou/103654/new-wearable-health-monitoring-device-analyzes-your-sweat",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>OK, who \u003cem>wouldn't\u003c/em> want their very own perspiration analysis system?\u003c/p>\n\u003cp>Well, good news, my friends. In a \u003ca href=\"http://www.nature.com/news/wearable-sweat-sensor-paves-way-for-real-time-analysis-of-body-chemistry-1.19254\" target=\"_blank\">paper published Wednesday\u003c/a> in the journal Nature, researchers at Stanford University and UC Berkeley say they have created just such a gadget.\u003c/p>\n\u003cp>And naturally, you can wear it -- as a flexible head or wrist band.\u003c/p>\n\u003cp>The device works by marrying sensors that detect and analyze sodium, potassium, glucose and lactate -- elements found in sweat -- to a wireless circuit board of interconnected chips. The circuit board then beams its analysis to a smartphone or other device.\u003c/p>\n\u003cp>The new system's inventors say the technology could potentially issue alerts for problems like fatigue, dehydration and overheating, as well as open up new fields of research.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\u003c/p>\u003cp>\u003cspan class='utils-parseShortcode-shortcodes-__youtubeShortcode__embedYoutube'>\n \u003cspan class='utils-parseShortcode-shortcodes-__youtubeShortcode__embedYoutubeInside'>\n \u003ciframe\n loading='lazy'\n class='utils-parseShortcode-shortcodes-__youtubeShortcode__youtubePlayer'\n type='text/html'\n src='//www.youtube.com/embed/OzZBVOF8u-0'\n title='//www.youtube.com/embed/OzZBVOF8u-0'\n allowfullscreen='true'\n style='border:0;'>\u003c/iframe>\n \u003c/span>\n \u003c/span>\u003c/p>\u003cp>\u003cp>\"With continuous, real-time monitoring of populations of people, we’ll be able to mine the collected data for patterns that can guide clinically oriented investigations and deliver personalized medicine,”said Stanford Genome Technology Center Director Ron Davis, who worked on the project with Sam Emaminejad, a postdoctoral scholar at Stanford and UC Berkeley, and Ali Javey, a UCB researcher in electronic materials.\u003c/p>\n\u003cp>The team tested the device by having individuals exercise for different durations and intensity.\u003c/p>\n\u003cp>\"We were able to show how well the device worked,\" said UC Berkeley's George Brooks, a researcher in exercise physiology and metabolism who worked with the inventors. \"A medical technician could get a reading on somebody instantaneously and then follow that, instead of taking a blood sample and then sending that to a laboratory and waiting several hours for a result.\"\u003c/p>\n\u003cp>So when you can buy it? Well, maybe not next Christmas. From \u003ca href=\"http://www.nature.com/news/wearable-sweat-sensor-paves-way-for-real-time-analysis-of-body-chemistry-1.19254\" target=\"_blank\">Nature\u003c/a>:\u003c/p>\n\u003cp>\u003cem>Javey says he has applied for patents on the technology. But there are still many challenges to overcome before you can expect to buy a sweat sensor incorporated into a wearable fitness band. For one thing, scientists aren’t used to working with such tiny quantities of fluid, and people aren’t always sweating. “Many applications will be outside athletics, where wearable bands or patches will have to locally stimulate sweat,” says [wearable technology researcher Jason] Heikenfeld. \u003c/em>\u003c/p>\n\u003cp>Also in the article, Javey cautions that sweat sensors are not as accurate as blood tests.\u003c/p>\n\u003cp>So for now, don't sweat the results. But maybe soon ...\u003c/p>\n\u003cp>\u003c/p>\n\u003cp> \u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/103654/new-wearable-health-monitoring-device-analyzes-your-sweat",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_80",
"futureofyou_729",
"futureofyou_53"
],
"featImg": "futureofyou_104009",
"label": "futureofyou_54"
},
"futureofyou_103581": {
"type": "posts",
"id": "futureofyou_103581",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "103581",
"score": null,
"sort": [
1453857335000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1453857335,
"format": "standard",
"disqusTitle": "For Theranos, the Bad News Keeps Coming",
"title": "For Theranos, the Bad News Keeps Coming",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>\u003cstrong>Update Jan. 28\u003c/strong> And yet \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/28/walgreens-suspends-theranos-service-at-palo-alto/\" target=\"_blank\">more bad news\u003c/a> for Theranos -- from its biggest public supporter, Walgreens.\u003c/p>\n\u003cp>\u003cstrong>Update Jan. 27\u003c/strong> The Centers for Medicare & Medicaid Services has given Theranos 10 days to correct deficiences at its Newark lab. A government inspection of the lab found problems that “pose immediate jeopardy to patient health and safety,” CMS said. \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/27/government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients/\" target=\"_blank\">See the story here\u003c/a>.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003c/p>\n\u003cp>So how much do Theranos employees \u003cem>not\u003c/em> look forward to the morning delivery of The Wall Street Journal?\u003c/p>\n\u003cp>On Sunday, the paper \u003ca href=\"http://www.wsj.com/articles/problems-found-at-theranos-lab-1453684743?utm_content=buffer2ea86&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\" target=\"_blank\">published another damaging report\u003c/a> documenting the blood-testing company's swift fall from grace. Citing \"people familiar with the matter,\" the Journal said an inspection of Theranos' lab in Newark, Calif. by the Centers for Medicare and Medicaid Services turned up \"serious deficiencies.\"\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>If Theranos is found to be out of compliance with CMS standards, then it could potentially be decertified and barred from Medicare and Medicaid. Decertifications are rare, and providers are usually given the right to correct deficiencies.The paper said the inspection findings were \"about to be made public.\" A spokesperson for CMS told KQED in an email the agency could not say when the report will be released. Theranos did not respond to a request for comment but told the Journal it had not yet seen the report.\u003c/p>\n\u003cp>The Journal story is reporter John Carreyrou's latest bubble-deflating piece on Palo Alto-based Theranos. The company, founded in 2003 by 19-year-old Elizabeth Holmes, was once the epitome of a \"disruptive\" high-flying health care startup, introducing diagnostic tests that required only a pinprick's worth of blood.\u003c/p>\n\u003cp>Last year, the private firm was valued at $9 billion, and \u003ca href=\"http://www.forbes.com/sites/matthewherper/2015/07/15/giving-theranos-a-few-tests/#5e2e7b1c1721\" target=\"_blank\">Fortune called\u003c/a> Holmes the \"world's youngest female billionaire\" (she'll be 32 next week).\u003c/p>\n\u003cp>But over the past several months, the story of Theranos has taken an unpleasant turn. Last October, the FDA said Theranos vials (\"nanotainers\"), which collect the blood from patients' fingers, had been improperly listed by the company as exempt from FDA review and approval. The FDA also said Theranos had inadequate procedures for reviewing complaints — including those suggesting the devices may be faulty.\u003c/p>\n\u003cp>Meanwhile, The Wall Street Journal reported Theranos was having \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\"> a lot of problems\u003c/a> with its breakthrough technology:\u003c/p>\n\u003cblockquote>\u003cp>One former senior employee says Theranos was routinely using the device, named Edison after the prolific inventor, for only 15 tests in December 2014. Some employees were leery about the machine’s accuracy, according to the former employees and emails reviewed by The Wall Street Journal.\u003c/p>\n\u003cp>In a complaint to regulators, one Theranos employee accused the company of failing to report test results that raised questions about the precision of the Edison system. Such a failure could be a violation of federal rules for laboratories, the former employee said.\u003c/p>\n\u003cp>Theranos also hasn’t disclosed publicly that it does the vast majority of its tests with traditional machines bought from companies like Siemens AG.\u003c/p>\u003c/blockquote>\n\u003cp>Theranos stopped using Edison for \u003ca href=\"http://www.bloomberg.com/news/articles/2015-10-16/theranos-limits-new-blood-technology-to-one-in-200-tests\" target=\"_blank\">all but one\u003c/a> of the 200 tests it \u003ca href=\"https://www.theranos.com/test-menu\" target=\"_blank\">lists\u003c/a>. In late December, the Journal published another \u003ca href=\"http://www.wsj.com/articles/at-theranos-many-strategies-and-snags-1451259629\" target=\"_blank\">article\u003c/a> with more revelations, including an alleged incident in which managers at the company deleted data from a quality control test to make Edison's results appear more accurate than they really were, sending the faulty results to the patient.\u003c/p>\n\u003cp>A spokesperson for Theranos told the Journal the company did not believe the incident occurred.\u003c/p>\n\u003cp>Walgreens, meanwhile, has \u003ca href=\"http://www.usatoday.com/story/tech/2015/10/24/walgreens-halts-expansion-its-theranos-centers/74537868/\" target=\"_blank\">put on hold plans to expand\u003c/a> the Theranos stations it hosts in dozens of stores in three states.\u003c/p>\n\u003cp>As the Journal has published its reports, Theranos has issued a \u003ca href=\"https://www.theranos.com/news/press-releases\" target=\"_blank\">string of responses \u003c/a>denouncing the accuracy of the stories. The latest statement is from Dec. 21, in the form of a \u003ca href=\"https://www.theranos.com/news/posts/wall-street-journal-letter-to-the-editor\" target=\"_blank\">letter to the Journal's editor\u003c/a>.\u003c/p>\n\u003cblockquote>\u003cp>The Journal has relied almost entirely on anonymous sources – without disclosing those sources’ qualifications, biases, affiliations, motives, or even how recently they were employed. Theranos has not only made its top scientists and engineers available to the Journal, but has provided exhaustive information and on-the-record statements to address every allegation raised by the Journal. ...\u003c/p>\n\u003cp>By continually relying on mostly anonymous sources, while dismissing concrete facts, documents, and expert scientists and engineers in the field provided by Theranos, the Journal denies its readers the ability to scrutinize and weigh the sources’ identities, motives, and the veracity of their statements.\u003c/p>\u003c/blockquote>\n\u003cp>But last October, Christina Farr, reporting for Future of You,\u003ca href=\"http://ww2.kqed.org/futureofyou/2015/10/15/critics-demand-theranos-lift-veil-of-secrecy-on-blood-test/\" target=\"_blank\"> wrote frankly\u003c/a> about the skepticism surrounding Theranos beyond that of The Wall Street Journal's:\u003c/p>\n\u003cblockquote>\u003cp>(S)ome scientists and health writers saw past the hype months ago. They took to their personal blogs and social media to ask some pertinent questions about the science behind Theranos’ test, which largely went unanswered. Some requested that Theranos publish peer-reviewed studies to prove the validity of its test.\u003c/p>\n\u003cp>At health conferences and gatherings, I’ve heard similar skepticism about Theranos’ science and its multi-billion dollar valuation, as well as increasing calls for proof to back up its claims. Theranos has sought FDA approval for its tests, but it \u003ca href=\"http://www.businessinsider.com/science-of-elizabeth-holmes-theranos-2015-4\" target=\"_blank\">has evaded questions about its technology. \u003c/a>\u003c/p>\n\u003cp>As Dr. David Koch, president of the American Association for Clinical Chemistry and a professor at Emory University \u003ca href=\"http://www.businessinsider.com/science-of-elizabeth-holmes-theranos-2015-4\" target=\"_blank\">told Business Insider in April\u003c/a>: “It’s impossible to comment on how good this is going to be — it may be wonderful and it may bomb, but I really can’t be more definitive because there’s nothing to really look at, to read, to react to.”\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>More, we're quite sure, to come...\u003c/p>\n\n",
"disqusIdentifier": "103581 http://ww2.kqed.org/futureofyou/?p=103581",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/26/for-theranos-the-bad-news-keeps-coming/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 973,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 26
},
"modified": 1454542130,
"excerpt": "The Wall Street Journal reported this weekend that the government has found serious deficiencies in the Theranos lab.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The Wall Street Journal reported this weekend that the government has found serious deficiencies in the Theranos lab.",
"title": "For Theranos, the Bad News Keeps Coming | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "For Theranos, the Bad News Keeps Coming",
"datePublished": "2016-01-26T17:15:35-08:00",
"dateModified": "2016-02-03T15:28:50-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "for-theranos-the-bad-news-keeps-coming",
"status": "publish",
"path": "/futureofyou/103581/for-theranos-the-bad-news-keeps-coming",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>\u003cstrong>Update Jan. 28\u003c/strong> And yet \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/28/walgreens-suspends-theranos-service-at-palo-alto/\" target=\"_blank\">more bad news\u003c/a> for Theranos -- from its biggest public supporter, Walgreens.\u003c/p>\n\u003cp>\u003cstrong>Update Jan. 27\u003c/strong> The Centers for Medicare & Medicaid Services has given Theranos 10 days to correct deficiences at its Newark lab. A government inspection of the lab found problems that “pose immediate jeopardy to patient health and safety,” CMS said. \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/27/government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients/\" target=\"_blank\">See the story here\u003c/a>.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003c/p>\n\u003cp>So how much do Theranos employees \u003cem>not\u003c/em> look forward to the morning delivery of The Wall Street Journal?\u003c/p>\n\u003cp>On Sunday, the paper \u003ca href=\"http://www.wsj.com/articles/problems-found-at-theranos-lab-1453684743?utm_content=buffer2ea86&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\" target=\"_blank\">published another damaging report\u003c/a> documenting the blood-testing company's swift fall from grace. Citing \"people familiar with the matter,\" the Journal said an inspection of Theranos' lab in Newark, Calif. by the Centers for Medicare and Medicaid Services turned up \"serious deficiencies.\"\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>If Theranos is found to be out of compliance with CMS standards, then it could potentially be decertified and barred from Medicare and Medicaid. Decertifications are rare, and providers are usually given the right to correct deficiencies.The paper said the inspection findings were \"about to be made public.\" A spokesperson for CMS told KQED in an email the agency could not say when the report will be released. Theranos did not respond to a request for comment but told the Journal it had not yet seen the report.\u003c/p>\n\u003cp>The Journal story is reporter John Carreyrou's latest bubble-deflating piece on Palo Alto-based Theranos. The company, founded in 2003 by 19-year-old Elizabeth Holmes, was once the epitome of a \"disruptive\" high-flying health care startup, introducing diagnostic tests that required only a pinprick's worth of blood.\u003c/p>\n\u003cp>Last year, the private firm was valued at $9 billion, and \u003ca href=\"http://www.forbes.com/sites/matthewherper/2015/07/15/giving-theranos-a-few-tests/#5e2e7b1c1721\" target=\"_blank\">Fortune called\u003c/a> Holmes the \"world's youngest female billionaire\" (she'll be 32 next week).\u003c/p>\n\u003cp>But over the past several months, the story of Theranos has taken an unpleasant turn. Last October, the FDA said Theranos vials (\"nanotainers\"), which collect the blood from patients' fingers, had been improperly listed by the company as exempt from FDA review and approval. The FDA also said Theranos had inadequate procedures for reviewing complaints — including those suggesting the devices may be faulty.\u003c/p>\n\u003cp>Meanwhile, The Wall Street Journal reported Theranos was having \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\"> a lot of problems\u003c/a> with its breakthrough technology:\u003c/p>\n\u003cblockquote>\u003cp>One former senior employee says Theranos was routinely using the device, named Edison after the prolific inventor, for only 15 tests in December 2014. Some employees were leery about the machine’s accuracy, according to the former employees and emails reviewed by The Wall Street Journal.\u003c/p>\n\u003cp>In a complaint to regulators, one Theranos employee accused the company of failing to report test results that raised questions about the precision of the Edison system. Such a failure could be a violation of federal rules for laboratories, the former employee said.\u003c/p>\n\u003cp>Theranos also hasn’t disclosed publicly that it does the vast majority of its tests with traditional machines bought from companies like Siemens AG.\u003c/p>\u003c/blockquote>\n\u003cp>Theranos stopped using Edison for \u003ca href=\"http://www.bloomberg.com/news/articles/2015-10-16/theranos-limits-new-blood-technology-to-one-in-200-tests\" target=\"_blank\">all but one\u003c/a> of the 200 tests it \u003ca href=\"https://www.theranos.com/test-menu\" target=\"_blank\">lists\u003c/a>. In late December, the Journal published another \u003ca href=\"http://www.wsj.com/articles/at-theranos-many-strategies-and-snags-1451259629\" target=\"_blank\">article\u003c/a> with more revelations, including an alleged incident in which managers at the company deleted data from a quality control test to make Edison's results appear more accurate than they really were, sending the faulty results to the patient.\u003c/p>\n\u003cp>A spokesperson for Theranos told the Journal the company did not believe the incident occurred.\u003c/p>\n\u003cp>Walgreens, meanwhile, has \u003ca href=\"http://www.usatoday.com/story/tech/2015/10/24/walgreens-halts-expansion-its-theranos-centers/74537868/\" target=\"_blank\">put on hold plans to expand\u003c/a> the Theranos stations it hosts in dozens of stores in three states.\u003c/p>\n\u003cp>As the Journal has published its reports, Theranos has issued a \u003ca href=\"https://www.theranos.com/news/press-releases\" target=\"_blank\">string of responses \u003c/a>denouncing the accuracy of the stories. The latest statement is from Dec. 21, in the form of a \u003ca href=\"https://www.theranos.com/news/posts/wall-street-journal-letter-to-the-editor\" target=\"_blank\">letter to the Journal's editor\u003c/a>.\u003c/p>\n\u003cblockquote>\u003cp>The Journal has relied almost entirely on anonymous sources – without disclosing those sources’ qualifications, biases, affiliations, motives, or even how recently they were employed. Theranos has not only made its top scientists and engineers available to the Journal, but has provided exhaustive information and on-the-record statements to address every allegation raised by the Journal. ...\u003c/p>\n\u003cp>By continually relying on mostly anonymous sources, while dismissing concrete facts, documents, and expert scientists and engineers in the field provided by Theranos, the Journal denies its readers the ability to scrutinize and weigh the sources’ identities, motives, and the veracity of their statements.\u003c/p>\u003c/blockquote>\n\u003cp>But last October, Christina Farr, reporting for Future of You,\u003ca href=\"http://ww2.kqed.org/futureofyou/2015/10/15/critics-demand-theranos-lift-veil-of-secrecy-on-blood-test/\" target=\"_blank\"> wrote frankly\u003c/a> about the skepticism surrounding Theranos beyond that of The Wall Street Journal's:\u003c/p>\n\u003cblockquote>\u003cp>(S)ome scientists and health writers saw past the hype months ago. They took to their personal blogs and social media to ask some pertinent questions about the science behind Theranos’ test, which largely went unanswered. Some requested that Theranos publish peer-reviewed studies to prove the validity of its test.\u003c/p>\n\u003cp>At health conferences and gatherings, I’ve heard similar skepticism about Theranos’ science and its multi-billion dollar valuation, as well as increasing calls for proof to back up its claims. Theranos has sought FDA approval for its tests, but it \u003ca href=\"http://www.businessinsider.com/science-of-elizabeth-holmes-theranos-2015-4\" target=\"_blank\">has evaded questions about its technology. \u003c/a>\u003c/p>\n\u003cp>As Dr. David Koch, president of the American Association for Clinical Chemistry and a professor at Emory University \u003ca href=\"http://www.businessinsider.com/science-of-elizabeth-holmes-theranos-2015-4\" target=\"_blank\">told Business Insider in April\u003c/a>: “It’s impossible to comment on how good this is going to be — it may be wonderful and it may bomb, but I really can’t be more definitive because there’s nothing to really look at, to read, to react to.”\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>More, we're quite sure, to come...\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/103581/for-theranos-the-bad-news-keeps-coming",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_80",
"futureofyou_617"
],
"featImg": "futureofyou_103649",
"label": "futureofyou_54"
},
"futureofyou_100556": {
"type": "posts",
"id": "futureofyou_100556",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "100556",
"score": null,
"sort": [
1453769123000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1453769123,
"format": "image",
"disqusTitle": "Hacked Medical Devices Still a Big Threat in 2016",
"title": "Hacked Medical Devices Still a Big Threat in 2016",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Hackers aren’t just breaking into email accounts and online banking systems anymore. They’re also exploiting healthcare—going after \u003ca href=\"http://www.latimes.com/business/la-fi-anthem-hack-fallout-20150206-story.html\">electronic medical records\u003c/a>, wifi enabled medical devices and even remotely controlled surgical robots.\u003c/p>\n\u003cp>Medical devices and records have emerged as big cyber security risks. That’s why the \u003ca href=\"http://www.fda.gov/\">Food and Drug Administration\u003c/a> recently proposed \u003ca href=\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm481968.htm\">new guidelines\u003c/a> for how medical device manufacturers should secure their products.\u003c/p>\n\u003cp>Among the FDA's recommendations, manufacturers are being asked to:\u003c/p>\n\u003cul>\n\u003cli>Develop a risk management program that includes a plan for when a vulnerability is discovered.\u003c/li>\n\u003cli>Write disclosure policies, so hospitals and patients understand which aspects of a device may be less secure.\u003c/li>\n\u003cli>Release regular software and hardware updates for medical devices after they’re on the market.\u003c/li>\n\u003c/ul>\n\u003cp>\u003cstrong>\u003cem>[Scroll down to see three real life cyber security attacks] \u003c/em>\u003c/strong>\u003c/p>\n\u003cp>But security experts, like \u003ca href=\"https://www.schneier.com/\">Bruce Schneier\u003c/a>, say non-legally binding guidelines are just not enough.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\"It's basically industry best practice,\" says Schneier. \"But without enforcement, it's just pleading.\"\u003c/p>\n\u003cp>Critics are concerned that the responsibility is still primarily left up to manufacturers to disclose when a device has been hacked.\u003c/p>\n\u003cp>Consumer Watchdog president Jamie Court says recommendations are not enough and we won't see new laws until public officials are affected. \"All its gonna take is one congressman’s defibrillator being hacked and we’ll have some new laws really quickly,\" according to Court.\u003c/p>\n\u003cp>The FDA is \u003ca href=\"https://www.federalregister.gov/articles/2016/01/22/2016-01172/postmarket-management-of-cybersecurity-in-medical-devices-draft-guidance-for-industry-and-food-and\">taking public comments\u003c/a> on its \u003ca href=\"http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM482022.pdf\">guidelines\u003c/a> until April 21.\u003c/p>\n\u003cp>Read on to see three real life situations the FDA guidance is designed to prevent.\u003c/p>\n\u003cp>\u003cstrong>Security Experts Hack a Surgical Robot\u003c/strong>\u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-full wp-image-103162\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot.jpg\" alt=\"FDA_Icon_SurgicalRobot\" width=\"142\" height=\"142\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot.jpg 142w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-32x32.jpg 32w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-64x64.jpg 64w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-96x96.jpg 96w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-128x128.jpg 128w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-75x75.jpg 75w\" sizes=\"(max-width: 142px) 100vw, 142px\">Remote surgery—where a surgeon in one location controls a medical robot in another—is extremely useful in places that don't have trained medical experts.\u003c/p>\n\u003cp>For these long distance operations, doctors often use a low-quality connection to the internet, or even wifi. But \u003ca href=\"http://www.washington.edu/news/2015/05/07/uw-researchers-hack-a-teleoperated-surgical-robot-to-reveal-security-flaws/\">researchers at the University of Washington\u003c/a> proved they could hack into these public communication systems that control teleoperated robots.\u003c/p>\n\u003cp>They accessed the network that controlled the robot and disrupted the signals, making the robot’s movement jerky and difficult to control. And by moving the robotic arms too quickly or beyond a predetermined point they could get the robot to shut down completely.\u003c/p>\n\u003cp>If this had occurred during an actual life-saving procedure the outcome could have been fatal. Fortunately the researchers also figured out ways to encrypt the device—the exact type of precaution the FDA encourages in its new draft guidance.\u003c/p>\n\u003cp>\u003cstrong>Hacker Proves He Can Kill a Patient Through a Drug Pump\u003c/strong>\u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-full wp-image-103164\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125.jpg\" alt=\"FDA_Icon_InfusionPump_160125\" width=\"142\" height=\"142\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125.jpg 142w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-32x32.jpg 32w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-64x64.jpg 64w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-96x96.jpg 96w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-128x128.jpg 128w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-75x75.jpg 75w\" sizes=\"(max-width: 142px) 100vw, 142px\">In 2013 cybersecurity expert \u003ca href=\"https://www.linkedin.com/in/billyrios\">Billy Rios\u003c/a> remotely \u003ca href=\"http://ww2.kqed.org/futureofyou/2015/08/03/millions-of-americans-use-medical-devices-that-are-vulnerable-to-hacking/\">hacked into a Hospira infusion pump\u003c/a>. The pump releases controlled amounts of a substance and can be used to administer insulin to a diabetic or chemotherapy drugs to a cancer patient.\u003c/p>\n\u003cp>They're found in almost every hospital and usually sit next to a patient's bed. Hundreds of them can be monitored and controlled from a central station in the hospital.\u003c/p>\n\u003cp>Rios ordered the pump off of eBay for $100 and was able to figure out the device's pre-programmed password by reading its technical manuals. This information, in conjunction with knowledge about the device's software and what network it was operating on was enough to give him access.\u003c/p>\n\u003cp>He then proved he could remotely administer a lethal dose of drugs through the Hospira pump. Luckily Rios is a benign or \"white hat hacker\" and turned over his findings to the Department of Homeland security. His report galvanized the FDA to \u003ca href=\"http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm456815.htm\">issue its first warning\u003c/a> about a medical device.\u003c/p>\n\u003cp>\u003cstrong>Hackers Demand Ransom for Medical Records\u003c/strong>\u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-full wp-image-103165\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/FDA_Icon_MediaRecords.jpg\" alt=\"FDA_Icon_MediaRecords\" width=\"142\" height=\"142\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords.jpg 142w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-32x32.jpg 32w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-64x64.jpg 64w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-96x96.jpg 96w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-128x128.jpg 128w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-75x75.jpg 75w\" sizes=\"(max-width: 142px) 100vw, 142px\">When \u003ca href=\"http://www.latimes.com/business/la-fi-ucla-medical-data-20150717-story.html\">4.5 million UCLA medical records\u003c/a> and \u003ca href=\"http://www.wsj.com/articles/anthem-hacked-database-included-78-8-million-people-1424807364\">78.8 million Anthem medical records \u003c/a>were hacked it made major headlines.\u003c/p>\n\u003cp>But smaller healthcare organizations aren't immune and one incident, north of Chicago, resembled a bank heist.\u003c/p>\n\u003cp>In 2012, \u003ca href=\"http://www.healthgrades.com/group-directory/il-illinois/libertyville/surgeons-of-lake-county-llc-ooo8pmb\">Surgeons of Lake County\u003c/a>, a small medical practice in Illinois, \u003ca href=\"https://www.send2press.com/newswire/2012-07-0720-001.shtml\">fell victim to a digital data breach\u003c/a>.\u003c/p>\n\u003cp>Hackers accessed the practice's server where e-mails and more than 7,000 electronic medical records were stored. The hackers then encrypted the files and demanded a ransom.\u003c/p>\n\u003cp>The doctors refused to comply and alerted local authorities. They also offered free credit monitoring services to patients following the attack.\u003c/p>\n\u003cp>The medical practice would not discuss the investigation. But the practice issued a press release to alert the public and the Department of Health and Human Services included the hack on its website, which lists \u003ca href=\"https://ocrportal.hhs.gov/ocr/breach/breach_report.jsf\">breaches affecting 500 or more individuals\u003c/a>.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>The good news—the FDA says it hasn't received any reports of fatal cybersecurity breaches, which hospitals and device makers are required to report.\u003c/p>\n\n",
"disqusIdentifier": "100556 http://ww2.kqed.org/futureofyou/?p=100556",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/25/hacked-medical-devices-still-a-big-threat-in-2016/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 813,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 30
},
"modified": 1456895911,
"excerpt": "In the U.S., hackers and security experts have accessed medical records, drug pumps and surgical robots, but the FDA is hoping to prevent this with its new cybersecurity guide.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "In the U.S., hackers and security experts have accessed medical records, drug pumps and surgical robots, but the FDA is hoping to prevent this with its new cybersecurity guide.",
"title": "Hacked Medical Devices Still a Big Threat in 2016 | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Hacked Medical Devices Still a Big Threat in 2016",
"datePublished": "2016-01-25T16:45:23-08:00",
"dateModified": "2016-03-01T21:18:31-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "hacked-medical-devices-still-a-big-threat-in-2016",
"status": "publish",
"path": "/futureofyou/100556/hacked-medical-devices-still-a-big-threat-in-2016",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Hackers aren’t just breaking into email accounts and online banking systems anymore. They’re also exploiting healthcare—going after \u003ca href=\"http://www.latimes.com/business/la-fi-anthem-hack-fallout-20150206-story.html\">electronic medical records\u003c/a>, wifi enabled medical devices and even remotely controlled surgical robots.\u003c/p>\n\u003cp>Medical devices and records have emerged as big cyber security risks. That’s why the \u003ca href=\"http://www.fda.gov/\">Food and Drug Administration\u003c/a> recently proposed \u003ca href=\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm481968.htm\">new guidelines\u003c/a> for how medical device manufacturers should secure their products.\u003c/p>\n\u003cp>Among the FDA's recommendations, manufacturers are being asked to:\u003c/p>\n\u003cul>\n\u003cli>Develop a risk management program that includes a plan for when a vulnerability is discovered.\u003c/li>\n\u003cli>Write disclosure policies, so hospitals and patients understand which aspects of a device may be less secure.\u003c/li>\n\u003cli>Release regular software and hardware updates for medical devices after they’re on the market.\u003c/li>\n\u003c/ul>\n\u003cp>\u003cstrong>\u003cem>[Scroll down to see three real life cyber security attacks] \u003c/em>\u003c/strong>\u003c/p>\n\u003cp>But security experts, like \u003ca href=\"https://www.schneier.com/\">Bruce Schneier\u003c/a>, say non-legally binding guidelines are just not enough.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"It's basically industry best practice,\" says Schneier. \"But without enforcement, it's just pleading.\"\u003c/p>\n\u003cp>Critics are concerned that the responsibility is still primarily left up to manufacturers to disclose when a device has been hacked.\u003c/p>\n\u003cp>Consumer Watchdog president Jamie Court says recommendations are not enough and we won't see new laws until public officials are affected. \"All its gonna take is one congressman’s defibrillator being hacked and we’ll have some new laws really quickly,\" according to Court.\u003c/p>\n\u003cp>The FDA is \u003ca href=\"https://www.federalregister.gov/articles/2016/01/22/2016-01172/postmarket-management-of-cybersecurity-in-medical-devices-draft-guidance-for-industry-and-food-and\">taking public comments\u003c/a> on its \u003ca href=\"http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM482022.pdf\">guidelines\u003c/a> until April 21.\u003c/p>\n\u003cp>Read on to see three real life situations the FDA guidance is designed to prevent.\u003c/p>\n\u003cp>\u003cstrong>Security Experts Hack a Surgical Robot\u003c/strong>\u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-full wp-image-103162\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot.jpg\" alt=\"FDA_Icon_SurgicalRobot\" width=\"142\" height=\"142\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot.jpg 142w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-32x32.jpg 32w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-64x64.jpg 64w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-96x96.jpg 96w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-128x128.jpg 128w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_SurgicalRobot-75x75.jpg 75w\" sizes=\"(max-width: 142px) 100vw, 142px\">Remote surgery—where a surgeon in one location controls a medical robot in another—is extremely useful in places that don't have trained medical experts.\u003c/p>\n\u003cp>For these long distance operations, doctors often use a low-quality connection to the internet, or even wifi. But \u003ca href=\"http://www.washington.edu/news/2015/05/07/uw-researchers-hack-a-teleoperated-surgical-robot-to-reveal-security-flaws/\">researchers at the University of Washington\u003c/a> proved they could hack into these public communication systems that control teleoperated robots.\u003c/p>\n\u003cp>They accessed the network that controlled the robot and disrupted the signals, making the robot’s movement jerky and difficult to control. And by moving the robotic arms too quickly or beyond a predetermined point they could get the robot to shut down completely.\u003c/p>\n\u003cp>If this had occurred during an actual life-saving procedure the outcome could have been fatal. Fortunately the researchers also figured out ways to encrypt the device—the exact type of precaution the FDA encourages in its new draft guidance.\u003c/p>\n\u003cp>\u003cstrong>Hacker Proves He Can Kill a Patient Through a Drug Pump\u003c/strong>\u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-full wp-image-103164\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125.jpg\" alt=\"FDA_Icon_InfusionPump_160125\" width=\"142\" height=\"142\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125.jpg 142w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-32x32.jpg 32w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-64x64.jpg 64w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-96x96.jpg 96w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-128x128.jpg 128w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_InfusionPump_160125-75x75.jpg 75w\" sizes=\"(max-width: 142px) 100vw, 142px\">In 2013 cybersecurity expert \u003ca href=\"https://www.linkedin.com/in/billyrios\">Billy Rios\u003c/a> remotely \u003ca href=\"http://ww2.kqed.org/futureofyou/2015/08/03/millions-of-americans-use-medical-devices-that-are-vulnerable-to-hacking/\">hacked into a Hospira infusion pump\u003c/a>. The pump releases controlled amounts of a substance and can be used to administer insulin to a diabetic or chemotherapy drugs to a cancer patient.\u003c/p>\n\u003cp>They're found in almost every hospital and usually sit next to a patient's bed. Hundreds of them can be monitored and controlled from a central station in the hospital.\u003c/p>\n\u003cp>Rios ordered the pump off of eBay for $100 and was able to figure out the device's pre-programmed password by reading its technical manuals. This information, in conjunction with knowledge about the device's software and what network it was operating on was enough to give him access.\u003c/p>\n\u003cp>He then proved he could remotely administer a lethal dose of drugs through the Hospira pump. Luckily Rios is a benign or \"white hat hacker\" and turned over his findings to the Department of Homeland security. His report galvanized the FDA to \u003ca href=\"http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm456815.htm\">issue its first warning\u003c/a> about a medical device.\u003c/p>\n\u003cp>\u003cstrong>Hackers Demand Ransom for Medical Records\u003c/strong>\u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-full wp-image-103165\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/FDA_Icon_MediaRecords.jpg\" alt=\"FDA_Icon_MediaRecords\" width=\"142\" height=\"142\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords.jpg 142w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-32x32.jpg 32w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-64x64.jpg 64w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-96x96.jpg 96w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-128x128.jpg 128w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/FDA_Icon_MediaRecords-75x75.jpg 75w\" sizes=\"(max-width: 142px) 100vw, 142px\">When \u003ca href=\"http://www.latimes.com/business/la-fi-ucla-medical-data-20150717-story.html\">4.5 million UCLA medical records\u003c/a> and \u003ca href=\"http://www.wsj.com/articles/anthem-hacked-database-included-78-8-million-people-1424807364\">78.8 million Anthem medical records \u003c/a>were hacked it made major headlines.\u003c/p>\n\u003cp>But smaller healthcare organizations aren't immune and one incident, north of Chicago, resembled a bank heist.\u003c/p>\n\u003cp>In 2012, \u003ca href=\"http://www.healthgrades.com/group-directory/il-illinois/libertyville/surgeons-of-lake-county-llc-ooo8pmb\">Surgeons of Lake County\u003c/a>, a small medical practice in Illinois, \u003ca href=\"https://www.send2press.com/newswire/2012-07-0720-001.shtml\">fell victim to a digital data breach\u003c/a>.\u003c/p>\n\u003cp>Hackers accessed the practice's server where e-mails and more than 7,000 electronic medical records were stored. The hackers then encrypted the files and demanded a ransom.\u003c/p>\n\u003cp>The doctors refused to comply and alerted local authorities. They also offered free credit monitoring services to patients following the attack.\u003c/p>\n\u003cp>The medical practice would not discuss the investigation. But the practice issued a press release to alert the public and the Department of Health and Human Services included the hack on its website, which lists \u003ca href=\"https://ocrportal.hhs.gov/ocr/breach/breach_report.jsf\">breaches affecting 500 or more individuals\u003c/a>.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>The good news—the FDA says it hasn't received any reports of fatal cybersecurity breaches, which hospitals and device makers are required to report.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/100556/hacked-medical-devices-still-a-big-threat-in-2016",
"authors": [
"5432"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_508",
"futureofyou_38",
"futureofyou_509",
"futureofyou_80",
"futureofyou_510"
],
"featImg": "futureofyou_103139",
"label": "futureofyou"
},
"futureofyou_100995": {
"type": "posts",
"id": "futureofyou_100995",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "100995",
"score": null,
"sort": [
1453424422000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1453424422,
"format": "standard",
"disqusTitle": "Lumosity CEO Admits Brain-Training Games May Not Ward Off Mental Decline",
"title": "Lumosity CEO Admits Brain-Training Games May Not Ward Off Mental Decline",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>Lumos Labs CEO Steve Berkowitz says his company is no longer making claims that its suite of cognitive training games can make your brain healthier. In fact, he admits \"the jury is still out\" on the efficacy of so-called brain-training.\u003c/p>\n\u003cp>\"We're not out there saying that there are direct benefits to it. We're not out there saying anything other than, 'Hey you know, this is something, give it a try.' \"\u003c/p>\n\u003caside class=\"pullquote alignright\">\"We're not out there saying anything other than, 'Hey you know, this is something, give it a try.' \"\u003c/aside>\n\u003cp>Lumos, based in San Francisco, was recently slammed by the Federal Trade Commission for deceptive advertising. \"Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” the FTC said. “But Lumosity simply did not have the science to back up its ads.”\u003c/p>\n\u003cp>[contextly_sidebar id=\"pkXcCDOpysj05BqIY91OSL0YKzMO6UeP\"]Berkowitz's comments came in an interview with KQED Wednesday, a couple of weeks after the FTC announced Lumos would pay a $2 million penalty that would go to partial refunds to Lumosity customers. These users pay $14.95 per month or $299.95 per year to play games intended to improve memory, attention and other cognitive abilities, as well as potentially ward off maladies of aging like dementia.\u003c/p>\n\u003cp>The CEO said the company had \"pivoted\" to becoming a research platform for the study of cognitive training and that it wanted to put together a coalition of stakeholders in industry and academia to create guidelines and standards for future studies in the field.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\"The foundation of all of this stuff is that it's new,\" he said. \"Any new industry is divisive and creates debate. And I think that's the good news about innovation.\"\u003c/p>\n\u003cp>\u003cstrong>Lumosity: Rapid Growth ... and Controversial\u003c/strong>\u003c/p>\n\u003cp>A little history:\u003c/p>\n\u003cp>Lumos Labs was founded in 2005 by \u003ca href=\"http://techcrunch.com/2013/04/03/founder-stories-lumositys-mike-scanlon-on-exercising-the-brain/\" target=\"_blank\">Michael Scanlon\u003c/a>, a Stanford Ph.D. student in neuroscience, David Drescher and Kunal Sarkar.\u003c/p>\n\u003cp>The idea was to create an online training program for your brain, leveraging research in \u003ca href=\"https://www.google.com/search?q=neuroplasticity\" target=\"_blank\">neuroplasticity \u003c/a>-- the mutable quality of the brain -- that showed the possibility of enhanced cognition through changing environment. In 2007, the company launched Lumosity, a website where you could exercise your brain by playing games and -- so its advertising went -- improve your memory, attention and other mental abilities.\u003c/p>\n\u003cp>By 2013, the company had \u003ca href=\"http://www.forbes.com/companies/lumosity/\" target=\"_blank\">made it onto Forbes’ list\u003c/a> of America’s Most Promising Companies, capitalizing on a brain-training \u003ca href=\"http://usatoday30.usatoday.com/tech/products/story/2011-08-24/Brain-training-games-are-new-exercise-craze/50125152/1\" target=\"_blank\">craze \u003c/a>and earning rave reviews in the \u003ca href=\"http://www.inc.com/magazine/201312/robin-schatz/from-research-lab-to-market-leader-in-no-time.html\" target=\"_blank\">business press\u003c/a>. In 2014, CNN Health \u003ca href=\"http://www.cnn.com/2014/09/09/health/brain-training-apps/\" target=\"_blank\">published a report\u003c/a> that rated Lumosity the best app to train your brain. More than 70 million people in 182 countries have played its games, Lumosity says.\u003c/p>\n\u003cp>As it grew, the company marketed itself on TV, radio and online. (In fact, the public radio audience has been one of its target audiences, as listeners can attest.) The general thrust of the ads was that Lumosity could “improve key skills and affect quality of life\" and that “healthy people have (used) brain training to sharpen their daily lives and ward off cognitive decline.” It published “success stories” on its website, including wide-eyed testimonials like this:\u003c/p>\n\u003cp>“In 2007, we learned that my mother had early onset Alzheimer’s. I joined Lumosity at first for my mother. I now use this site not only for her, but for my brain as well.”\u003c/p>\n\u003cp>Not everyone was on board. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/22708717\" target=\"_blank\">Researchers \u003c/a>studying the topic found \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/22708717\" target=\"_blank\">little to no evidence\u003c/a> of sustained cognitive benefits from such exercises. Some studies determined they did \u003ca href=\"http://www.sciencedirect.com/science/article/pii/S0160289612000839\" target=\"_blank\">little more\u003c/a> than improve an ability to perform the narrow task a player was accessing in each game. In 2014, the Stanford Center on Longevity issued “\u003ca href=\"http://longevity3.stanford.edu/blog/2014/10/15/the-consensus-on-the-brain-training-industry-from-the-scientific-community-2/\" target=\"_blank\">A Consensus on the Brain Training Industry From the Scientific Community\u003c/a>,” signed by dozens of scientists in the field.\u003c/p>\n\u003cp>“To date, there is little evidence that playing brain games improves underlying broad cognitive abilities,” the analysis said, “or that it enables one to better navigate a complex realm of everyday life.\"\u003c/p>\n\u003cp>Currently, many researchers believe that although brain-training companies have greatly exaggerated the benefits of their products, \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/15/lumosity-cant-prove-claims-say-scientists-but-brain-training-worth-researching/\" target=\"_blank\">further study in the field is warranted\u003c/a>.\u003c/p>\n\u003cp>But the government did not feel the need to wait for the final verdict. It wanted Lumos to pay $50 million in redress, but \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/05/federal-court-orders-lumosity-to-stop-claiming-games-prevent-dementia/\" target=\"_blank\">settled for $2 million\u003c/a> after reviewing the company's finances. It also required Lumosity to notify customers it had settled “a deceptive advertising lawsuit” and provide a link to turn off auto-renewal of subscriptions.\u003c/p>\n\u003cp>\u003cstrong>'Passionate About the Product'\u003c/strong>\u003c/p>\n\u003cp>In the interview Wednesday, Berkowitz, who has only been on the job since November, seemed eager to distance the company from the controversial claims it has made in the past, and also renounce any notion that a product like Lumosity could be a panacea for the brain's inevitable decline.\u003c/p>\n\u003cp>\"It's never been a driver of this company, to be some health-related solution,” Berkowitz said. “As we go back and look at the kind of reasons why we're building the product, it really is to bring the idea of science back out to people.”\u003c/p>\n\u003cp>He said the type of hyperbolic language the FTC cited had been removed in 2014, before the FTC was involved, and was in any event \"a very small piece\" of the company's marketing. He likened the customer testimonials to which the FTC objected (you can \u003ca href=\"https://web.archive.org/web/20130112214959/http://www.lumosity.com/why-lumosity/success-stories\" target=\"_blank\">still see some of those here\u003c/a>, on the Internet Archive's WayBack Machine) to the user-generated reviews on Apple's App Store or Google Play.\u003c/p>\n\u003cp>\"These are things run by those companies and are independent,\" he said.\u003c/p>\n\u003cp>But didn't Lumosity choose to publish those particular testimonials?\u003c/p>\n\u003cp>\"It was on the website. So if you call it choosing to run it, yeah. Today, they're not up there.\"\u003c/p>\n\u003cp>The FTC also slammed Lumosity for soliciting users' success stories by offering prizes, without disclosing this fact on its site. Berkowitz attributed such problematic marketing decisions to growing pains.\u003c/p>\n\u003cp>\"As a young company, what you're doing, people are very passionate about the product,\" he said. Now \"we're focusing on making sure that the things that we're doing have a basis in fact.\"\u003c/p>\n\u003cp>As to the question of how many of his customers had availed themselves of the FTC-mandated option to cancel their auto-renewal, he said, \"We've had some, but I think nothing's been outside of our expectation.\"\u003c/p>\n\u003cp>Last August, market research firm MarketsandMarkets \u003ca href=\"http://www.marketsandmarkets.com/Market-Reports/cognitive-assessment-market-1039.html\" target=\"_blank\">predicted\u003c/a> that the cognitive assessment and training market will grow from $2.4 billion in 2015 to $7.5 billion by 2020.\u003c/p>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>Whether that number will have to be reassessed due to consumer doubt is anyone's guess.\u003c/p>\n\n",
"disqusIdentifier": "100995 http://ww2.kqed.org/futureofyou/?p=100995",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/21/lumosity-ceo-admits-brain-training-games-may-produce-no-direct-benefits/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 1199,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 31
},
"modified": 1453504687,
"excerpt": "After company's $2 million settlement with the FTC for deceptive advertising, Steve Berkowitz says Lumosity focused on becoming research platform.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "After company's $2 million settlement with the FTC for deceptive advertising, Steve Berkowitz says Lumosity focused on becoming research platform.",
"title": "Lumosity CEO Admits Brain-Training Games May Not Ward Off Mental Decline | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Lumosity CEO Admits Brain-Training Games May Not Ward Off Mental Decline",
"datePublished": "2016-01-21T17:00:22-08:00",
"dateModified": "2016-01-22T15:18:07-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "lumosity-ceo-admits-brain-training-games-may-produce-no-direct-benefits",
"status": "publish",
"path": "/futureofyou/100995/lumosity-ceo-admits-brain-training-games-may-produce-no-direct-benefits",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Lumos Labs CEO Steve Berkowitz says his company is no longer making claims that its suite of cognitive training games can make your brain healthier. In fact, he admits \"the jury is still out\" on the efficacy of so-called brain-training.\u003c/p>\n\u003cp>\"We're not out there saying that there are direct benefits to it. We're not out there saying anything other than, 'Hey you know, this is something, give it a try.' \"\u003c/p>\n\u003caside class=\"pullquote alignright\">\"We're not out there saying anything other than, 'Hey you know, this is something, give it a try.' \"\u003c/aside>\n\u003cp>Lumos, based in San Francisco, was recently slammed by the Federal Trade Commission for deceptive advertising. \"Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” the FTC said. “But Lumosity simply did not have the science to back up its ads.”\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003c/p>\u003cp>Berkowitz's comments came in an interview with KQED Wednesday, a couple of weeks after the FTC announced Lumos would pay a $2 million penalty that would go to partial refunds to Lumosity customers. These users pay $14.95 per month or $299.95 per year to play games intended to improve memory, attention and other cognitive abilities, as well as potentially ward off maladies of aging like dementia.\u003c/p>\n\u003cp>The CEO said the company had \"pivoted\" to becoming a research platform for the study of cognitive training and that it wanted to put together a coalition of stakeholders in industry and academia to create guidelines and standards for future studies in the field.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"The foundation of all of this stuff is that it's new,\" he said. \"Any new industry is divisive and creates debate. And I think that's the good news about innovation.\"\u003c/p>\n\u003cp>\u003cstrong>Lumosity: Rapid Growth ... and Controversial\u003c/strong>\u003c/p>\n\u003cp>A little history:\u003c/p>\n\u003cp>Lumos Labs was founded in 2005 by \u003ca href=\"http://techcrunch.com/2013/04/03/founder-stories-lumositys-mike-scanlon-on-exercising-the-brain/\" target=\"_blank\">Michael Scanlon\u003c/a>, a Stanford Ph.D. student in neuroscience, David Drescher and Kunal Sarkar.\u003c/p>\n\u003cp>The idea was to create an online training program for your brain, leveraging research in \u003ca href=\"https://www.google.com/search?q=neuroplasticity\" target=\"_blank\">neuroplasticity \u003c/a>-- the mutable quality of the brain -- that showed the possibility of enhanced cognition through changing environment. In 2007, the company launched Lumosity, a website where you could exercise your brain by playing games and -- so its advertising went -- improve your memory, attention and other mental abilities.\u003c/p>\n\u003cp>By 2013, the company had \u003ca href=\"http://www.forbes.com/companies/lumosity/\" target=\"_blank\">made it onto Forbes’ list\u003c/a> of America’s Most Promising Companies, capitalizing on a brain-training \u003ca href=\"http://usatoday30.usatoday.com/tech/products/story/2011-08-24/Brain-training-games-are-new-exercise-craze/50125152/1\" target=\"_blank\">craze \u003c/a>and earning rave reviews in the \u003ca href=\"http://www.inc.com/magazine/201312/robin-schatz/from-research-lab-to-market-leader-in-no-time.html\" target=\"_blank\">business press\u003c/a>. In 2014, CNN Health \u003ca href=\"http://www.cnn.com/2014/09/09/health/brain-training-apps/\" target=\"_blank\">published a report\u003c/a> that rated Lumosity the best app to train your brain. More than 70 million people in 182 countries have played its games, Lumosity says.\u003c/p>\n\u003cp>As it grew, the company marketed itself on TV, radio and online. (In fact, the public radio audience has been one of its target audiences, as listeners can attest.) The general thrust of the ads was that Lumosity could “improve key skills and affect quality of life\" and that “healthy people have (used) brain training to sharpen their daily lives and ward off cognitive decline.” It published “success stories” on its website, including wide-eyed testimonials like this:\u003c/p>\n\u003cp>“In 2007, we learned that my mother had early onset Alzheimer’s. I joined Lumosity at first for my mother. I now use this site not only for her, but for my brain as well.”\u003c/p>\n\u003cp>Not everyone was on board. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/22708717\" target=\"_blank\">Researchers \u003c/a>studying the topic found \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/22708717\" target=\"_blank\">little to no evidence\u003c/a> of sustained cognitive benefits from such exercises. Some studies determined they did \u003ca href=\"http://www.sciencedirect.com/science/article/pii/S0160289612000839\" target=\"_blank\">little more\u003c/a> than improve an ability to perform the narrow task a player was accessing in each game. In 2014, the Stanford Center on Longevity issued “\u003ca href=\"http://longevity3.stanford.edu/blog/2014/10/15/the-consensus-on-the-brain-training-industry-from-the-scientific-community-2/\" target=\"_blank\">A Consensus on the Brain Training Industry From the Scientific Community\u003c/a>,” signed by dozens of scientists in the field.\u003c/p>\n\u003cp>“To date, there is little evidence that playing brain games improves underlying broad cognitive abilities,” the analysis said, “or that it enables one to better navigate a complex realm of everyday life.\"\u003c/p>\n\u003cp>Currently, many researchers believe that although brain-training companies have greatly exaggerated the benefits of their products, \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/15/lumosity-cant-prove-claims-say-scientists-but-brain-training-worth-researching/\" target=\"_blank\">further study in the field is warranted\u003c/a>.\u003c/p>\n\u003cp>But the government did not feel the need to wait for the final verdict. It wanted Lumos to pay $50 million in redress, but \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/05/federal-court-orders-lumosity-to-stop-claiming-games-prevent-dementia/\" target=\"_blank\">settled for $2 million\u003c/a> after reviewing the company's finances. It also required Lumosity to notify customers it had settled “a deceptive advertising lawsuit” and provide a link to turn off auto-renewal of subscriptions.\u003c/p>\n\u003cp>\u003cstrong>'Passionate About the Product'\u003c/strong>\u003c/p>\n\u003cp>In the interview Wednesday, Berkowitz, who has only been on the job since November, seemed eager to distance the company from the controversial claims it has made in the past, and also renounce any notion that a product like Lumosity could be a panacea for the brain's inevitable decline.\u003c/p>\n\u003cp>\"It's never been a driver of this company, to be some health-related solution,” Berkowitz said. “As we go back and look at the kind of reasons why we're building the product, it really is to bring the idea of science back out to people.”\u003c/p>\n\u003cp>He said the type of hyperbolic language the FTC cited had been removed in 2014, before the FTC was involved, and was in any event \"a very small piece\" of the company's marketing. He likened the customer testimonials to which the FTC objected (you can \u003ca href=\"https://web.archive.org/web/20130112214959/http://www.lumosity.com/why-lumosity/success-stories\" target=\"_blank\">still see some of those here\u003c/a>, on the Internet Archive's WayBack Machine) to the user-generated reviews on Apple's App Store or Google Play.\u003c/p>\n\u003cp>\"These are things run by those companies and are independent,\" he said.\u003c/p>\n\u003cp>But didn't Lumosity choose to publish those particular testimonials?\u003c/p>\n\u003cp>\"It was on the website. So if you call it choosing to run it, yeah. Today, they're not up there.\"\u003c/p>\n\u003cp>The FTC also slammed Lumosity for soliciting users' success stories by offering prizes, without disclosing this fact on its site. Berkowitz attributed such problematic marketing decisions to growing pains.\u003c/p>\n\u003cp>\"As a young company, what you're doing, people are very passionate about the product,\" he said. Now \"we're focusing on making sure that the things that we're doing have a basis in fact.\"\u003c/p>\n\u003cp>As to the question of how many of his customers had availed themselves of the FTC-mandated option to cancel their auto-renewal, he said, \"We've had some, but I think nothing's been outside of our expectation.\"\u003c/p>\n\u003cp>Last August, market research firm MarketsandMarkets \u003ca href=\"http://www.marketsandmarkets.com/Market-Reports/cognitive-assessment-market-1039.html\" target=\"_blank\">predicted\u003c/a> that the cognitive assessment and training market will grow from $2.4 billion in 2015 to $7.5 billion by 2020.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Whether that number will have to be reassessed due to consumer doubt is anyone's guess.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/100995/lumosity-ceo-admits-brain-training-games-may-produce-no-direct-benefits",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_692",
"futureofyou_596",
"futureofyou_80",
"futureofyou_691",
"futureofyou_720",
"futureofyou_721"
],
"featImg": "futureofyou_100997",
"label": "futureofyou_54"
},
"futureofyou_100084": {
"type": "posts",
"id": "futureofyou_100084",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "100084",
"score": null,
"sort": [
1453252903000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1453252903,
"format": "standard",
"disqusTitle": "Five Criticisms of Obama and Biden's 'Cancer Moonshot'",
"title": "Five Criticisms of Obama and Biden's 'Cancer Moonshot'",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>Vice President Joe Biden \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/19/cancer-moonshot-video-replay-of-davos-roundtable/\" target=\"_blank\">convened a panel of cancer research experts \u003c/a>today at the Davos World Economic Forum, the culmination of a week's worth of discussion and media coverage since President Obama announced \u003ca href=\"http://thehill.com/policy/healthcare/265671-obama-launches-effort-to-cure-cancer-once-and-for-all\" target=\"_blank\">during his State of the Union address\u003c/a> that he would put Biden \"in charge of mission control\" for a cancer moonshot -- a national initiative to cure the disease (or rather, group of diseases), which the American Cancer Society \u003ca href=\"http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/\" target=\"_blank\">projected would kill more than 589,000 Americans\u003c/a> in 2015 alone.\u003c/p>\n\u003cp>To be sure, there's been much \u003ca href=\"http://www.cnn.com/2016/01/14/health/brawley-obamas-cancer-moonshot-save-lives/\" target=\"_blank\">excitement\u003c/a> and \u003ca href=\"http://www.theguardian.com/us-news/2016/jan/14/cancer-cure-joe-biden-medical-research\" target=\"_blank\">optimism\u003c/a> about a well-funded national commitment for a cure. And the \u003ca href=\"https://www.washingtonpost.com/politics/2015/05/30/e1ac5a2a-0731-11e5-a428-c984eb077d4e_story.html\" target=\"_blank\">death last year of the vice president's son\u003c/a>, Beau Biden, from brain cancer has brought to the effort a high-profile reminder of the toll cancer takes on so many lives.\u003c/p>\n\u003cp>However, the initiative is not completely without its skeptics. Here are extracts from five criticisms around the web:\u003c/p>\n\u003cul>\n\u003cli>\u003ca href=\"http://www.nytimes.com/2016/01/14/health/moonshot-to-cure-cancer-to-be-led-by-biden-relies-on-outmoded-view-of-disease.html\" target=\"_blank\">‘Moonshot’ to Cure Cancer, to Be Led by Biden, Relies on Outmoded View of Disease\u003c/a> (NY Times)\u003cbr>\n\u003cblockquote>\u003cp>While Mr. Biden’s focus has already made some meaningful difference — he negotiated with Republican congressional leaders a $264 million increase in funding for the National Cancer Institute, the largest in a decade for an agency that has been squeezed by static budgets in recent years — the chances of reaching a moment of victory as the analogy “moonshot” suggests seem entirely unrealistic.\u003c/p>\n\u003cp>“This is not about getting to one point in a certain period of time,” said Dr. Harold Varmus, a Nobel laureate and former director of the National Cancer Institute.\u003c/p>\n\u003cp>Unlike in 1971, when President Nixon launched his cancer war, researchers now understand that cancer is not one disease but essentially hundreds. The very notion of a single cure — or as Mr. Obama put it, making “America the country that cures cancer once and for all” — is misleading and outdated.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.businessinsider.com/obama-cancer-moonshot-is-misinformed-2016-1\" target=\"_blank\">There's a worrisome problem with Obama's 'moonshot for cancer' plan\u003c/a> (Business Insider)\u003cbr>\n\u003cblockquote>\u003cp>Cancer is different from many genetic diseases, such as sickle cell or Huntington's, in that it is not linked with a few specific, identifiable genes. Instead it is the result of a whole bunch of mutations, tens of hundreds of tiny twists and pinches in our genes. These mutations are constantly changing and evolving, becoming increasingly resistant to our drugs. And genetics, of course, is not the only cause of cancer — environmental and behavioral factors matter. ...\u003c/p>\n\u003cp>To say each cancer tumor is unique would be an understatement. \"Virtually every tumor looks different from every other tumor,\" Varmus said. That makes designing drugs to beat them difficult. Many new treatments work only for a tiny subsection of patients, those with a specific subtype of one particular kind of cancer. These are exciting developments, but they don't begin to move the needle on treating — not to mention curing — cancer as a whole.\u003ca target=\"_blank\"> \u003c/a>\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.macleans.ca/politics/washington/is-obamas-plan-to-cure-cancer-a-moonshot-or-a-pluto-shot/\" target=\"_blank\">Is Obama’s plan to cure cancer a ‘moonshot’? Or a ‘Pluto-shot’?\u003c/a>(Maclean's)\u003cbr>\n\u003cblockquote>\u003cp>New thinking suggests that seeking to “cure” or eradicate cancer is misbegotten. In his acclaimed 2013 book The Cancer Chronicles: Unlocking Medicine’s Deepest Mystery, George Johnson writes that decades of research have forced scientists to reconcile themselves to the paradox that most cancers result from the very cellular activities that support life, not only from destructive environmental culprits like cigarette smoke and UV rays. That means fixing the mechanisms that underlie cancer would also disrupt the cellular functions that keep us alive and evolving. Cancers in children tend to include fewer mutations, which make them more curable, Johnson writes. That’s not the case for cancers in older patients which are believed to result from the accumulation of many mutations over time. Johnson’s conclusion upends the orthodoxy underlying an entrenched cancer treatment complex worth $100 billion globally: “The best response might not be to fight back with chemotherapy and radiation, increasing the stress,” Johnson writes, “but to somehow maintain the exuberant cells—the tumor—in a quiescent state, something that can be lived with.”\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://time.com/4178742/cancer-moonshot-obama/\" target=\"_blank\">Why Curing Cancer Is Not a ‘Moonshot’\u003c/a> (Time)\u003cbr>\n\u003cblockquote>\u003cp>Scientists have long known cancer isn’t one disease—it’s perhaps 100 or more, with the number growing as different types and sub-types are better understood. Making things worse, there will be perhaps 1.6 million Americans diagnosed with cancer in the U.S. alone this year, and each of those cases will be in some ways unique. That’s part of the reason two people with the same kind of cancer diagnosed at the same stage and receiving the same treatment can have radically different outcomes.\u003c/p>\n\u003cp>Actually “curing cancer”—in the larger global sense of simply wiping it out—would require personalized care, designed around every single patient with any single type of the disease. And in order to administer that kind of tailored care to every single person diagnosed with cancer, a whole lot more research is going to be needed. That may not be an unattainable goal—but it’s a devilishly complicated one.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\n\u003cblockquote>\u003cp>\u003ca href=\"http://arstechnica.com/science/2016/01/dear-mr-president-please-stop-with-these-science-moonshots/\" target=\"_blank\">Dear Mr. President: Please stop with these science “moonshots”\u003c/a> (Ars Technica) Nebulous concepts like \"end all cancer\" get good applause—curing all cancers is right up there with sunshine and puppies. But such concepts are effectively meaningless. Richard Nixon declared a war on cancer back in 1971. The National Cancer Institute is the largest of all NIH institutes and in Fiscal Year 2016 its budget is $5.1 billion (out of NIH's total of $31 billion). Is the implication that that money is just being wasted right now? That it was insufficient all along, and nobody cared or realized?\"\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003c/ul>\n\u003cp>[ad fullwidth]\u003c/p>\u003cp>\u003c/p>\n",
"disqusIdentifier": "100084 http://ww2.kqed.org/futureofyou/?p=100084",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/19/five-criticisms-of-obama-and-bidens-cancer-moonshot/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 989,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 14
},
"modified": 1453252964,
"excerpt": "There's much excitement about a national commitment for a cancer cure. But there are skeptics, as well.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "There's much excitement about a national commitment for a cancer cure. But there are skeptics, as well.",
"title": "Five Criticisms of Obama and Biden's 'Cancer Moonshot' | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Five Criticisms of Obama and Biden's 'Cancer Moonshot'",
"datePublished": "2016-01-19T17:21:43-08:00",
"dateModified": "2016-01-19T17:22:44-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "five-criticisms-of-obama-and-bidens-cancer-moonshot",
"status": "publish",
"path": "/futureofyou/100084/five-criticisms-of-obama-and-bidens-cancer-moonshot",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Vice President Joe Biden \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/19/cancer-moonshot-video-replay-of-davos-roundtable/\" target=\"_blank\">convened a panel of cancer research experts \u003c/a>today at the Davos World Economic Forum, the culmination of a week's worth of discussion and media coverage since President Obama announced \u003ca href=\"http://thehill.com/policy/healthcare/265671-obama-launches-effort-to-cure-cancer-once-and-for-all\" target=\"_blank\">during his State of the Union address\u003c/a> that he would put Biden \"in charge of mission control\" for a cancer moonshot -- a national initiative to cure the disease (or rather, group of diseases), which the American Cancer Society \u003ca href=\"http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/\" target=\"_blank\">projected would kill more than 589,000 Americans\u003c/a> in 2015 alone.\u003c/p>\n\u003cp>To be sure, there's been much \u003ca href=\"http://www.cnn.com/2016/01/14/health/brawley-obamas-cancer-moonshot-save-lives/\" target=\"_blank\">excitement\u003c/a> and \u003ca href=\"http://www.theguardian.com/us-news/2016/jan/14/cancer-cure-joe-biden-medical-research\" target=\"_blank\">optimism\u003c/a> about a well-funded national commitment for a cure. And the \u003ca href=\"https://www.washingtonpost.com/politics/2015/05/30/e1ac5a2a-0731-11e5-a428-c984eb077d4e_story.html\" target=\"_blank\">death last year of the vice president's son\u003c/a>, Beau Biden, from brain cancer has brought to the effort a high-profile reminder of the toll cancer takes on so many lives.\u003c/p>\n\u003cp>However, the initiative is not completely without its skeptics. Here are extracts from five criticisms around the web:\u003c/p>\n\u003cul>\n\u003cli>\u003ca href=\"http://www.nytimes.com/2016/01/14/health/moonshot-to-cure-cancer-to-be-led-by-biden-relies-on-outmoded-view-of-disease.html\" target=\"_blank\">‘Moonshot’ to Cure Cancer, to Be Led by Biden, Relies on Outmoded View of Disease\u003c/a> (NY Times)\u003cbr>\n\u003cblockquote>\u003cp>While Mr. Biden’s focus has already made some meaningful difference — he negotiated with Republican congressional leaders a $264 million increase in funding for the National Cancer Institute, the largest in a decade for an agency that has been squeezed by static budgets in recent years — the chances of reaching a moment of victory as the analogy “moonshot” suggests seem entirely unrealistic.\u003c/p>\n\u003cp>“This is not about getting to one point in a certain period of time,” said Dr. Harold Varmus, a Nobel laureate and former director of the National Cancer Institute.\u003c/p>\n\u003cp>Unlike in 1971, when President Nixon launched his cancer war, researchers now understand that cancer is not one disease but essentially hundreds. The very notion of a single cure — or as Mr. Obama put it, making “America the country that cures cancer once and for all” — is misleading and outdated.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.businessinsider.com/obama-cancer-moonshot-is-misinformed-2016-1\" target=\"_blank\">There's a worrisome problem with Obama's 'moonshot for cancer' plan\u003c/a> (Business Insider)\u003cbr>\n\u003cblockquote>\u003cp>Cancer is different from many genetic diseases, such as sickle cell or Huntington's, in that it is not linked with a few specific, identifiable genes. Instead it is the result of a whole bunch of mutations, tens of hundreds of tiny twists and pinches in our genes. These mutations are constantly changing and evolving, becoming increasingly resistant to our drugs. And genetics, of course, is not the only cause of cancer — environmental and behavioral factors matter. ...\u003c/p>\n\u003cp>To say each cancer tumor is unique would be an understatement. \"Virtually every tumor looks different from every other tumor,\" Varmus said. That makes designing drugs to beat them difficult. Many new treatments work only for a tiny subsection of patients, those with a specific subtype of one particular kind of cancer. These are exciting developments, but they don't begin to move the needle on treating — not to mention curing — cancer as a whole.\u003ca target=\"_blank\"> \u003c/a>\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.macleans.ca/politics/washington/is-obamas-plan-to-cure-cancer-a-moonshot-or-a-pluto-shot/\" target=\"_blank\">Is Obama’s plan to cure cancer a ‘moonshot’? Or a ‘Pluto-shot’?\u003c/a>(Maclean's)\u003cbr>\n\u003cblockquote>\u003cp>New thinking suggests that seeking to “cure” or eradicate cancer is misbegotten. In his acclaimed 2013 book The Cancer Chronicles: Unlocking Medicine’s Deepest Mystery, George Johnson writes that decades of research have forced scientists to reconcile themselves to the paradox that most cancers result from the very cellular activities that support life, not only from destructive environmental culprits like cigarette smoke and UV rays. That means fixing the mechanisms that underlie cancer would also disrupt the cellular functions that keep us alive and evolving. Cancers in children tend to include fewer mutations, which make them more curable, Johnson writes. That’s not the case for cancers in older patients which are believed to result from the accumulation of many mutations over time. Johnson’s conclusion upends the orthodoxy underlying an entrenched cancer treatment complex worth $100 billion globally: “The best response might not be to fight back with chemotherapy and radiation, increasing the stress,” Johnson writes, “but to somehow maintain the exuberant cells—the tumor—in a quiescent state, something that can be lived with.”\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://time.com/4178742/cancer-moonshot-obama/\" target=\"_blank\">Why Curing Cancer Is Not a ‘Moonshot’\u003c/a> (Time)\u003cbr>\n\u003cblockquote>\u003cp>Scientists have long known cancer isn’t one disease—it’s perhaps 100 or more, with the number growing as different types and sub-types are better understood. Making things worse, there will be perhaps 1.6 million Americans diagnosed with cancer in the U.S. alone this year, and each of those cases will be in some ways unique. That’s part of the reason two people with the same kind of cancer diagnosed at the same stage and receiving the same treatment can have radically different outcomes.\u003c/p>\n\u003cp>Actually “curing cancer”—in the larger global sense of simply wiping it out—would require personalized care, designed around every single patient with any single type of the disease. And in order to administer that kind of tailored care to every single person diagnosed with cancer, a whole lot more research is going to be needed. That may not be an unattainable goal—but it’s a devilishly complicated one.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\n\u003cblockquote>\u003cp>\u003ca href=\"http://arstechnica.com/science/2016/01/dear-mr-president-please-stop-with-these-science-moonshots/\" target=\"_blank\">Dear Mr. President: Please stop with these science “moonshots”\u003c/a> (Ars Technica) Nebulous concepts like \"end all cancer\" get good applause—curing all cancers is right up there with sunshine and puppies. But such concepts are effectively meaningless. Richard Nixon declared a war on cancer back in 1971. The National Cancer Institute is the largest of all NIH institutes and in Fiscal Year 2016 its budget is $5.1 billion (out of NIH's total of $31 billion). Is the implication that that money is just being wasted right now? That it was insufficient all along, and nobody cared or realized?\"\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003c/ul>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\u003cp>\u003c/p>\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/100084/five-criticisms-of-obama-and-bidens-cancer-moonshot",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_713",
"futureofyou_716"
],
"featImg": "futureofyou_100173",
"label": "futureofyou_54"
},
"futureofyou_94815": {
"type": "posts",
"id": "futureofyou_94815",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "94815",
"score": null,
"sort": [
1452924642000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1452924642,
"format": "standard",
"disqusTitle": "Government Slams Lumosity 'Brain Training,' But What Does Research Say?",
"title": "Government Slams Lumosity 'Brain Training,' But What Does Research Say?",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>The company behind the \"brain-training\" program Lumosity settled a complaint by the Federal Trade Commission last week that it engaged in false advertising when it claimed its online games could delay cognitive impairments -- painful indignities of aging like dementia, memory loss and even Alzheimer's.\u003c/p>\n\u003cp>The \u003ca href=\"https://www.ftc.gov/system/files/documents/cases/160105lumoslabsstip.pdf\" target=\"_blank\">agreement\u003c/a> calls for Lumos Labs to cough up $2 million for partial refunds and \"\u003ca href=\"https://www.ftc.gov/system/files/documents/public_statements/903353/160104lumositystatement.pdf\" target=\"_blank\">prohibits deceptive conduct in the future\u003c/a>.\" Lumos also had to inform subscribers it \"decided to settle a deceptive advertising lawsuit\" and -- this one's gotta hurt -- provide customers with a link to turn off automatic subscription renewal.\u003c/p>\n\u003caside class=\"pullquote alignright\">'I think claims these companies have been making — and Lumosity is not alone — have been grossly exaggerated.'\u003ccite>Dr. Laura Carstensen, Stanford University\u003c/cite>\u003c/aside>\n\u003cp>In response to questions about the settlement, Lumos Labs said in a statement: \"We agreed to settle for $2m so we can move on and focus on our mission: Delivering engaging cognitive training products to our 70+ million members, continuing research both in-house and with our partner network of 100+ collaborators, and promoting innovation within the field of cognitive training.\"\u003c/p>\n\u003cp>The statement listed research being done by the company's \u003ca href=\"http://www.lumosity.com/hcp\" target=\"_blank\">Human Cognition Project\u003c/a>, said it is a firm believer in the peer-review process, and suggested people contact independent researchers to evaluate studies by Lumos and others.\u003c/p>\n\u003cp>\u003cstrong>So What \u003cem>Does\u003c/em> the Research Say?\u003c/strong>\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>In 2010, QUEST reporter Amy Standen\u003ca href=\"http://ww2.kqed.org/quest/2010/10/15/when-brains-hit-the-gym-2/\" target=\"_blank\"> talked to several researchers about the efficacy of games\u003c/a> like those offered by Lumosity and Posit Science, advertised as beneficial for improving cognitive ability and a defense against age-related mental decline.\u003c/p>\n\u003cp>“Can you improve your brain so that it’s faster, more adept, more vital?\" Dr. Laura Carstensen, founding director of the \u003ca href=\"http://longevity3.stanford.edu/\" target=\"_blank\">Stanford Center on Longevity\u003c/a>, asked Standen, rhetorically. \"That’s what the claims are, and I don’t think there’s really any evidence for that.\"\u003c/p>\n\u003cp>Dr. Joel Kramer, head of neuropsychology at \u003ca href=\"http://memory.ucsf.edu/\" target=\"_blank\">UCSF’s Memory and Aging Center\u003c/a>, invoked the one word scientists do agree on.\u003c/p>\n\u003cp>“I think that the research thus far demonstrates a much clearer link between exercise and brain health,” he said. (He means physical exercise, not mental strain while sitting.)\u003c/p>\n\u003cp>Okay. That was then, a week before the iPad was released, for crying out loud. What about now, in 2016? Any new developments that may have buttressed the claims of the companies selling these products?\u003c/p>\n\u003cp>Not according to Dr. Carstensen.\u003c/p>\n\u003cp>\"I think claims these companies have been making -- and Lumosity is not alone -- have been grossly exaggerated,\" she said this week. “They’re trying to argue that we’re going to take you out of that active world … and that we’re going to put you in a room alone in front of a computer screen and you’ll play a game that will make you smarter, and you’re going to pay us to do it.”\u003c/p>\n\u003cp>“There is no compelling evidence for that,” she said.\u003c/p>\n\u003cp>This assessment is pretty much in line with the 2014 Stanford Center's critique of the so-called brain-training industry. Called \"\u003ca href=\"http://longevity3.stanford.edu/blog/2014/10/15/the-consensus-on-the-brain-training-industry-from-the-scientific-community-2/\" target=\"_blank\">A Consensus on the Brain Training Industry From the Scientific Community\u003c/a>,\" it was signed by dozens of scientists in the field.\u003c/p>\n\u003cp>\"To date, there is little evidence that playing brain games improves underlying broad cognitive abilities,\" the analysis said, \"or that it enables one to better navigate a complex realm of everyday life.\"\u003c/p>\n\u003cp>\u003cstrong>Get Off the Computer and Onto Your Bike\u003c/strong>\u003c/p>\n\u003cp>Carstensen believes exercise is the only evidence-based activity that will improve cognitive fitness. But even those effects are modest, she said. And most of the studies have been relatively short-term.\u003c/p>\n\u003cp>\"You’re looking at a boost to your cognitive benefit over your baseline after six weeks,\" she said. \"But it’s not huge.”\u003c/p>\n\u003cp>Exercise, however, can help stave off the mental decline that comes with many physical diseases.\u003c/p>\n\u003cp>\"If you get cardiosvascular disease, it’s likely to effect your cognitive functioning,\" she said. \"Getting blood clots means you’re more likely to get a stroke. There’s a lot of evidence that diabetes is related to brain diseases as well.”\u003c/p>\n\u003cp>Physical exercise is \"one of the more reliable approaches,\" agreed Dr. Kramer. He said studies have shown “fairly convincingly\" that people who engage in higher levels of physical activity have less chance of developing dementia.\u003c/p>\n\u003cp>\u003cstrong>The Trouble With Cognitive Training Research\u003c/strong>\u003c/p>\n\u003cp>Many researchers in the field of cognitive science think the studies that have found a positive effect from playing brain-training games -- research often touted by the companies -- have a fundamental problem: The evaluative tests to measure improvement are too similar to the games themselves.\u003c/p>\n\u003cp>[contextly_sidebar id=\"2gnysOx73RyyKbj3eWqtryCdsCPqlRHG\"]“One of the big criticisms of the cognitive training paradigm is this issue of teaching to the test,\" said Dr. Joel Sneed, a professor of medical psychology at Columbia University who has researched the effect of computer cognitive training on depression.\u003c/p>\n\u003cp>“If I give you a test to see if you got better in something like memory, and your game looks a lot like my test,\" he said, \"then you’ve just been taking the test a lot, so you’ve gotten better at the test. But that doesn’t mean you can find your keys or stop yourself from losing your wallet.”\u003c/p>\n\u003cp>In other words, there is no evidence the skills learned through the games will transfer to the skills people use to navigate the real world.\u003c/p>\n\u003cp>Another problem, researchers say, is that the control groups have often not been engaged in any activity.\u003c/p>\n\u003cp>\"A lot of these studies say, 'Come to the lab and play games,' and they compare them to people who don’t do anything,\" said Carstensen.\u003c/p>\n\u003cp>Such inactivity will negatively affect mental performance, she said.\u003c/p>\n\u003cp>Dr. Sneed agreed.\u003c/p>\n\u003cp>“Comparing people who take the training with people who aren’t doing anything is a completely unfair comparison,\" he said.\u003c/p>\n\u003cp>The people doing brain training, Sneed continued, are getting dings and whistles and positive messages onscreen, so researchers don’t know if that’s the reason for improvement or if the training actually works.\u003c/p>\n\u003cp>\u003cstrong>Some Breakthroughs?\u003c/strong>\u003c/p>\n\u003cp>Dr. Murali Doraiswamy of the \u003ca href=\"https://dibs.duke.edu/\" target=\"_blank\">Duke Institute for Brain Sciences\u003c/a>, who was less cynical about the potential of brain fitness games in 2010 , is still hopeful today.\u003c/p>\n\u003cp>“I still believe in the potential of brain training as a therapeutic modality,\" he said in an email, \"but what we need now are long-term randomized trials to prove they can improve daily performance and delay dementia.”\u003c/p>\n\u003cp>Doraiswamy, as well as Dr. Sneed, cited a \u003ca href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557999/\" target=\"_blank\">study published in PLoS One\u003c/a> in September, which was conducted largely by scientists from Lumos Labs and used a methodology aimed at reducing some of the pitfalls of previous research.\u003c/p>\n\u003cp>The study divided 4,715 people into two groups: those who went through a Lumosity program of 49 exercises, and a non-passive control group who solved online crossword puzzles. Both groups completed their activities in one 15-minute session at least five days per week, for 10 weeks.\u003c/p>\n\u003cp>The Lumosity group showed more improvement than the crossword puzzle group on tests measuring memory, problem solving, reasoning, and speed of brain processing. They also showed greater improvement on “self-reported measures of cognitive functioning.”\u003c/p>\n\u003cp>Sneed said having participants do crossword puzzles is “the kind of equivalence you need in order to be able to say something about your games. … You’re able to make a comparison that is way more realistic\" than comparisons made with passive control groups.\u003c/p>\n\u003cp>Carstensen isn't buying it. She said having a control group do crossword puzzles is not equivalent to the game-playing of the treatment group\u003c/p>\n\u003cp>“Crossword puzzles have been shown over and over to have no effects on cognition,\" she said. \"You don’t learn something new when you do crossword puzzles, because you retrieve information you already know.”\u003c/p>\n\u003cp>Another study, commonly called the \u003ca href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055506/\" target=\"_blank\">ACTIVE trial\u003c/a>, was cited by Dr. Kramer as research that showed promise for cognitive brain training.\u003c/p>\n\u003cp>The research was led by Dr. George W. Rebok of Johns Hopkins' \u003ca href=\"http://coah.jhu.edu/about/\" target=\"_blank\">Center on Aging and Health\u003c/a> and includes scientists from 11 institutions, including several affiliated with Posit Science. The study \u003cspan style=\"line-height: 1.5\">looked at 2,832 people who were almost 74 years old on average. Three groups were given 10 training sessions for either memory, reasoning, or speed of processing, then booster sessions 11 and 35 months later. A control group received no treatment.\u003c/span>\u003c/p>\n\u003cp>The study found that 60 percent of the participants who underwent the training reported the same or greater ability to perform the so-called \u003ca href=\"http://www.healthcare.uiowa.edu/igec/tools/function/lawtonbrody.pdf\" target=\"_blank\">instrumental activities of daily living\u003c/a>, such as doing laundry and managing medication, while only 50 percent of the control group did.\u003c/p>\n\u003cp>The study also found that 10 years after the original treatment, those who received training in speed processing and reasoning did better on tests measuring those skills than the control group. The memory training showed no effect.\u003c/p>\n\u003cp>But the study found \"no effect of training or added booster training\" on actual tests, as opposed to self-reports, designed to measure daily cognitive function.\u003c/p>\n\u003cp>\u003cstrong>More Research Needed\u003c/strong>\u003c/p>\n\u003cp>All of the researchers agreed that the advertising claims of companies like Lumosity have not been borne out yet by the research. Dr. Dorasiswamy says the FTC action \"will serve as a broadshot to move the entire field away from marketing-driven claims to science-driven claims.\"\u003c/p>\n\u003cp>Dr. Sneed says more -- and better -- research is needed if the industry wants to uncover the smoking gun that will prove what they're peddling is beneficial.\u003c/p>\n\u003cp>\"Several studies are promising, but you need a large double-blind placebo trial,\" he said.\" You need more than one. And you have to be able to show the effect of doing the treatment generalizes to other cognitive skills.\"\u003c/p>\n\u003cp>Even the Stanford Center for Longevity's \u003ca href=\"http://longevity3.stanford.edu/blog/2014/10/15/the-consensus-on-the-brain-training-industry-from-the-scientific-community-2/\" target=\"_blank\">call-to-arms against the brain-training industry \u003c/a>in 2014 acknowledged that \"some intriguing isolated reports do inspire additional research.\"\u003c/p>\n\u003cp>Dr. Kramer, for his part, thinks that Lumosity and other brain-training games could one day prove beneficial.\u003c/p>\n\u003cp>\"The lack of evidence is not the same as evidence of a lack of efficacy,\" he said. \"There’s still the possibility that Lumosity or other kinds of brain training or cognitive enhancement approaches will have some efficacy.\"\u003c/p>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>\"It just hasn’t been adequately established yet,\" he said.\u003c/p>\n\n",
"disqusIdentifier": "94815 http://ww2.kqed.org/futureofyou/?p=94815",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/15/lumosity-cant-prove-claims-say-scientists-but-brain-training-worth-researching/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 1827,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 56
},
"modified": 1487726017,
"excerpt": "While some research has turned up 'intriguing' results on the efficacy of brain training, the science is a long way from being established.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "While some research has turned up 'intriguing' results on the efficacy of brain training, the science is a long way from being established.",
"title": "Government Slams Lumosity 'Brain Training,' But What Does Research Say? | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Government Slams Lumosity 'Brain Training,' But What Does Research Say?",
"datePublished": "2016-01-15T22:10:42-08:00",
"dateModified": "2017-02-21T17:13:37-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "lumosity-cant-prove-claims-say-scientists-but-brain-training-worth-researching",
"status": "publish",
"path": "/futureofyou/94815/lumosity-cant-prove-claims-say-scientists-but-brain-training-worth-researching",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>The company behind the \"brain-training\" program Lumosity settled a complaint by the Federal Trade Commission last week that it engaged in false advertising when it claimed its online games could delay cognitive impairments -- painful indignities of aging like dementia, memory loss and even Alzheimer's.\u003c/p>\n\u003cp>The \u003ca href=\"https://www.ftc.gov/system/files/documents/cases/160105lumoslabsstip.pdf\" target=\"_blank\">agreement\u003c/a> calls for Lumos Labs to cough up $2 million for partial refunds and \"\u003ca href=\"https://www.ftc.gov/system/files/documents/public_statements/903353/160104lumositystatement.pdf\" target=\"_blank\">prohibits deceptive conduct in the future\u003c/a>.\" Lumos also had to inform subscribers it \"decided to settle a deceptive advertising lawsuit\" and -- this one's gotta hurt -- provide customers with a link to turn off automatic subscription renewal.\u003c/p>\n\u003caside class=\"pullquote alignright\">'I think claims these companies have been making — and Lumosity is not alone — have been grossly exaggerated.'\u003ccite>Dr. Laura Carstensen, Stanford University\u003c/cite>\u003c/aside>\n\u003cp>In response to questions about the settlement, Lumos Labs said in a statement: \"We agreed to settle for $2m so we can move on and focus on our mission: Delivering engaging cognitive training products to our 70+ million members, continuing research both in-house and with our partner network of 100+ collaborators, and promoting innovation within the field of cognitive training.\"\u003c/p>\n\u003cp>The statement listed research being done by the company's \u003ca href=\"http://www.lumosity.com/hcp\" target=\"_blank\">Human Cognition Project\u003c/a>, said it is a firm believer in the peer-review process, and suggested people contact independent researchers to evaluate studies by Lumos and others.\u003c/p>\n\u003cp>\u003cstrong>So What \u003cem>Does\u003c/em> the Research Say?\u003c/strong>\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>In 2010, QUEST reporter Amy Standen\u003ca href=\"http://ww2.kqed.org/quest/2010/10/15/when-brains-hit-the-gym-2/\" target=\"_blank\"> talked to several researchers about the efficacy of games\u003c/a> like those offered by Lumosity and Posit Science, advertised as beneficial for improving cognitive ability and a defense against age-related mental decline.\u003c/p>\n\u003cp>“Can you improve your brain so that it’s faster, more adept, more vital?\" Dr. Laura Carstensen, founding director of the \u003ca href=\"http://longevity3.stanford.edu/\" target=\"_blank\">Stanford Center on Longevity\u003c/a>, asked Standen, rhetorically. \"That’s what the claims are, and I don’t think there’s really any evidence for that.\"\u003c/p>\n\u003cp>Dr. Joel Kramer, head of neuropsychology at \u003ca href=\"http://memory.ucsf.edu/\" target=\"_blank\">UCSF’s Memory and Aging Center\u003c/a>, invoked the one word scientists do agree on.\u003c/p>\n\u003cp>“I think that the research thus far demonstrates a much clearer link between exercise and brain health,” he said. (He means physical exercise, not mental strain while sitting.)\u003c/p>\n\u003cp>Okay. That was then, a week before the iPad was released, for crying out loud. What about now, in 2016? Any new developments that may have buttressed the claims of the companies selling these products?\u003c/p>\n\u003cp>Not according to Dr. Carstensen.\u003c/p>\n\u003cp>\"I think claims these companies have been making -- and Lumosity is not alone -- have been grossly exaggerated,\" she said this week. “They’re trying to argue that we’re going to take you out of that active world … and that we’re going to put you in a room alone in front of a computer screen and you’ll play a game that will make you smarter, and you’re going to pay us to do it.”\u003c/p>\n\u003cp>“There is no compelling evidence for that,” she said.\u003c/p>\n\u003cp>This assessment is pretty much in line with the 2014 Stanford Center's critique of the so-called brain-training industry. Called \"\u003ca href=\"http://longevity3.stanford.edu/blog/2014/10/15/the-consensus-on-the-brain-training-industry-from-the-scientific-community-2/\" target=\"_blank\">A Consensus on the Brain Training Industry From the Scientific Community\u003c/a>,\" it was signed by dozens of scientists in the field.\u003c/p>\n\u003cp>\"To date, there is little evidence that playing brain games improves underlying broad cognitive abilities,\" the analysis said, \"or that it enables one to better navigate a complex realm of everyday life.\"\u003c/p>\n\u003cp>\u003cstrong>Get Off the Computer and Onto Your Bike\u003c/strong>\u003c/p>\n\u003cp>Carstensen believes exercise is the only evidence-based activity that will improve cognitive fitness. But even those effects are modest, she said. And most of the studies have been relatively short-term.\u003c/p>\n\u003cp>\"You’re looking at a boost to your cognitive benefit over your baseline after six weeks,\" she said. \"But it’s not huge.”\u003c/p>\n\u003cp>Exercise, however, can help stave off the mental decline that comes with many physical diseases.\u003c/p>\n\u003cp>\"If you get cardiosvascular disease, it’s likely to effect your cognitive functioning,\" she said. \"Getting blood clots means you’re more likely to get a stroke. There’s a lot of evidence that diabetes is related to brain diseases as well.”\u003c/p>\n\u003cp>Physical exercise is \"one of the more reliable approaches,\" agreed Dr. Kramer. He said studies have shown “fairly convincingly\" that people who engage in higher levels of physical activity have less chance of developing dementia.\u003c/p>\n\u003cp>\u003cstrong>The Trouble With Cognitive Training Research\u003c/strong>\u003c/p>\n\u003cp>Many researchers in the field of cognitive science think the studies that have found a positive effect from playing brain-training games -- research often touted by the companies -- have a fundamental problem: The evaluative tests to measure improvement are too similar to the games themselves.\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003c/p>\u003cp>“One of the big criticisms of the cognitive training paradigm is this issue of teaching to the test,\" said Dr. Joel Sneed, a professor of medical psychology at Columbia University who has researched the effect of computer cognitive training on depression.\u003c/p>\n\u003cp>“If I give you a test to see if you got better in something like memory, and your game looks a lot like my test,\" he said, \"then you’ve just been taking the test a lot, so you’ve gotten better at the test. But that doesn’t mean you can find your keys or stop yourself from losing your wallet.”\u003c/p>\n\u003cp>In other words, there is no evidence the skills learned through the games will transfer to the skills people use to navigate the real world.\u003c/p>\n\u003cp>Another problem, researchers say, is that the control groups have often not been engaged in any activity.\u003c/p>\n\u003cp>\"A lot of these studies say, 'Come to the lab and play games,' and they compare them to people who don’t do anything,\" said Carstensen.\u003c/p>\n\u003cp>Such inactivity will negatively affect mental performance, she said.\u003c/p>\n\u003cp>Dr. Sneed agreed.\u003c/p>\n\u003cp>“Comparing people who take the training with people who aren’t doing anything is a completely unfair comparison,\" he said.\u003c/p>\n\u003cp>The people doing brain training, Sneed continued, are getting dings and whistles and positive messages onscreen, so researchers don’t know if that’s the reason for improvement or if the training actually works.\u003c/p>\n\u003cp>\u003cstrong>Some Breakthroughs?\u003c/strong>\u003c/p>\n\u003cp>Dr. Murali Doraiswamy of the \u003ca href=\"https://dibs.duke.edu/\" target=\"_blank\">Duke Institute for Brain Sciences\u003c/a>, who was less cynical about the potential of brain fitness games in 2010 , is still hopeful today.\u003c/p>\n\u003cp>“I still believe in the potential of brain training as a therapeutic modality,\" he said in an email, \"but what we need now are long-term randomized trials to prove they can improve daily performance and delay dementia.”\u003c/p>\n\u003cp>Doraiswamy, as well as Dr. Sneed, cited a \u003ca href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557999/\" target=\"_blank\">study published in PLoS One\u003c/a> in September, which was conducted largely by scientists from Lumos Labs and used a methodology aimed at reducing some of the pitfalls of previous research.\u003c/p>\n\u003cp>The study divided 4,715 people into two groups: those who went through a Lumosity program of 49 exercises, and a non-passive control group who solved online crossword puzzles. Both groups completed their activities in one 15-minute session at least five days per week, for 10 weeks.\u003c/p>\n\u003cp>The Lumosity group showed more improvement than the crossword puzzle group on tests measuring memory, problem solving, reasoning, and speed of brain processing. They also showed greater improvement on “self-reported measures of cognitive functioning.”\u003c/p>\n\u003cp>Sneed said having participants do crossword puzzles is “the kind of equivalence you need in order to be able to say something about your games. … You’re able to make a comparison that is way more realistic\" than comparisons made with passive control groups.\u003c/p>\n\u003cp>Carstensen isn't buying it. She said having a control group do crossword puzzles is not equivalent to the game-playing of the treatment group\u003c/p>\n\u003cp>“Crossword puzzles have been shown over and over to have no effects on cognition,\" she said. \"You don’t learn something new when you do crossword puzzles, because you retrieve information you already know.”\u003c/p>\n\u003cp>Another study, commonly called the \u003ca href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055506/\" target=\"_blank\">ACTIVE trial\u003c/a>, was cited by Dr. Kramer as research that showed promise for cognitive brain training.\u003c/p>\n\u003cp>The research was led by Dr. George W. Rebok of Johns Hopkins' \u003ca href=\"http://coah.jhu.edu/about/\" target=\"_blank\">Center on Aging and Health\u003c/a> and includes scientists from 11 institutions, including several affiliated with Posit Science. The study \u003cspan style=\"line-height: 1.5\">looked at 2,832 people who were almost 74 years old on average. Three groups were given 10 training sessions for either memory, reasoning, or speed of processing, then booster sessions 11 and 35 months later. A control group received no treatment.\u003c/span>\u003c/p>\n\u003cp>The study found that 60 percent of the participants who underwent the training reported the same or greater ability to perform the so-called \u003ca href=\"http://www.healthcare.uiowa.edu/igec/tools/function/lawtonbrody.pdf\" target=\"_blank\">instrumental activities of daily living\u003c/a>, such as doing laundry and managing medication, while only 50 percent of the control group did.\u003c/p>\n\u003cp>The study also found that 10 years after the original treatment, those who received training in speed processing and reasoning did better on tests measuring those skills than the control group. The memory training showed no effect.\u003c/p>\n\u003cp>But the study found \"no effect of training or added booster training\" on actual tests, as opposed to self-reports, designed to measure daily cognitive function.\u003c/p>\n\u003cp>\u003cstrong>More Research Needed\u003c/strong>\u003c/p>\n\u003cp>All of the researchers agreed that the advertising claims of companies like Lumosity have not been borne out yet by the research. Dr. Dorasiswamy says the FTC action \"will serve as a broadshot to move the entire field away from marketing-driven claims to science-driven claims.\"\u003c/p>\n\u003cp>Dr. Sneed says more -- and better -- research is needed if the industry wants to uncover the smoking gun that will prove what they're peddling is beneficial.\u003c/p>\n\u003cp>\"Several studies are promising, but you need a large double-blind placebo trial,\" he said.\" You need more than one. And you have to be able to show the effect of doing the treatment generalizes to other cognitive skills.\"\u003c/p>\n\u003cp>Even the Stanford Center for Longevity's \u003ca href=\"http://longevity3.stanford.edu/blog/2014/10/15/the-consensus-on-the-brain-training-industry-from-the-scientific-community-2/\" target=\"_blank\">call-to-arms against the brain-training industry \u003c/a>in 2014 acknowledged that \"some intriguing isolated reports do inspire additional research.\"\u003c/p>\n\u003cp>Dr. Kramer, for his part, thinks that Lumosity and other brain-training games could one day prove beneficial.\u003c/p>\n\u003cp>\"The lack of evidence is not the same as evidence of a lack of efficacy,\" he said. \"There’s still the possibility that Lumosity or other kinds of brain training or cognitive enhancement approaches will have some efficacy.\"\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"It just hasn’t been adequately established yet,\" he said.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/94815/lumosity-cant-prove-claims-say-scientists-but-brain-training-worth-researching",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_692",
"futureofyou_693",
"futureofyou_596",
"futureofyou_80",
"futureofyou_691"
],
"featImg": "futureofyou_93427",
"label": "futureofyou_54"
},
"futureofyou_94302": {
"type": "posts",
"id": "futureofyou_94302",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "94302",
"score": null,
"sort": [
1452845049000
]
},
"parent": 0,
"labelTerm": {},
"blocks": [],
"publishDate": 1452845049,
"format": "standard",
"disqusTitle": "CRISPR Patent War: Billions at Stake for UC Berkeley",
"title": "CRISPR Patent War: Billions at Stake for UC Berkeley",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>This isn't an everyday patent dispute.\u003c/p>\n\u003cp>This is a battle for who invented the powerful gene-editing technique that Science magazine named the Breakthrough of the Year for 2015: CRISPR-Cas9.\u003c/p>\n\u003cp>CRISPR is like \u003ca href=\"http://ww2.kqed.org/futureofyou/2015/12/30/a-crispr-solution-to-bubble-boy-disease/\" target=\"_blank\">a molecular scalpel\u003c/a> that uses the enzyme Cas9 to locate and snip out bits of DNA. One day it could cut out and replace the tiny bit of mutant genetic material that contributes to disease.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Whoever has a patent on this could charge as much in royalties as they want and can set their price because they now have a monopoly.'\u003ccite>Mildred Cho, Stanford University\u003c/cite>\u003c/aside>\n\u003cp>The process could yield new therapies for certain cancers or genetic disorders.\u003c/p>\n\u003cp>Potentially, billions of dollars are at stake that could flow either to UC Berkeley or to the \u003ca href=\"https://www.broadinstitute.org/\">Broad Institute\u003c/a> (rhymes with \"road\") in Cambridge, Mass., jointly owned by \u003ca href=\"http://www.harvard.edu/\">Harvard University\u003c/a> and the \u003ca href=\"http://web.mit.edu/\">Massachusetts Institute of Technology\u003c/a>.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>The U.S. Patent and Trademark Office (USPTO) agreed this week to resolve the competing claims for the discovery of the revolutionary tool.\u003c/p>\n\u003cp>On Monday, the office declared an interference, recognizing a conflict between \u003ca href=\"http://www.google.com/patents/US8697359\">patent rights granted\u003c/a> to the Broad Institute and rights claimed by a pending \u003ca href=\"http://www.berkeley.edu/\">UC Berkeley\u003c/a> patent application.\u003c/p>\n\u003cp>Whoever gets the patent will be an important player in university research and the future of medicine, because that institution will set the terms for how the technology is used.\u003c/p>\n\u003cp>But the case also raises serious questions about the ethics surrounding sole ownership of a life-saving device or technique.\u003c/p>\n\u003caside class=\"alignright\">\n\u003ch2>PATENT FILING TIMELINE\u003c/h2>\n\u003cul>\n\u003cli>\u003cem>“First-to-invent” system in place\u003c/em>\u003c/li>\n\u003cli>\u003cstrong>September 16, 2011:\u003c/strong> Leahy-Smith America Invents Act signed into law\u003c/li>\n\u003cli>\u003cstrong>May 25, 2012:\u003c/strong> UC Berkeley submits a provisional patent claim\u003c/li>\n\u003cli>\u003cstrong>December 12, 2012:\u003c/strong> Broad Institute submits a provisional patent claim\u003c/li>\n\u003cli>\u003cstrong>March 15, 2013:\u003c/strong> UC Berkeley files a completed patent application\u003c/li>\n\u003cli>\u003cstrong>March 16, 2013:\u003c/strong> The Act goes into effect\u003c/li>\n\u003cli>\u003cem>“First-to-file” system in place\u003c/em>\u003c/li>\n\u003cli>\u003cstrong>October 13, 2013:\u003c/strong> Broad Institute files an expedited patent application\u003c/li>\n\u003c/ul>\n\u003c/aside>\n\u003cp>\u003cstrong>A Tricky Timeline\u003c/strong>\u003c/p>\n\u003cp>Scientists at UC Berkeley and the Broad Institute were working on CRISPR simultaneously. Biologists Jennifer Doudna and Emmanuelle Charpentier led Berkeley's research. Synthetic biologist Feng Zhang led research at Broad.\u003c/p>\n\u003cp>Each institution filed patent claims—UC Berkeley filed first—and while they were filing, the U.S. changed the terms of how it awards patents.\u003c/p>\n\u003cp>Before 2013, the U.S. operated under a \"first to invent\" rule: whomever developed the invention first was awarded the patent.\u003c/p>\n\u003cp>But when the \u003ca href=\"https://en.wikipedia.org/wiki/Leahy-Smith_America_Invents_Act\">Leahy-Smith America Invents Act\u003c/a> took effect in March 2013, a “first-to-file” system became law.\u003c/p>\n\u003cp>Zhang's team filed after the \"first-to-file\" rule was enacted and paid extra to have its application expedited. The average wait time for patent approval is three years but an expedited patent application takes around a year.\u003c/p>\n\u003cp>So while UC Berkeley's application was under review the USPTO approved Zhang's application, even though it was submitted later.\u003c/p>\n\u003cp>Now, having granted an interference, the USPTO will determine which team was the first to invent the gene-editing technique.\u003c/p>\n\u003cp>Each side will have to prove, via notes and lab records, that it was the first inventor.\u003c/p>\n\u003cp>If Doudna's team wins, all 13 of the Broad's CRISPR patents will be canceled.\u003c/p>\n\u003cp>\u003cstrong>Billions Riding on One Decision\u003c/strong>\u003c/p>\n\u003cp>Many companies are \u003ca href=\"http://www.fiercebiotech.com/story/patent-battle-brews-celgene-leads-64m-raise-crispr-therapeutics/2015-04-28\">already making money off CRISPR\u003c/a>. Startups that use the tool, like \u003ca href=\"http://crisprtx.com/\">CRISPR Therapeutics\u003c/a>, have raised millions in venture capital funding.\u003c/p>\n\u003cfigure id=\"attachment_121794\" class=\"wp-caption alignright\" style=\"max-width: 331px\">\u003cimg class=\" wp-image-121794\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/CRISPR-DNA_no-caption.jpg\" alt=\"The enzyme Cas9, shown in blue and gray, can cut DNA, in gold, at selected sites, as seen in this model from electron microscope images. \" width=\"331\" height=\"367\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/CRISPR-DNA_no-caption.jpg 405w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/CRISPR-DNA_no-caption-400x444.jpg 400w\" sizes=\"(max-width: 331px) 100vw, 331px\">\u003cfigcaption class=\"wp-caption-text\">The enzyme Cas9, shown in blue and gray, can cut DNA, in gold, at selected sites, as seen in this model from electron microscope images. \u003ccite>(David Taylor and Jennifer Doudna)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>Editas Medicine in Cambridge, which uses CRISPR to develop novel drugs, filed to go public late last year and set its initial public offering at $100 million.\u003c/p>\n\u003cp>\"This patent is potentially worth billions of dollars,\" says Stanford University bioethicist \u003ca href=\"https://med.stanford.edu/profiles/mildred-cho\">Mildred Cho\u003c/a>. \"Whoever has a patent on this could charge as much in royalties as they want and can set their price because they now have a monopoly.\"\u003c/p>\n\u003cp>Some experts caution that the patent for CRISPR-Cas9 is just one of many possible CRISPR patents. Cas9 is an enzyme used in the gene-editing technique, and there are \u003ca href=\"http://www.nature.com/nrmicro/journal/v9/n6/abs/nrmicro2577.html\" target=\"_blank\">many enzymes\u003c/a> that could be used. How lucrative any one patent is depends on how broadly or narrowly it's written.\u003c/p>\n\u003cp>After the patent is awarded, a lot rides on how the patent is enforced. Cho says the patent holder may encourage other groups to use the technology for a small fee or it could assert its monopoly ownership and charge exorbitant fees for its use.\u003c/p>\n\u003cp>Universities across the country are watching this case, says New York Law School Associate Professor \u003ca href=\"http://www.nyls.edu/faculty/faculty-profiles/faculty_profiles/jacob-s-sherkow/\">Jake Sherkow\u003c/a>, both for what it will tell them about their own abilities to pursue similar research, or file for lucrative patent claims.\u003c/p>\n\u003cp>\"Other universities may be more aggressive about pursuing patents because of this case,\" Sherkow says.\u003c/p>\n\u003cp>But even bigger than this is the ethical question, according to Cho.\u003c/p>\n\u003cp>\u003cstrong>Should Life-Saving Health Tools Be Patented?\u003c/strong>\u003c/p>\n\u003cp>[contextly_sidebar id=\"W3NFPgf5ldgwcoylE8W7c9dtbvsSZL94\"]\"If this biotech is going to cure previously incurable diseases through altering DNA, do we allow patent holders to collect royalties and if so how much?\" Cho asks.\u003c/p>\n\u003cp>\"Should they even be allowed to have those patents at all?\" she continues. \"Should we have the same considerations for patents used for health purposes as other types of patents that apply to phones and cars?\"\u003c/p>\n\u003cp>The victor won't be announced in 2016. Sherkow says the trial will take years. It could go all the way to the Supreme Court, but he says that's not likely.\u003c/p>\n\u003cp>\"The chances of it going to the Supreme Court are only slightly better than the Powerball we had [this week],” he says.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Three members of the Patent Appeals and Interferences Board will start discussing the case on March 9.\u003c/p>\n\n",
"disqusIdentifier": "94302 http://ww2.kqed.org/futureofyou/?p=94302",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/15/crispr-patent-war-billions-at-stake-for-uc-berkeley/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 993,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 36
},
"modified": 1458627617,
"excerpt": "This week, the U.S. Patent and Trademark Office said it would review conflicting claims for a revolutionary gene-editing technique, known as CRISPR–Cas9.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "This week, the U.S. Patent and Trademark Office said it would review conflicting claims for a revolutionary gene-editing technique, known as CRISPR–Cas9.",
"title": "CRISPR Patent War: Billions at Stake for UC Berkeley | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "CRISPR Patent War: Billions at Stake for UC Berkeley",
"datePublished": "2016-01-15T00:04:09-08:00",
"dateModified": "2016-03-21T23:20:17-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "crispr-patent-war-billions-at-stake-for-uc-berkeley",
"status": "publish",
"source": "Big Ideas",
"path": "/futureofyou/94302/crispr-patent-war-billions-at-stake-for-uc-berkeley",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>This isn't an everyday patent dispute.\u003c/p>\n\u003cp>This is a battle for who invented the powerful gene-editing technique that Science magazine named the Breakthrough of the Year for 2015: CRISPR-Cas9.\u003c/p>\n\u003cp>CRISPR is like \u003ca href=\"http://ww2.kqed.org/futureofyou/2015/12/30/a-crispr-solution-to-bubble-boy-disease/\" target=\"_blank\">a molecular scalpel\u003c/a> that uses the enzyme Cas9 to locate and snip out bits of DNA. One day it could cut out and replace the tiny bit of mutant genetic material that contributes to disease.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Whoever has a patent on this could charge as much in royalties as they want and can set their price because they now have a monopoly.'\u003ccite>Mildred Cho, Stanford University\u003c/cite>\u003c/aside>\n\u003cp>The process could yield new therapies for certain cancers or genetic disorders.\u003c/p>\n\u003cp>Potentially, billions of dollars are at stake that could flow either to UC Berkeley or to the \u003ca href=\"https://www.broadinstitute.org/\">Broad Institute\u003c/a> (rhymes with \"road\") in Cambridge, Mass., jointly owned by \u003ca href=\"http://www.harvard.edu/\">Harvard University\u003c/a> and the \u003ca href=\"http://web.mit.edu/\">Massachusetts Institute of Technology\u003c/a>.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>The U.S. Patent and Trademark Office (USPTO) agreed this week to resolve the competing claims for the discovery of the revolutionary tool.\u003c/p>\n\u003cp>On Monday, the office declared an interference, recognizing a conflict between \u003ca href=\"http://www.google.com/patents/US8697359\">patent rights granted\u003c/a> to the Broad Institute and rights claimed by a pending \u003ca href=\"http://www.berkeley.edu/\">UC Berkeley\u003c/a> patent application.\u003c/p>\n\u003cp>Whoever gets the patent will be an important player in university research and the future of medicine, because that institution will set the terms for how the technology is used.\u003c/p>\n\u003cp>But the case also raises serious questions about the ethics surrounding sole ownership of a life-saving device or technique.\u003c/p>\n\u003caside class=\"alignright\">\n\u003ch2>PATENT FILING TIMELINE\u003c/h2>\n\u003cul>\n\u003cli>\u003cem>“First-to-invent” system in place\u003c/em>\u003c/li>\n\u003cli>\u003cstrong>September 16, 2011:\u003c/strong> Leahy-Smith America Invents Act signed into law\u003c/li>\n\u003cli>\u003cstrong>May 25, 2012:\u003c/strong> UC Berkeley submits a provisional patent claim\u003c/li>\n\u003cli>\u003cstrong>December 12, 2012:\u003c/strong> Broad Institute submits a provisional patent claim\u003c/li>\n\u003cli>\u003cstrong>March 15, 2013:\u003c/strong> UC Berkeley files a completed patent application\u003c/li>\n\u003cli>\u003cstrong>March 16, 2013:\u003c/strong> The Act goes into effect\u003c/li>\n\u003cli>\u003cem>“First-to-file” system in place\u003c/em>\u003c/li>\n\u003cli>\u003cstrong>October 13, 2013:\u003c/strong> Broad Institute files an expedited patent application\u003c/li>\n\u003c/ul>\n\u003c/aside>\n\u003cp>\u003cstrong>A Tricky Timeline\u003c/strong>\u003c/p>\n\u003cp>Scientists at UC Berkeley and the Broad Institute were working on CRISPR simultaneously. Biologists Jennifer Doudna and Emmanuelle Charpentier led Berkeley's research. Synthetic biologist Feng Zhang led research at Broad.\u003c/p>\n\u003cp>Each institution filed patent claims—UC Berkeley filed first—and while they were filing, the U.S. changed the terms of how it awards patents.\u003c/p>\n\u003cp>Before 2013, the U.S. operated under a \"first to invent\" rule: whomever developed the invention first was awarded the patent.\u003c/p>\n\u003cp>But when the \u003ca href=\"https://en.wikipedia.org/wiki/Leahy-Smith_America_Invents_Act\">Leahy-Smith America Invents Act\u003c/a> took effect in March 2013, a “first-to-file” system became law.\u003c/p>\n\u003cp>Zhang's team filed after the \"first-to-file\" rule was enacted and paid extra to have its application expedited. The average wait time for patent approval is three years but an expedited patent application takes around a year.\u003c/p>\n\u003cp>So while UC Berkeley's application was under review the USPTO approved Zhang's application, even though it was submitted later.\u003c/p>\n\u003cp>Now, having granted an interference, the USPTO will determine which team was the first to invent the gene-editing technique.\u003c/p>\n\u003cp>Each side will have to prove, via notes and lab records, that it was the first inventor.\u003c/p>\n\u003cp>If Doudna's team wins, all 13 of the Broad's CRISPR patents will be canceled.\u003c/p>\n\u003cp>\u003cstrong>Billions Riding on One Decision\u003c/strong>\u003c/p>\n\u003cp>Many companies are \u003ca href=\"http://www.fiercebiotech.com/story/patent-battle-brews-celgene-leads-64m-raise-crispr-therapeutics/2015-04-28\">already making money off CRISPR\u003c/a>. Startups that use the tool, like \u003ca href=\"http://crisprtx.com/\">CRISPR Therapeutics\u003c/a>, have raised millions in venture capital funding.\u003c/p>\n\u003cfigure id=\"attachment_121794\" class=\"wp-caption alignright\" style=\"max-width: 331px\">\u003cimg class=\" wp-image-121794\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/01/CRISPR-DNA_no-caption.jpg\" alt=\"The enzyme Cas9, shown in blue and gray, can cut DNA, in gold, at selected sites, as seen in this model from electron microscope images. \" width=\"331\" height=\"367\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/01/CRISPR-DNA_no-caption.jpg 405w, https://ww2.kqed.org/app/uploads/sites/13/2016/01/CRISPR-DNA_no-caption-400x444.jpg 400w\" sizes=\"(max-width: 331px) 100vw, 331px\">\u003cfigcaption class=\"wp-caption-text\">The enzyme Cas9, shown in blue and gray, can cut DNA, in gold, at selected sites, as seen in this model from electron microscope images. \u003ccite>(David Taylor and Jennifer Doudna)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>Editas Medicine in Cambridge, which uses CRISPR to develop novel drugs, filed to go public late last year and set its initial public offering at $100 million.\u003c/p>\n\u003cp>\"This patent is potentially worth billions of dollars,\" says Stanford University bioethicist \u003ca href=\"https://med.stanford.edu/profiles/mildred-cho\">Mildred Cho\u003c/a>. \"Whoever has a patent on this could charge as much in royalties as they want and can set their price because they now have a monopoly.\"\u003c/p>\n\u003cp>Some experts caution that the patent for CRISPR-Cas9 is just one of many possible CRISPR patents. Cas9 is an enzyme used in the gene-editing technique, and there are \u003ca href=\"http://www.nature.com/nrmicro/journal/v9/n6/abs/nrmicro2577.html\" target=\"_blank\">many enzymes\u003c/a> that could be used. How lucrative any one patent is depends on how broadly or narrowly it's written.\u003c/p>\n\u003cp>After the patent is awarded, a lot rides on how the patent is enforced. Cho says the patent holder may encourage other groups to use the technology for a small fee or it could assert its monopoly ownership and charge exorbitant fees for its use.\u003c/p>\n\u003cp>Universities across the country are watching this case, says New York Law School Associate Professor \u003ca href=\"http://www.nyls.edu/faculty/faculty-profiles/faculty_profiles/jacob-s-sherkow/\">Jake Sherkow\u003c/a>, both for what it will tell them about their own abilities to pursue similar research, or file for lucrative patent claims.\u003c/p>\n\u003cp>\"Other universities may be more aggressive about pursuing patents because of this case,\" Sherkow says.\u003c/p>\n\u003cp>But even bigger than this is the ethical question, according to Cho.\u003c/p>\n\u003cp>\u003cstrong>Should Life-Saving Health Tools Be Patented?\u003c/strong>\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003c/p>\u003cp>\"If this biotech is going to cure previously incurable diseases through altering DNA, do we allow patent holders to collect royalties and if so how much?\" Cho asks.\u003c/p>\n\u003cp>\"Should they even be allowed to have those patents at all?\" she continues. \"Should we have the same considerations for patents used for health purposes as other types of patents that apply to phones and cars?\"\u003c/p>\n\u003cp>The victor won't be announced in 2016. Sherkow says the trial will take years. It could go all the way to the Supreme Court, but he says that's not likely.\u003c/p>\n\u003cp>\"The chances of it going to the Supreme Court are only slightly better than the Powerball we had [this week],” he says.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Three members of the Patent Appeals and Interferences Board will start discussing the case on March 9.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/94302/crispr-patent-war-billions-at-stake-for-uc-berkeley",
"authors": [
"5432"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_647",
"futureofyou_94",
"futureofyou_80",
"futureofyou_709",
"futureofyou_702"
],
"featImg": "futureofyou_97441",
"label": "source_futureofyou_94302"
},
"futureofyou_94836": {
"type": "posts",
"id": "futureofyou_94836",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "94836",
"score": null,
"sort": [
1452292251000
]
},
"parent": 0,
"labelTerm": {},
"blocks": [],
"publishDate": 1452292251,
"format": "standard",
"disqusTitle": "Fitbit Hit With Class Action Lawsuit Over Alleged Misreading of Heart Rates",
"title": "Fitbit Hit With Class Action Lawsuit Over Alleged Misreading of Heart Rates",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>Some consumers are throwing a spitfit over Fitbit.\u003c/p>\n\u003cp>The maker of\u003ca href=\"http://www.fitbit.com/home\" target=\"_blank\"> wearable activity trackers\u003c/a> was hit with a \u003ca href=\"http://lchbdocs.com/pdf/Fitbit-class-action-complaint.pdf\" target=\"_blank\">class action lawsuit\u003c/a> Tuesday claiming the device used to measure heart rates in the company's Charge HR and Surge fitness watches \"do not and cannot consistently and accurately record wearers' heart rates\" during exercise.\u003c/p>\n\u003cp>The company advertises using the slogan \"every beat counts.\"\u003c/p>\n\u003cp>The suit was filed in San Francisco federal court on behalf of three Fitbit users and all others who have used the products.\u003c/p>\n\u003cp>The lawsuit claims testing has confirmed that the San Francisco-based company's PurePulse Trackers \"consistently mis-record heart rates by a very significant margin, particularly during exercise.\"\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>According to the suit, one of the plaintiffs, Kate McLellan, of Murietta, California, compared her real-time heart rate readings from a Charge HR with those on a stationary exercise machine and noticed a discrepancy. She called Fitbit and was told to reboot the device. That didn't work, so she asked for a refund in an online chat with a company rep, but that was denied.\u003cbr>\n\u003c!-- iframe plugin v.4.3 wordpress.org/plugins/iframe/ -->\u003cbr>\n\u003ciframe src=\"http://www.today.com/offsite/fitbit-facing-class-action-lawsuit-over-heart-rate-reading-accuracy-598328899503\" scrolling=\"no\" frameborder=\"0\" width=\"100%\" height=\"500\" class=\"iframe-class\">\u003c/iframe>\u003cbr>\nFitbit issued a statement to various media, standing by the accuracy of the monitors. \"PurePulse provides better overall heart rate tracking than cardio machines at the gym, as it tracks your heart rate continuously – even while you’re not at the gym or working out,\" the statement said. \"But it’s also important to note that Fitbit trackers are designed to provide meaningful data to our users to help them reach their health and fitness goals, and are not intended to be scientific or medical devices.'\u003c/p>\n\u003cp>The lawsuit was filed the same day as Fitbit introduced, at the Consumer Electronics Show in Las Vegas, the Fitbit Blaze, which some reviewers have called an \u003ca href=\"http://www.smh.com.au/digital-life/wearables/fitbit-hits-back-at-apple-watch-with-the-blaze-20160105-gm02aq.html\" target=\"_blank\">answer\u003c/a> to the Apple Watch. \u003ca href=\"http://www.engadget.com/2016/01/07/fitbit-blaze-smartwatch-hands-on/\" target=\"_blank\"> Not everyone was impressed,\u003c/a> however, and the company's\u003ca href=\"http://www.dcrainmaker.com/2016/01/fitbits-multiple-lawsuits.html\" target=\"_blank\"> stock hit the skids\u003c/a>. (Fitbit, along with Apple, was also hit with a\u003ca href=\"http://www.patentlyapple.com/patently-apple/2016/01/valencell-a-biometrics-company-sues-apple-by-claiming-the-apple-watch-infringes-their-technology.html\" target=\"_blank\"> patent infringement lawsuit\u003c/a> on the same day.)\u003c/p>\n\u003cp>\u003cstrong>Arbitration Test Case\u003c/strong>\u003c/p>\n\u003cp>There's an interesting wrinkle to this lawsuit. You may have read, a couple of months back, \u003ca href=\"http://www.nytimes.com/2015/11/01/business/dealbook/arbitration-everywhere-stacking-the-deck-of-justice.html\" target=\"_blank\">The New York Times series on the widespread use of arbitration agreements\u003c/a>. It's long and involved, so we'll boil it down for you: You can't barely purchase a stick of gum anymore without agreeing to forego your right to sue in a court of law. That's an exaggeration, but only slightly.\u003c/p>\n\u003cp>The Times reported that \"clauses buried in tens of millions of contracts have deprived Americans of one of their most fundamental rights: their day in court.\" Meaning that any time you sign up for a service or product, like cable TV, a credit card or health insurance, part of the terms of service is a prohibition against joining other consumers in a class-action lawsuit, as well as suing on your own. Instead, you must agree to resolve any dispute by going before a \u003ca href=\"http://www.nytimes.com/2015/11/02/business/dealbook/in-arbitration-a-privatization-of-the-justice-system.html\" target=\"_blank\">private arbitrator\u003c/a>, usually the employee of a company hired by the defendant.\u003c/p>\n\u003cp>Well, as Alison Frankel\u003ca href=\"http://blogs.reuters.com/alison-frankel/2016/01/06/how-fitbit-heart-rate-class-action-intends-to-bust-arbitration-agreement/\" target=\"_blank\"> explains for Reuters\u003c/a>, Fitbit, like many companies, also employs an arbitration clause; it's included in the terms of service you sign when you register at the company's website. And you need to do that for the device to work.\u003c/p>\n\u003cp>However, the three plaintiffs named in the suit all bought their Fitbits at other retailers. Says the lawsuit, in identical language referring to all three plaintiffs:\u003c/p>\n\u003cp>\"At no point before or during the purchase of her Charge HR was [the plaintiff] provided with or required to agree to an arbitration clause or class action ban, nor was she put on notice that she would be required to agree to an arbitration clause or class action ban for her Charge HR to function as intended.\"\u003c/p>\n\u003cp>That, says the lawsuit, brought by San Francisco's Lieff, Cabraser Heimann & Bernstein and Robert H. Klonoff, constitutes an \"unconscionable post-purchase agreement, which class members were required to accept in order to render operational\" the Fitbits they purchased.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Fitbit doesn't agree. Wrote Alison Frankel:\u003c/p>\n\u003cblockquote>\u003cp>In a response to my email about whether the class waiver applies to users who bought their devices elsewhere, a Fitbit representative said, “All end users agree to the terms of service when they set up a Fitbit account regardless of where they purchased the device.” She [the representative] also said Fitbit “stands behind our heart rate technology and strongly disagrees with the statements made in the complaint and plans to vigorously defend the lawsuit.”\u003c/p>\u003c/blockquote>\n\n",
"disqusIdentifier": "94836 http://ww2.kqed.org/futureofyou/?p=94836",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/08/fitbit-hit-with-class-action-lawsuit-over-alleged-misreading-of-heart-rates/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 785,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 18
},
"modified": 1453243370,
"excerpt": "The lawsuit claims Fitbit's Charge HR and Surge products \"do not and cannot consistently and accurately\" record heart rates during exercise.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The lawsuit claims Fitbit's Charge HR and Surge products "do not and cannot consistently and accurately" record heart rates during exercise.",
"title": "Fitbit Hit With Class Action Lawsuit Over Alleged Misreading of Heart Rates | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Fitbit Hit With Class Action Lawsuit Over Alleged Misreading of Heart Rates",
"datePublished": "2016-01-08T14:30:51-08:00",
"dateModified": "2016-01-19T14:42:50-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "fitbit-hit-with-class-action-lawsuit-over-alleged-misreading-of-heart-rates",
"status": "publish",
"source": "Mobile Health & Wearables",
"path": "/futureofyou/94836/fitbit-hit-with-class-action-lawsuit-over-alleged-misreading-of-heart-rates",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Some consumers are throwing a spitfit over Fitbit.\u003c/p>\n\u003cp>The maker of\u003ca href=\"http://www.fitbit.com/home\" target=\"_blank\"> wearable activity trackers\u003c/a> was hit with a \u003ca href=\"http://lchbdocs.com/pdf/Fitbit-class-action-complaint.pdf\" target=\"_blank\">class action lawsuit\u003c/a> Tuesday claiming the device used to measure heart rates in the company's Charge HR and Surge fitness watches \"do not and cannot consistently and accurately record wearers' heart rates\" during exercise.\u003c/p>\n\u003cp>The company advertises using the slogan \"every beat counts.\"\u003c/p>\n\u003cp>The suit was filed in San Francisco federal court on behalf of three Fitbit users and all others who have used the products.\u003c/p>\n\u003cp>The lawsuit claims testing has confirmed that the San Francisco-based company's PurePulse Trackers \"consistently mis-record heart rates by a very significant margin, particularly during exercise.\"\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>According to the suit, one of the plaintiffs, Kate McLellan, of Murietta, California, compared her real-time heart rate readings from a Charge HR with those on a stationary exercise machine and noticed a discrepancy. She called Fitbit and was told to reboot the device. That didn't work, so she asked for a refund in an online chat with a company rep, but that was denied.\u003cbr>\n\u003c!-- iframe plugin v.4.3 wordpress.org/plugins/iframe/ -->\u003cbr>\n\u003ciframe src=\"http://www.today.com/offsite/fitbit-facing-class-action-lawsuit-over-heart-rate-reading-accuracy-598328899503\" scrolling=\"no\" frameborder=\"0\" width=\"100%\" height=\"500\" class=\"iframe-class\">\u003c/iframe>\u003cbr>\nFitbit issued a statement to various media, standing by the accuracy of the monitors. \"PurePulse provides better overall heart rate tracking than cardio machines at the gym, as it tracks your heart rate continuously – even while you’re not at the gym or working out,\" the statement said. \"But it’s also important to note that Fitbit trackers are designed to provide meaningful data to our users to help them reach their health and fitness goals, and are not intended to be scientific or medical devices.'\u003c/p>\n\u003cp>The lawsuit was filed the same day as Fitbit introduced, at the Consumer Electronics Show in Las Vegas, the Fitbit Blaze, which some reviewers have called an \u003ca href=\"http://www.smh.com.au/digital-life/wearables/fitbit-hits-back-at-apple-watch-with-the-blaze-20160105-gm02aq.html\" target=\"_blank\">answer\u003c/a> to the Apple Watch. \u003ca href=\"http://www.engadget.com/2016/01/07/fitbit-blaze-smartwatch-hands-on/\" target=\"_blank\"> Not everyone was impressed,\u003c/a> however, and the company's\u003ca href=\"http://www.dcrainmaker.com/2016/01/fitbits-multiple-lawsuits.html\" target=\"_blank\"> stock hit the skids\u003c/a>. (Fitbit, along with Apple, was also hit with a\u003ca href=\"http://www.patentlyapple.com/patently-apple/2016/01/valencell-a-biometrics-company-sues-apple-by-claiming-the-apple-watch-infringes-their-technology.html\" target=\"_blank\"> patent infringement lawsuit\u003c/a> on the same day.)\u003c/p>\n\u003cp>\u003cstrong>Arbitration Test Case\u003c/strong>\u003c/p>\n\u003cp>There's an interesting wrinkle to this lawsuit. You may have read, a couple of months back, \u003ca href=\"http://www.nytimes.com/2015/11/01/business/dealbook/arbitration-everywhere-stacking-the-deck-of-justice.html\" target=\"_blank\">The New York Times series on the widespread use of arbitration agreements\u003c/a>. It's long and involved, so we'll boil it down for you: You can't barely purchase a stick of gum anymore without agreeing to forego your right to sue in a court of law. That's an exaggeration, but only slightly.\u003c/p>\n\u003cp>The Times reported that \"clauses buried in tens of millions of contracts have deprived Americans of one of their most fundamental rights: their day in court.\" Meaning that any time you sign up for a service or product, like cable TV, a credit card or health insurance, part of the terms of service is a prohibition against joining other consumers in a class-action lawsuit, as well as suing on your own. Instead, you must agree to resolve any dispute by going before a \u003ca href=\"http://www.nytimes.com/2015/11/02/business/dealbook/in-arbitration-a-privatization-of-the-justice-system.html\" target=\"_blank\">private arbitrator\u003c/a>, usually the employee of a company hired by the defendant.\u003c/p>\n\u003cp>Well, as Alison Frankel\u003ca href=\"http://blogs.reuters.com/alison-frankel/2016/01/06/how-fitbit-heart-rate-class-action-intends-to-bust-arbitration-agreement/\" target=\"_blank\"> explains for Reuters\u003c/a>, Fitbit, like many companies, also employs an arbitration clause; it's included in the terms of service you sign when you register at the company's website. And you need to do that for the device to work.\u003c/p>\n\u003cp>However, the three plaintiffs named in the suit all bought their Fitbits at other retailers. Says the lawsuit, in identical language referring to all three plaintiffs:\u003c/p>\n\u003cp>\"At no point before or during the purchase of her Charge HR was [the plaintiff] provided with or required to agree to an arbitration clause or class action ban, nor was she put on notice that she would be required to agree to an arbitration clause or class action ban for her Charge HR to function as intended.\"\u003c/p>\n\u003cp>That, says the lawsuit, brought by San Francisco's Lieff, Cabraser Heimann & Bernstein and Robert H. Klonoff, constitutes an \"unconscionable post-purchase agreement, which class members were required to accept in order to render operational\" the Fitbits they purchased.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Fitbit doesn't agree. Wrote Alison Frankel:\u003c/p>\n\u003cblockquote>\u003cp>In a response to my email about whether the class waiver applies to users who bought their devices elsewhere, a Fitbit representative said, “All end users agree to the terms of service when they set up a Fitbit account regardless of where they purchased the device.” She [the representative] also said Fitbit “stands behind our heart rate technology and strongly disagrees with the statements made in the complaint and plans to vigorously defend the lawsuit.”\u003c/p>\u003c/blockquote>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/94836/fitbit-hit-with-class-action-lawsuit-over-alleged-misreading-of-heart-rates",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_49",
"futureofyou_80",
"futureofyou_53"
],
"featImg": "futureofyou_96633",
"label": "source_futureofyou_94836"
},
"futureofyou_93348": {
"type": "posts",
"id": "futureofyou_93348",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "93348",
"score": null,
"sort": [
1452039278000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1452039278,
"format": "standard",
"disqusTitle": "Federal Court Orders Lumosity to Stop Claiming Games Prevent Dementia",
"title": "Federal Court Orders Lumosity to Stop Claiming Games Prevent Dementia",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>The company that developed Lumosity has agreed to settle complaints it puts out false advertising by withdrawing the company's primary advertising message: that its \"brain-training games\" can prevent dementia, delay age-related loss of memory and cognitive decline, improve brain performance, and provide other, similar benefits.\u003c/p>\n\u003cp>The company also must pay $2 million to the Federal Trade Commission, which could be used for consumer education.\u003c/p>\n\u003cp>The Federal Trade Commission \u003ca href=\"https://www.ftc.gov/system/files/documents/cases/160105lumoslabscmpt.pdf\" target=\"_blank\">filed a complaint\u003c/a> against Lumos Labs, Monday in U.S. District Court in San Francisco. Federal regulators argued that the San Francisco brain-game company engaged in false advertising and deceived consumers by making claims that were \u003ca href=\"http://ww2.kqed.org/quest/2010/10/15/when-brains-hit-the-gym-2/\" target=\"_blank\">unsubstantiated by reliable scientific studies\u003c/a>.\u003c/p>\n\u003cp>The \u003ca href=\"https://www.ftc.gov/system/files/documents/cases/160105lumoslabsstipjdgmt.pdf\" target=\"_blank\">court order\u003c/a>, also filed Monday, permanently bans Lumosity from making any statement that using its games can improve performance in school, at work, or in athletics; delay or protect against age-related decline in memory or other cognitive function, including Alzheimer’s disease; or reduce cognitive impairment caused by health conditions, such as post-traumatic stress disorder or attention-deficit-hyperactivity disorder.\u003c/p>\n\u003cp>The order also requires that any future claim of medical benefit be based on human clinical trials using accepted scientific protocols.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Lumosity also drew fire for its use of testimonials praising the company's products, and was ordered to disclose when it uses prizes to solicit testimonials.\u003c/p>\n\n",
"disqusIdentifier": "93348 http://ww2.kqed.org/futureofyou/?p=93348",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/01/05/federal-court-orders-lumosity-to-stop-claiming-games-prevent-dementia/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 226,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 8
},
"modified": 1452039278,
"excerpt": "Lumosity has built its reputation on promises its games will delay cognitive decline. Federal regulators say that's false advertising.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "Lumosity has built its reputation on promises its games will delay cognitive decline. Federal regulators say that's false advertising.",
"title": "Federal Court Orders Lumosity to Stop Claiming Games Prevent Dementia | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Federal Court Orders Lumosity to Stop Claiming Games Prevent Dementia",
"datePublished": "2016-01-05T16:14:38-08:00",
"dateModified": "2016-01-05T16:14:38-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "federal-court-orders-lumosity-to-stop-claiming-games-prevent-dementia",
"status": "publish",
"path": "/futureofyou/93348/federal-court-orders-lumosity-to-stop-claiming-games-prevent-dementia",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>The company that developed Lumosity has agreed to settle complaints it puts out false advertising by withdrawing the company's primary advertising message: that its \"brain-training games\" can prevent dementia, delay age-related loss of memory and cognitive decline, improve brain performance, and provide other, similar benefits.\u003c/p>\n\u003cp>The company also must pay $2 million to the Federal Trade Commission, which could be used for consumer education.\u003c/p>\n\u003cp>The Federal Trade Commission \u003ca href=\"https://www.ftc.gov/system/files/documents/cases/160105lumoslabscmpt.pdf\" target=\"_blank\">filed a complaint\u003c/a> against Lumos Labs, Monday in U.S. District Court in San Francisco. Federal regulators argued that the San Francisco brain-game company engaged in false advertising and deceived consumers by making claims that were \u003ca href=\"http://ww2.kqed.org/quest/2010/10/15/when-brains-hit-the-gym-2/\" target=\"_blank\">unsubstantiated by reliable scientific studies\u003c/a>.\u003c/p>\n\u003cp>The \u003ca href=\"https://www.ftc.gov/system/files/documents/cases/160105lumoslabsstipjdgmt.pdf\" target=\"_blank\">court order\u003c/a>, also filed Monday, permanently bans Lumosity from making any statement that using its games can improve performance in school, at work, or in athletics; delay or protect against age-related decline in memory or other cognitive function, including Alzheimer’s disease; or reduce cognitive impairment caused by health conditions, such as post-traumatic stress disorder or attention-deficit-hyperactivity disorder.\u003c/p>\n\u003cp>The order also requires that any future claim of medical benefit be based on human clinical trials using accepted scientific protocols.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Lumosity also drew fire for its use of testimonials praising the company's products, and was ordered to disclose when it uses prizes to solicit testimonials.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/93348/federal-court-orders-lumosity-to-stop-claiming-games-prevent-dementia",
"authors": [
"235"
],
"categories": [
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_692",
"futureofyou_693",
"futureofyou_691"
],
"featImg": "futureofyou_93427",
"label": "futureofyou"
},
"futureofyou_64080": {
"type": "posts",
"id": "futureofyou_64080",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "64080",
"score": null,
"sort": [
1448904037000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1448904037,
"format": "image",
"disqusTitle": "A Cure for AIDS: Scientists Say It's 'On the Horizon'",
"title": "A Cure for AIDS: Scientists Say It's 'On the Horizon'",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>\u003cspan style=\"font-size: 4.6875em;float: left;line-height: 0.733em;padding: 0.05em 0.1em 0 0;font-family: times, serif, georgia\">P\u003c/span>aul Volberding is a UCSF oncologist who treated San Francisco's first HIV patients in the early 1980s.\u003c/p>\n\u003cp>\"The patients were, in many cases, blind and demented and had cancer and had infections in their brains causing pressure and headaches,\" says Volberding. \"People now can’t imagine it, it was so bad.\"\u003c/p>\n\u003cp>Volberding says for years, HIV infection was a rapid death sentence. But in the 35 years since the epidemic began—thanks to sophisticated anti-retrovirals—it’s become a chronic illness that people can live with for decades.\u003c/p>\n\u003cp>Today, on the eve of World AIDS Day, UCSF is scheduled to announce that it's receiving a $20 million grant to find a cure for AIDS over the next five years. It's part of a $100 million effort by the \u003ca href=\"http://www.amfar.org/\" target=\"_blank\">American Foundation for AIDS Research\u003c/a> or amfAR, to fund the most promising research that could lead to curing AIDS.\u003c/p>\n\u003cp>Not long ago this might have sounded unbelievable.\u003c/p>\n\u003cfigure id=\"attachment_65878\" class=\"wp-caption alignleft\" style=\"max-width: 766px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Paul-Volberding_1981-e1447277818233.jpg\">\u003cimg class=\"size-medium wp-image-65878\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Paul-Volberding_1981-766x600.jpg\" alt=\"In 1981 Marcus Conant, MD (left) and Paul Volberding, MD (right) discuss Kaposi's Sarcoma, a disease that became one of the original AIDS-defining illnesses. \" width=\"766\" height=\"600\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">In 1981, Dr. Marcus Conant (left) and Dr. Paul Volberding (right) discuss Kaposi's Sarcoma, which became one of the original AIDS-defining illnesses. \u003ccite>(UCSF)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>“I think it would have felt a lot like a moonshot, maybe five or six years ago,” Volberding says.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>But today, Volberding's lab and others in San Francisco are working for that moonshot: to develop treatments over the next several years that can drive the viral load down low enough that the body's own immune system can control or eliminate it.\u003c/p>\n\u003cp>\"If it can be done anywhere, it can be done here,\" he says. \"It's a really exciting moment.\"\u003c/p>\n\u003cp>\u003cstrong>The Problem With Treatment\u003c/strong>\u003c/p>\n\u003cp>The U.S. Food and Drug Administration \u003ca href=\"http://hab.hrsa.gov/livinghistory/timeline/1987.htm\" target=\"_blank\">approved zidovudine or AZT\u003c/a> in 1987; it was the first antiretroviral medication to treat HIV.\u003c/p>\n\u003cp>By 1996, \u003ca href=\"http://www.cdc.gov/hiv/prevention/research/tap/\" target=\"_blank\">drug \"cocktails\" to treat HIV\u003c/a> became the standard of care for most patients. These highly active anti-retroviral therapies (HAART) helped manage the patient's viral load, maintained function of the immune system and prevented infections that could become fatal.\u003c/p>\n\u003cp>After HAART became widespread, the Centers for Disease Control and Prevention \u003ca href=\"http://www.cdc.gov/nchs/hus/chartbook.htm\" target=\"_blank\">reported a marked reduction in HIV-related deaths\u003c/a>.\u003c/p>\n\u003cp>But these medications have side effects.\u003c/p>\n\u003cp>\"Antiretrovirals are not a panacea,\" says amfAR CEO Kevin Robert Frost, who's based at the organization's headquarters in New York.\u003c/p>\n\u003cfigure id=\"attachment_72312\" class=\"wp-caption alignright\" style=\"max-width: 480px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad.jpg\">\u003cimg class=\"wp-image-72312 size-medium\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756-480x600.jpg\" alt=\"A Kenneth Cole/amfAR ad from 1993 when 234,225 died of AIDS.\" width=\"480\" height=\"600\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756-480x600.jpg 480w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756-400x500.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756.jpg 574w\" sizes=\"(max-width: 480px) 100vw, 480px\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">A Kenneth Cole/amfAR ad from 1993 when 234,225 people died of AIDS. \u003ccite>(amfAR)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>Frost says the drugs have side effects that include chronic inflammation and a range of infections that attack the weakened immune system.\u003c/p>\n\u003cp>That's why amfAR is spending $100 million to find a cure for the \u003ca href=\"http://www.amfar.org/worldwide-aids-stats/\" target=\"_blank\">nearly 37 million people living with HIV\u003c/a> around the world.\u003c/p>\n\u003cp>\"The only real way out of an epidemic like this is through a cure and a vaccine,\" says Frost. \"Because we’re gonna have to cure the people who have it now and we’re gonna have to vaccinate those to prevent them from getting it in the future.\"\u003c/p>\n\u003cp>\u003cstrong>'Shock and Kill' the Virus\u003c/strong>\u003c/p>\n\u003cp>Like many HIV patients, TJ Lee is active and pain-free.\u003c/p>\n\u003cp>\"Once you get on meds and take care of yourself, you can live a very normal life,\" says Lee, who has been HIV-positive for 16 years.\u003c/p>\n\u003cp>The San Francisco resident takes just one pill a day to manage his HIV. As a program manager at the San Francisco AIDS Foundation he works with newly diagnosed people who don't know HIV is no longer a death sentence.\u003c/p>\n\u003cp>\"I had somebody call me about a month ago,\" Lee says. \"He recently found out he had HIV and he thought he was going to die soon.\"\u003c/p>\n\u003cp>For people who have access to treatment, that's not really a concern anymore.\u003c/p>\n\u003cp>However, even people who are free of symptoms can have HIV lying dormant in their body’s T cells for years. The inactive virus could one day become active and reproduce.\u003c/p>\n\u003cp>Eliminating that latent virus is the focus of UCSF's research. With the $20 million amfAR grant, Volberding wants to target these viral cells with a method he calls shock and kill.\u003c/p>\n\u003cp>\u003cem>The Shock and Kill Method of Eliminating the Virus\u003c/em>\u003cbr>\n\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Shock-and-kill_edited1.jpg\">\u003cimg class=\"size-medium wp-image-66472 aligncenter\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Shock-and-kill_edited1-800x230.jpg\" alt=\"Shock and kill_edited\" width=\"800\" height=\"230\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-800x230.jpg 800w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-400x115.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-1180x339.jpg 1180w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-960x276.jpg 960w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1.jpg 1592w\" sizes=\"(max-width: 800px) 100vw, 800px\">\u003c/a>\u003c/p>\n\u003cp>\"If the virus is dormant, we first need to wake up that cell to start producing the virus, that’s the shock part of it,\" Volberding says. \"And then, once the virus has been activated we want to do something to help the body kill off those cells, to get rid of the virus.\"\u003c/p>\n\u003cp>Researchers have to wake up the virus because when it’s dormant, the infected cell is invisible to the immune system. By shocking it out of latency, scientists can kill the infected cells, and kill the virus as it reproduces.\u003c/p>\n\u003cp>\u003cstrong>Listen to the Story:\u003c/strong>\u003cbr>\nhttp://www.kqed.org/.stream/anon/radio//2015/11/AIDSCure.mp3\u003c/p>\n\u003cp>This method could be \u003cem>an \u003c/em>answer, Frost says, not \u003cem>the\u003c/em> answer. Researchers are working on multiple ways of reducing the body's viral load, including rapid early treatment to abort the infection and gene therapy to engineer cells to make them resistant to infection. Plus, public health efforts aimed at prevention and treatment will continue to be important, especially in places like sub-Saharan Africa, where 28.5 million people are infected with HIV.\u003c/p>\n\u003cp>\"I don’t think we’re gonna wake up one day and see a headline in the newspaper that says 'Cure for AIDS Found,'” Frost says. \"It’s not that kind of a disease, it’s much more complicated than that.\"\u003c/p>\n\u003caside class=\"pullquote alignleft\">‘People who say a cure for AIDS is impossible simply don’t understand the science.’\u003ccite> Kevin Robert Frost,\u003cbr>\namfAR CEO\u003c/cite>\u003c/aside>\n\u003cp>Because HIV mutates so quickly, he adds, a cure is likely to come in stages—sort of like a cancer model where a patient goes into remission.\u003c/p>\n\u003cp>Remission would mean a point where the patient doesn’t need treatment, can’t infect anyone, and doesn't have chronic illnesses.\u003c/p>\n\u003cp>\"We’re likely to start out curing some of the people some of the time, then more of the people more of the time,\" he says, \"and hopefully get to a place where we cure most of the people most of the time, and everybody who needs it has access to it.\"\u003c/p>\n\u003cp>Frost says eliminating the virus will take not one, but a series of scientific breakthroughs, as researchers work on all fronts from latency to gene editing and gene therapy.\u003c/p>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>\"There are those who said space travel would never happen,\" says Frost. \"People who say a cure for AIDS is impossible simply don’t understand the science. We’re going to find a cure for AIDS; I can tell you that without the slightest hesitation or doubt in my mind.\"\u003c/p>\n\n",
"disqusIdentifier": "64080 http://ww2.kqed.org/futureofyou/?p=64080",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2015/11/30/a-cure-for-aids-scientists-say-its-on-the-horizon/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": true,
"hasPolis": false,
"wordCount": 1141,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 38
},
"modified": 1456901661,
"excerpt": "Thirty years since the AIDS epidemic broke out, we're closer than ever to finding a cure. And Bay Area scientists are getting $20 million to help find it.\r\n",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "Thirty years since the AIDS epidemic broke out, we're closer than ever to finding a cure. And Bay Area scientists are getting $20 million to help find it.\r\n",
"title": "A Cure for AIDS: Scientists Say It's 'On the Horizon' | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "A Cure for AIDS: Scientists Say It's 'On the Horizon'",
"datePublished": "2015-11-30T09:20:37-08:00",
"dateModified": "2016-03-01T22:54:21-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "a-cure-for-aids-scientists-say-its-on-the-horizon",
"status": "publish",
"path": "/futureofyou/64080/a-cure-for-aids-scientists-say-its-on-the-horizon",
"audioUrl": "http://www.kqed.org/.stream/anon/radio//2015/11/AIDSCure.mp3",
"audioDuration": null,
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>\u003cspan style=\"font-size: 4.6875em;float: left;line-height: 0.733em;padding: 0.05em 0.1em 0 0;font-family: times, serif, georgia\">P\u003c/span>aul Volberding is a UCSF oncologist who treated San Francisco's first HIV patients in the early 1980s.\u003c/p>\n\u003cp>\"The patients were, in many cases, blind and demented and had cancer and had infections in their brains causing pressure and headaches,\" says Volberding. \"People now can’t imagine it, it was so bad.\"\u003c/p>\n\u003cp>Volberding says for years, HIV infection was a rapid death sentence. But in the 35 years since the epidemic began—thanks to sophisticated anti-retrovirals—it’s become a chronic illness that people can live with for decades.\u003c/p>\n\u003cp>Today, on the eve of World AIDS Day, UCSF is scheduled to announce that it's receiving a $20 million grant to find a cure for AIDS over the next five years. It's part of a $100 million effort by the \u003ca href=\"http://www.amfar.org/\" target=\"_blank\">American Foundation for AIDS Research\u003c/a> or amfAR, to fund the most promising research that could lead to curing AIDS.\u003c/p>\n\u003cp>Not long ago this might have sounded unbelievable.\u003c/p>\n\u003cfigure id=\"attachment_65878\" class=\"wp-caption alignleft\" style=\"max-width: 766px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Paul-Volberding_1981-e1447277818233.jpg\">\u003cimg class=\"size-medium wp-image-65878\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Paul-Volberding_1981-766x600.jpg\" alt=\"In 1981 Marcus Conant, MD (left) and Paul Volberding, MD (right) discuss Kaposi's Sarcoma, a disease that became one of the original AIDS-defining illnesses. \" width=\"766\" height=\"600\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">In 1981, Dr. Marcus Conant (left) and Dr. Paul Volberding (right) discuss Kaposi's Sarcoma, which became one of the original AIDS-defining illnesses. \u003ccite>(UCSF)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>“I think it would have felt a lot like a moonshot, maybe five or six years ago,” Volberding says.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>But today, Volberding's lab and others in San Francisco are working for that moonshot: to develop treatments over the next several years that can drive the viral load down low enough that the body's own immune system can control or eliminate it.\u003c/p>\n\u003cp>\"If it can be done anywhere, it can be done here,\" he says. \"It's a really exciting moment.\"\u003c/p>\n\u003cp>\u003cstrong>The Problem With Treatment\u003c/strong>\u003c/p>\n\u003cp>The U.S. Food and Drug Administration \u003ca href=\"http://hab.hrsa.gov/livinghistory/timeline/1987.htm\" target=\"_blank\">approved zidovudine or AZT\u003c/a> in 1987; it was the first antiretroviral medication to treat HIV.\u003c/p>\n\u003cp>By 1996, \u003ca href=\"http://www.cdc.gov/hiv/prevention/research/tap/\" target=\"_blank\">drug \"cocktails\" to treat HIV\u003c/a> became the standard of care for most patients. These highly active anti-retroviral therapies (HAART) helped manage the patient's viral load, maintained function of the immune system and prevented infections that could become fatal.\u003c/p>\n\u003cp>After HAART became widespread, the Centers for Disease Control and Prevention \u003ca href=\"http://www.cdc.gov/nchs/hus/chartbook.htm\" target=\"_blank\">reported a marked reduction in HIV-related deaths\u003c/a>.\u003c/p>\n\u003cp>But these medications have side effects.\u003c/p>\n\u003cp>\"Antiretrovirals are not a panacea,\" says amfAR CEO Kevin Robert Frost, who's based at the organization's headquarters in New York.\u003c/p>\n\u003cfigure id=\"attachment_72312\" class=\"wp-caption alignright\" style=\"max-width: 480px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad.jpg\">\u003cimg class=\"wp-image-72312 size-medium\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756-480x600.jpg\" alt=\"A Kenneth Cole/amfAR ad from 1993 when 234,225 died of AIDS.\" width=\"480\" height=\"600\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756-480x600.jpg 480w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756-400x500.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Kenneth-Cole_AIDS_ad-e1448386139756.jpg 574w\" sizes=\"(max-width: 480px) 100vw, 480px\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">A Kenneth Cole/amfAR ad from 1993 when 234,225 people died of AIDS. \u003ccite>(amfAR)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>Frost says the drugs have side effects that include chronic inflammation and a range of infections that attack the weakened immune system.\u003c/p>\n\u003cp>That's why amfAR is spending $100 million to find a cure for the \u003ca href=\"http://www.amfar.org/worldwide-aids-stats/\" target=\"_blank\">nearly 37 million people living with HIV\u003c/a> around the world.\u003c/p>\n\u003cp>\"The only real way out of an epidemic like this is through a cure and a vaccine,\" says Frost. \"Because we’re gonna have to cure the people who have it now and we’re gonna have to vaccinate those to prevent them from getting it in the future.\"\u003c/p>\n\u003cp>\u003cstrong>'Shock and Kill' the Virus\u003c/strong>\u003c/p>\n\u003cp>Like many HIV patients, TJ Lee is active and pain-free.\u003c/p>\n\u003cp>\"Once you get on meds and take care of yourself, you can live a very normal life,\" says Lee, who has been HIV-positive for 16 years.\u003c/p>\n\u003cp>The San Francisco resident takes just one pill a day to manage his HIV. As a program manager at the San Francisco AIDS Foundation he works with newly diagnosed people who don't know HIV is no longer a death sentence.\u003c/p>\n\u003cp>\"I had somebody call me about a month ago,\" Lee says. \"He recently found out he had HIV and he thought he was going to die soon.\"\u003c/p>\n\u003cp>For people who have access to treatment, that's not really a concern anymore.\u003c/p>\n\u003cp>However, even people who are free of symptoms can have HIV lying dormant in their body’s T cells for years. The inactive virus could one day become active and reproduce.\u003c/p>\n\u003cp>Eliminating that latent virus is the focus of UCSF's research. With the $20 million amfAR grant, Volberding wants to target these viral cells with a method he calls shock and kill.\u003c/p>\n\u003cp>\u003cem>The Shock and Kill Method of Eliminating the Virus\u003c/em>\u003cbr>\n\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Shock-and-kill_edited1.jpg\">\u003cimg class=\"size-medium wp-image-66472 aligncenter\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2015/11/Shock-and-kill_edited1-800x230.jpg\" alt=\"Shock and kill_edited\" width=\"800\" height=\"230\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-800x230.jpg 800w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-400x115.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-1180x339.jpg 1180w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1-960x276.jpg 960w, https://ww2.kqed.org/app/uploads/sites/13/2015/11/Shock-and-kill_edited1.jpg 1592w\" sizes=\"(max-width: 800px) 100vw, 800px\">\u003c/a>\u003c/p>\n\u003cp>\"If the virus is dormant, we first need to wake up that cell to start producing the virus, that’s the shock part of it,\" Volberding says. \"And then, once the virus has been activated we want to do something to help the body kill off those cells, to get rid of the virus.\"\u003c/p>\n\u003cp>Researchers have to wake up the virus because when it’s dormant, the infected cell is invisible to the immune system. By shocking it out of latency, scientists can kill the infected cells, and kill the virus as it reproduces.\u003c/p>\n\u003cp>\u003cstrong>Listen to the Story:\u003c/strong>\u003cbr>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "audioLink",
"attributes": {
"named": {
"src": "http://www.kqed.org/.stream/anon/radio//2015/11/AIDSCure.mp3"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>This method could be \u003cem>an \u003c/em>answer, Frost says, not \u003cem>the\u003c/em> answer. Researchers are working on multiple ways of reducing the body's viral load, including rapid early treatment to abort the infection and gene therapy to engineer cells to make them resistant to infection. Plus, public health efforts aimed at prevention and treatment will continue to be important, especially in places like sub-Saharan Africa, where 28.5 million people are infected with HIV.\u003c/p>\n\u003cp>\"I don’t think we’re gonna wake up one day and see a headline in the newspaper that says 'Cure for AIDS Found,'” Frost says. \"It’s not that kind of a disease, it’s much more complicated than that.\"\u003c/p>\n\u003caside class=\"pullquote alignleft\">‘People who say a cure for AIDS is impossible simply don’t understand the science.’\u003ccite> Kevin Robert Frost,\u003cbr>\namfAR CEO\u003c/cite>\u003c/aside>\n\u003cp>Because HIV mutates so quickly, he adds, a cure is likely to come in stages—sort of like a cancer model where a patient goes into remission.\u003c/p>\n\u003cp>Remission would mean a point where the patient doesn’t need treatment, can’t infect anyone, and doesn't have chronic illnesses.\u003c/p>\n\u003cp>\"We’re likely to start out curing some of the people some of the time, then more of the people more of the time,\" he says, \"and hopefully get to a place where we cure most of the people most of the time, and everybody who needs it has access to it.\"\u003c/p>\n\u003cp>Frost says eliminating the virus will take not one, but a series of scientific breakthroughs, as researchers work on all fronts from latency to gene editing and gene therapy.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"There are those who said space travel would never happen,\" says Frost. \"People who say a cure for AIDS is impossible simply don’t understand the science. We’re going to find a cure for AIDS; I can tell you that without the slightest hesitation or doubt in my mind.\"\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/64080/a-cure-for-aids-scientists-say-its-on-the-horizon",
"authors": [
"5432"
],
"categories": [
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_650",
"futureofyou_669",
"futureofyou_80",
"futureofyou_113"
],
"featImg": "futureofyou_66445",
"label": "futureofyou"
}
},
"podcastsReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"podcasts": {}
},
"radioProgramsReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"radioPrograms": {}
},
"radioSearchSegmentsReducer": {},
"programsReducer": {
"all-things-considered": {
"id": "all-things-considered",
"title": "All Things Considered",
"info": "Every weekday, \u003cem>All Things Considered\u003c/em> hosts Robert Siegel, Audie Cornish, Ari Shapiro, and Kelly McEvers present the program's trademark mix of news, interviews, commentaries, reviews, and offbeat features. Michel Martin hosts on the weekends.",
"airtime": "MON-FRI 1pm-2pm, 4:30pm-6:30pm\u003cbr />SAT-SUN 5pm-6pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/All-Things-Considered-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/all-things-considered/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/all-things-considered"
},
"american-suburb-podcast": {
"id": "american-suburb-podcast",
"title": "American Suburb: The Podcast",
"tagline": "The flip side of gentrification, told through one town",
"info": "Gentrification is changing cities across America, forcing people from neighborhoods they have long called home. Call them the displaced. Now those priced out of the Bay Area are looking for a better life in an unlikely place. American Suburb follows this migration to one California town along the Delta, 45 miles from San Francisco. But is this once sleepy suburb ready for them?",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/American-Suburb-Podcast-Tile-703x703-1.jpg",
"officialWebsiteLink": "/news/series/american-suburb-podcast",
"meta": {
"site": "news",
"source": "kqed",
"order": 19
},
"link": "/news/series/american-suburb-podcast/",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/RBrW",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?mt=2&id=1287748328",
"tuneIn": "https://tunein.com/radio/American-Suburb-p1086805/",
"rss": "https://ww2.kqed.org/news/series/american-suburb-podcast/feed/podcast",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkMzMDExODgxNjA5"
}
},
"baycurious": {
"id": "baycurious",
"title": "Bay Curious",
"tagline": "Exploring the Bay Area, one question at a time",
"info": "KQED’s new podcast, Bay Curious, gets to the bottom of the mysteries — both profound and peculiar — that give the Bay Area its unique identity. And we’ll do it with your help! You ask the questions. You decide what Bay Curious investigates. And you join us on the journey to find the answers.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Bay-Curious-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Bay Curious",
"officialWebsiteLink": "/news/series/baycurious",
"meta": {
"site": "news",
"source": "kqed",
"order": 3
},
"link": "/podcasts/baycurious",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/bay-curious/id1172473406",
"npr": "https://www.npr.org/podcasts/500557090/bay-curious",
"rss": "https://ww2.kqed.org/news/category/bay-curious-podcast/feed/podcast",
"amazon": "https://music.amazon.com/podcasts/9a90d476-aa04-455d-9a4c-0871ed6216d4/bay-curious",
"stitcher": "https://www.stitcher.com/podcast/kqed/bay-curious",
"spotify": "https://open.spotify.com/show/6O76IdmhixfijmhTZLIJ8k"
}
},
"bbc-world-service": {
"id": "bbc-world-service",
"title": "BBC World Service",
"info": "The day's top stories from BBC News compiled twice daily in the week, once at weekends.",
"airtime": "MON-FRI 9pm-10pm, TUE-FRI 1am-2am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/BBC-World-Service-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.bbc.co.uk/sounds/play/live:bbc_world_service",
"meta": {
"site": "news",
"source": "BBC World Service"
},
"link": "/radio/program/bbc-world-service",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/global-news-podcast/id135067274?mt=2",
"tuneIn": "https://tunein.com/radio/BBC-World-Service-p455581/",
"rss": "https://podcasts.files.bbci.co.uk/p02nq0gn.rss"
}
},
"californiareport": {
"id": "californiareport",
"title": "The California Report",
"tagline": "California, day by day",
"info": "KQED’s statewide radio news program providing daily coverage of issues, trends and public policy decisions.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-California-Report-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The California Report",
"officialWebsiteLink": "/californiareport",
"meta": {
"site": "news",
"source": "kqed",
"order": 8
},
"link": "/californiareport",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/kqeds-the-california-report/id79681292",
"amazon": "https://music.amazon.com/podcasts/26099305-72af-4542-9dde-ac1807fe36d5/kqed-s-the-california-report",
"npr": "https://www.npr.org/podcasts/432285393/the-california-report",
"stitcher": "https://www.stitcher.com/podcast/kqedfm-kqeds-the-california-report-podcast-8838",
"rss": "https://ww2.kqed.org/news/tag/tcram/feed/podcast"
}
},
"californiareportmagazine": {
"id": "californiareportmagazine",
"title": "The California Report Magazine",
"tagline": "Your state, your stories",
"info": "Every week, The California Report Magazine takes you on a road trip for the ears: to visit the places and meet the people who make California unique. The in-depth storytelling podcast from the California Report.",
"airtime": "FRI 4:30pm-5pm, 6:30pm-7pm, 11pm-11:30pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-California-Report-Magazine-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The California Report Magazine",
"officialWebsiteLink": "/californiareportmagazine",
"meta": {
"site": "news",
"source": "kqed",
"order": 10
},
"link": "/californiareportmagazine",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-california-report-magazine/id1314750545",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM3NjkwNjk1OTAz",
"npr": "https://www.npr.org/podcasts/564733126/the-california-report-magazine",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-california-report-magazine",
"rss": "https://ww2.kqed.org/news/tag/tcrmag/feed/podcast"
}
},
"city-arts": {
"id": "city-arts",
"title": "City Arts & Lectures",
"info": "A one-hour radio program to hear celebrated writers, artists and thinkers address contemporary ideas and values, often discussing the creative process. Please note: tapes or transcripts are not available",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/05/cityartsandlecture-300x300.jpg",
"officialWebsiteLink": "https://www.cityarts.net/",
"airtime": "SUN 1pm-2pm, TUE 10pm, WED 1am",
"meta": {
"site": "news",
"source": "City Arts & Lectures"
},
"link": "https://www.cityarts.net",
"subscribe": {
"tuneIn": "https://tunein.com/radio/City-Arts-and-Lectures-p692/",
"rss": "https://www.cityarts.net/feed/"
}
},
"closealltabs": {
"id": "closealltabs",
"title": "Close All Tabs",
"tagline": "Your irreverent guide to the trends redefining our world",
"info": "Close All Tabs breaks down how digital culture shapes our world through thoughtful insights and irreverent humor.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/02/CAT_2_Tile-scaled.jpg",
"imageAlt": "KQED Close All Tabs",
"officialWebsiteLink": "/podcasts/closealltabs",
"meta": {
"site": "news",
"source": "kqed",
"order": 1
},
"link": "/podcasts/closealltabs",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/close-all-tabs/id214663465",
"rss": "https://feeds.megaphone.fm/KQINC6993880386",
"amazon": "https://music.amazon.com/podcasts/92d9d4ac-67a3-4eed-b10a-fb45d45b1ef2/close-all-tabs",
"spotify": "https://open.spotify.com/show/6LAJFHnGK1pYXYzv6SIol6?si=deb0cae19813417c"
}
},
"code-switch-life-kit": {
"id": "code-switch-life-kit",
"title": "Code Switch / Life Kit",
"info": "\u003cem>Code Switch\u003c/em>, which listeners will hear in the first part of the hour, has fearless and much-needed conversations about race. Hosted by journalists of color, the show tackles the subject of race head-on, exploring how it impacts every part of society — from politics and pop culture to history, sports and more.\u003cbr />\u003cbr />\u003cem>Life Kit\u003c/em>, which will be in the second part of the hour, guides you through spaces and feelings no one prepares you for — from finances to mental health, from workplace microaggressions to imposter syndrome, from relationships to parenting. The show features experts with real world experience and shares their knowledge. Because everyone needs a little help being human.\u003cbr />\u003cbr />\u003ca href=\"https://www.npr.org/podcasts/510312/codeswitch\">\u003cem>Code Switch\u003c/em> offical site and podcast\u003c/a>\u003cbr />\u003ca href=\"https://www.npr.org/lifekit\">\u003cem>Life Kit\u003c/em> offical site and podcast\u003c/a>\u003cbr />",
"airtime": "SUN 9pm-10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Code-Switch-Life-Kit-Podcast-Tile-360x360-1.jpg",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/code-switch-life-kit",
"subscribe": {
"apple": "https://podcasts.apple.com/podcast/1112190608?mt=2&at=11l79Y&ct=nprdirectory",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly93d3cubnByLm9yZy9yc3MvcG9kY2FzdC5waHA_aWQ9NTEwMzEy",
"spotify": "https://open.spotify.com/show/3bExJ9JQpkwNhoHvaIIuyV",
"rss": "https://feeds.npr.org/510312/podcast.xml"
}
},
"commonwealth-club": {
"id": "commonwealth-club",
"title": "Commonwealth Club of California Podcast",
"info": "The Commonwealth Club of California is the nation's oldest and largest public affairs forum. As a non-partisan forum, The Club brings to the public airwaves diverse viewpoints on important topics. The Club's weekly radio broadcast - the oldest in the U.S., dating back to 1924 - is carried across the nation on public radio stations and is now podcasting. Our website archive features audio of our recent programs, as well as selected speeches from our long and distinguished history. This podcast feed is usually updated twice a week and is always un-edited.",
"airtime": "THU 10pm, FRI 1am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Commonwealth-Club-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.commonwealthclub.org/podcasts",
"meta": {
"site": "news",
"source": "Commonwealth Club of California"
},
"link": "/radio/program/commonwealth-club",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/commonwealth-club-of-california-podcast/id976334034?mt=2",
"google": "https://podcasts.google.com/feed/aHR0cDovL3d3dy5jb21tb253ZWFsdGhjbHViLm9yZy9hdWRpby9wb2RjYXN0L3dlZWtseS54bWw",
"tuneIn": "https://tunein.com/radio/Commonwealth-Club-of-California-p1060/"
}
},
"forum": {
"id": "forum",
"title": "Forum",
"tagline": "The conversation starts here",
"info": "KQED’s live call-in program discussing local, state, national and international issues, as well as in-depth interviews.",
"airtime": "MON-FRI 9am-11am, 10pm-11pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Forum-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Forum with Mina Kim and Alexis Madrigal",
"officialWebsiteLink": "/forum",
"meta": {
"site": "news",
"source": "kqed",
"order": 9
},
"link": "/forum",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/kqeds-forum/id73329719",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM5NTU3MzgxNjMz",
"npr": "https://www.npr.org/podcasts/432307980/forum",
"stitcher": "https://www.stitcher.com/podcast/kqedfm-kqeds-forum-podcast",
"rss": "https://feeds.megaphone.fm/KQINC9557381633"
}
},
"freakonomics-radio": {
"id": "freakonomics-radio",
"title": "Freakonomics Radio",
"info": "Freakonomics Radio is a one-hour award-winning podcast and public-radio project hosted by Stephen Dubner, with co-author Steve Levitt as a regular guest. It is produced in partnership with WNYC.",
"imageSrc": "https://ww2.kqed.org/news/wp-content/uploads/sites/10/2018/05/freakonomicsRadio.png",
"officialWebsiteLink": "http://freakonomics.com/",
"airtime": "SUN 1am-2am, SAT 3pm-4pm",
"meta": {
"site": "radio",
"source": "WNYC"
},
"link": "/radio/program/freakonomics-radio",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/4s8b",
"apple": "https://itunes.apple.com/us/podcast/freakonomics-radio/id354668519",
"tuneIn": "https://tunein.com/podcasts/WNYC-Podcasts/Freakonomics-Radio-p272293/",
"rss": "https://feeds.feedburner.com/freakonomicsradio"
}
},
"fresh-air": {
"id": "fresh-air",
"title": "Fresh Air",
"info": "Hosted by Terry Gross, \u003cem>Fresh Air from WHYY\u003c/em> is the Peabody Award-winning weekday magazine of contemporary arts and issues. One of public radio's most popular programs, Fresh Air features intimate conversations with today's biggest luminaries.",
"airtime": "MON-FRI 7pm-8pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Fresh-Air-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/fresh-air/",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/fresh-air",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/4s8b",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=214089682&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Fresh-Air-p17/",
"rss": "https://feeds.npr.org/381444908/podcast.xml"
}
},
"here-and-now": {
"id": "here-and-now",
"title": "Here & Now",
"info": "A live production of NPR and WBUR Boston, in collaboration with stations across the country, Here & Now reflects the fluid world of news as it's happening in the middle of the day, with timely, in-depth news, interviews and conversation. Hosted by Robin Young, Jeremy Hobson and Tonya Mosley.",
"airtime": "MON-THU 11am-12pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Here-And-Now-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "http://www.wbur.org/hereandnow",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/here-and-now",
"subsdcribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?mt=2&id=426698661",
"tuneIn": "https://tunein.com/radio/Here--Now-p211/",
"rss": "https://feeds.npr.org/510051/podcast.xml"
}
},
"hidden-brain": {
"id": "hidden-brain",
"title": "Hidden Brain",
"info": "Shankar Vedantam uses science and storytelling to reveal the unconscious patterns that drive human behavior, shape our choices and direct our relationships.",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/05/hiddenbrain.jpg",
"officialWebsiteLink": "https://www.npr.org/series/423302056/hidden-brain",
"airtime": "SUN 7pm-8pm",
"meta": {
"site": "news",
"source": "NPR"
},
"link": "/radio/program/hidden-brain",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/hidden-brain/id1028908750?mt=2",
"tuneIn": "https://tunein.com/podcasts/Science-Podcasts/Hidden-Brain-p787503/",
"rss": "https://feeds.npr.org/510308/podcast.xml"
}
},
"how-i-built-this": {
"id": "how-i-built-this",
"title": "How I Built This with Guy Raz",
"info": "Guy Raz dives into the stories behind some of the world's best known companies. How I Built This weaves a narrative journey about innovators, entrepreneurs and idealists—and the movements they built.",
"imageSrc": "https://ww2.kqed.org/news/wp-content/uploads/sites/10/2018/05/howIBuiltThis.png",
"officialWebsiteLink": "https://www.npr.org/podcasts/510313/how-i-built-this",
"airtime": "SUN 7:30pm-8pm",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/how-i-built-this",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/3zxy",
"apple": "https://itunes.apple.com/us/podcast/how-i-built-this-with-guy-raz/id1150510297?mt=2",
"tuneIn": "https://tunein.com/podcasts/Arts--Culture-Podcasts/How-I-Built-This-p910896/",
"rss": "https://feeds.npr.org/510313/podcast.xml"
}
},
"hyphenacion": {
"id": "hyphenacion",
"title": "Hyphenación",
"tagline": "Where conversation and cultura meet",
"info": "What kind of no sabo word is Hyphenación? For us, it’s about living within a hyphenation. Like being a third-gen Mexican-American from the Texas border now living that Bay Area Chicano life. Like Xorje! Each week we bring together a couple of hyphenated Latinos to talk all about personal life choices: family, careers, relationships, belonging … everything is on the table. ",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/03/Hyphenacion_FinalAssets_PodcastTile.png",
"imageAlt": "KQED Hyphenación",
"officialWebsiteLink": "/podcasts/hyphenacion",
"meta": {
"site": "news",
"source": "kqed",
"order": 15
},
"link": "/podcasts/hyphenacion",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/hyphenaci%C3%B3n/id1191591838",
"spotify": "https://open.spotify.com/show/2p3Fifq96nw9BPcmFdIq0o?si=39209f7b25774f38",
"youtube": "https://www.youtube.com/c/kqedarts",
"amazon": "https://music.amazon.com/podcasts/6c3dd23c-93fb-4aab-97ba-1725fa6315f1/hyphenaci%C3%B3n",
"rss": "https://feeds.megaphone.fm/KQINC2275451163"
}
},
"jerrybrown": {
"id": "jerrybrown",
"title": "The Political Mind of Jerry Brown",
"tagline": "Lessons from a lifetime in politics",
"info": "The Political Mind of Jerry Brown brings listeners the wisdom of the former Governor, Mayor, and presidential candidate. Scott Shafer interviewed Brown for more than 40 hours, covering the former governor's life and half-century in the political game – and Brown has some lessons he'd like to share. ",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Political-Mind-of-Jerry-Brown-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Political Mind of Jerry Brown",
"officialWebsiteLink": "/podcasts/jerrybrown",
"meta": {
"site": "news",
"source": "kqed",
"order": 18
},
"link": "/podcasts/jerrybrown",
"subscribe": {
"npr": "https://www.npr.org/podcasts/790253322/the-political-mind-of-jerry-brown",
"apple": "https://itunes.apple.com/us/podcast/id1492194549",
"rss": "https://ww2.kqed.org/news/series/jerrybrown/feed/podcast/",
"tuneIn": "http://tun.in/pjGcK",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-political-mind-of-jerry-brown",
"spotify": "https://open.spotify.com/show/54C1dmuyFyKMFttY6X2j6r?si=K8SgRCoISNK6ZbjpXrX5-w",
"amazon": "https://music.amazon.com/podcasts/44420f75-3b0e-4301-ab3b-16da6b09e543/the-political-mind-of-jerry-brown"
}
},
"latino-usa": {
"id": "latino-usa",
"title": "Latino USA",
"airtime": "MON 1am-2am, SUN 6pm-7pm",
"info": "Latino USA, the radio journal of news and culture, is the only national, English-language radio program produced from a Latino perspective.",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/latinoUsa.jpg",
"officialWebsiteLink": "http://latinousa.org/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/latino-usa",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/xtTd",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=79681317&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Latino-USA-p621/",
"rss": "https://feeds.npr.org/510016/podcast.xml"
}
},
"marketplace": {
"id": "marketplace",
"title": "Marketplace",
"info": "Our flagship program, helmed by Kai Ryssdal, examines what the day in money delivered, through stories, conversations, newsworthy numbers and more. Updated Monday through Friday at about 3:30 p.m. PT.",
"airtime": "MON-FRI 4pm-4:30pm, MON-WED 6:30pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Marketplace-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.marketplace.org/",
"meta": {
"site": "news",
"source": "American Public Media"
},
"link": "/radio/program/marketplace",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=201853034&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/APM-Marketplace-p88/",
"rss": "https://feeds.publicradio.org/public_feeds/marketplace-pm/rss/rss"
}
},
"masters-of-scale": {
"id": "masters-of-scale",
"title": "Masters of Scale",
"info": "Masters of Scale is an original podcast in which LinkedIn co-founder and Greylock Partner Reid Hoffman sets out to describe and prove theories that explain how great entrepreneurs take their companies from zero to a gazillion in ingenious fashion.",
"airtime": "Every other Wednesday June 12 through October 16 at 8pm (repeats Thursdays at 2am)",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Masters-of-Scale-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://mastersofscale.com/",
"meta": {
"site": "radio",
"source": "WaitWhat"
},
"link": "/radio/program/masters-of-scale",
"subscribe": {
"apple": "http://mastersofscale.app.link/",
"rss": "https://rss.art19.com/masters-of-scale"
}
},
"mindshift": {
"id": "mindshift",
"title": "MindShift",
"tagline": "A podcast about the future of learning and how we raise our kids",
"info": "The MindShift podcast explores the innovations in education that are shaping how kids learn. Hosts Ki Sung and Katrina Schwartz introduce listeners to educators, researchers, parents and students who are developing effective ways to improve how kids learn. We cover topics like how fed-up administrators are developing surprising tactics to deal with classroom disruptions; how listening to podcasts are helping kids develop reading skills; the consequences of overparenting; and why interdisciplinary learning can engage students on all ends of the traditional achievement spectrum. This podcast is part of the MindShift education site, a division of KQED News. KQED is an NPR/PBS member station based in San Francisco. You can also visit the MindShift website for episodes and supplemental blog posts or tweet us \u003ca href=\"https://twitter.com/MindShiftKQED\">@MindShiftKQED\u003c/a> or visit us at \u003ca href=\"/mindshift\">MindShift.KQED.org\u003c/a>",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Mindshift-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED MindShift: How We Will Learn",
"officialWebsiteLink": "/mindshift/",
"meta": {
"site": "news",
"source": "kqed",
"order": 12
},
"link": "/podcasts/mindshift",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/mindshift-podcast/id1078765985",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM1NzY0NjAwNDI5",
"npr": "https://www.npr.org/podcasts/464615685/mind-shift-podcast",
"stitcher": "https://www.stitcher.com/podcast/kqed/stories-teachers-share",
"spotify": "https://open.spotify.com/show/0MxSpNYZKNprFLCl7eEtyx"
}
},
"morning-edition": {
"id": "morning-edition",
"title": "Morning Edition",
"info": "\u003cem>Morning Edition\u003c/em> takes listeners around the country and the world with multi-faceted stories and commentaries every weekday. Hosts Steve Inskeep, David Greene and Rachel Martin bring you the latest breaking news and features to prepare you for the day.",
"airtime": "MON-FRI 3am-9am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Morning-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/morning-edition/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/morning-edition"
},
"onourwatch": {
"id": "onourwatch",
"title": "On Our Watch",
"tagline": "Deeply-reported investigative journalism",
"info": "For decades, the process for how police police themselves has been inconsistent – if not opaque. In some states, like California, these proceedings were completely hidden. After a new police transparency law unsealed scores of internal affairs files, our reporters set out to examine these cases and the shadow world of police discipline. On Our Watch brings listeners into the rooms where officers are questioned and witnesses are interrogated to find out who this system is really protecting. Is it the officers, or the public they've sworn to serve?",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/On-Our-Watch-Podcast-Tile-703x703-1.jpg",
"imageAlt": "On Our Watch from NPR and KQED",
"officialWebsiteLink": "/podcasts/onourwatch",
"meta": {
"site": "news",
"source": "kqed",
"order": 11
},
"link": "/podcasts/onourwatch",
"subscribe": {
"apple": "https://podcasts.apple.com/podcast/id1567098962",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5ucHIub3JnLzUxMDM2MC9wb2RjYXN0LnhtbD9zYz1nb29nbGVwb2RjYXN0cw",
"npr": "https://rpb3r.app.goo.gl/onourwatch",
"spotify": "https://open.spotify.com/show/0OLWoyizopu6tY1XiuX70x",
"tuneIn": "https://tunein.com/radio/On-Our-Watch-p1436229/",
"stitcher": "https://www.stitcher.com/show/on-our-watch",
"rss": "https://feeds.npr.org/510360/podcast.xml"
}
},
"on-the-media": {
"id": "on-the-media",
"title": "On The Media",
"info": "Our weekly podcast explores how the media 'sausage' is made, casts an incisive eye on fluctuations in the marketplace of ideas, and examines threats to the freedom of information and expression in America and abroad. For one hour a week, the show tries to lift the veil from the process of \"making media,\" especially news media, because it's through that lens that we see the world and the world sees us",
"airtime": "SUN 2pm-3pm, MON 12am-1am",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/onTheMedia.png",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/otm",
"meta": {
"site": "news",
"source": "wnyc"
},
"link": "/radio/program/on-the-media",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/on-the-media/id73330715?mt=2",
"tuneIn": "https://tunein.com/radio/On-the-Media-p69/",
"rss": "http://feeds.wnyc.org/onthemedia"
}
},
"pbs-newshour": {
"id": "pbs-newshour",
"title": "PBS NewsHour",
"info": "Analysis, background reports and updates from the PBS NewsHour putting today's news in context.",
"airtime": "MON-FRI 3pm-4pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/PBS-News-Hour-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.pbs.org/newshour/",
"meta": {
"site": "news",
"source": "pbs"
},
"link": "/radio/program/pbs-newshour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/pbs-newshour-full-show/id394432287?mt=2",
"tuneIn": "https://tunein.com/radio/PBS-NewsHour---Full-Show-p425698/",
"rss": "https://www.pbs.org/newshour/feeds/rss/podcasts/show"
}
},
"perspectives": {
"id": "perspectives",
"title": "Perspectives",
"tagline": "KQED's series of daily listener commentaries since 1991",
"info": "KQED's series of daily listener commentaries since 1991.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/01/Perspectives_Tile_Final.jpg",
"imageAlt": "KQED Perspectives",
"officialWebsiteLink": "/perspectives/",
"meta": {
"site": "radio",
"source": "kqed",
"order": 14
},
"link": "/perspectives",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/id73801135",
"npr": "https://www.npr.org/podcasts/432309616/perspectives",
"rss": "https://ww2.kqed.org/perspectives/category/perspectives/feed/",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly93dzIua3FlZC5vcmcvcGVyc3BlY3RpdmVzL2NhdGVnb3J5L3BlcnNwZWN0aXZlcy9mZWVkLw"
}
},
"planet-money": {
"id": "planet-money",
"title": "Planet Money",
"info": "The economy explained. Imagine you could call up a friend and say, Meet me at the bar and tell me what's going on with the economy. Now imagine that's actually a fun evening.",
"airtime": "SUN 3pm-4pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/planetmoney.jpg",
"officialWebsiteLink": "https://www.npr.org/sections/money/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/planet-money",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/M4f5",
"apple": "https://itunes.apple.com/us/podcast/planet-money/id290783428?mt=2",
"tuneIn": "https://tunein.com/podcasts/Business--Economics-Podcasts/Planet-Money-p164680/",
"rss": "https://feeds.npr.org/510289/podcast.xml"
}
},
"politicalbreakdown": {
"id": "politicalbreakdown",
"title": "Political Breakdown",
"tagline": "Politics from a personal perspective",
"info": "Political Breakdown is a new series that explores the political intersection of California and the nation. Each week hosts Scott Shafer and Marisa Lagos are joined with a new special guest to unpack politics -- with personality — and offer an insider’s glimpse at how politics happens.",
"airtime": "THU 6:30pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Political-Breakdown-2024-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Political Breakdown",
"officialWebsiteLink": "/podcasts/politicalbreakdown",
"meta": {
"site": "radio",
"source": "kqed",
"order": 5
},
"link": "/podcasts/politicalbreakdown",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/political-breakdown/id1327641087",
"amazon": "https://music.amazon.com/podcasts/e0c2d153-ad36-4c8d-901d-f1da6a724824/political-breakdown",
"npr": "https://www.npr.org/podcasts/572155894/political-breakdown",
"stitcher": "https://www.stitcher.com/podcast/kqed/political-breakdown",
"spotify": "https://open.spotify.com/show/07RVyIjIdk2WDuVehvBMoN",
"rss": "https://ww2.kqed.org/news/tag/political-breakdown/feed/podcast"
}
},
"possible": {
"id": "possible",
"title": "Possible",
"info": "Possible is hosted by entrepreneur Reid Hoffman and writer Aria Finger. Together in Possible, Hoffman and Finger lead enlightening discussions about building a brighter collective future. The show features interviews with visionary guests like Trevor Noah, Sam Altman and Janette Sadik-Khan. Possible paints an optimistic portrait of the world we can create through science, policy, business, art and our shared humanity. It asks: What if everything goes right for once? How can we get there? Each episode also includes a short fiction story generated by advanced AI GPT-4, serving as a thought-provoking springboard to speculate how humanity could leverage technology for good.",
"airtime": "SUN 2pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Possible-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.possible.fm/",
"meta": {
"site": "news",
"source": "Possible"
},
"link": "/radio/program/possible",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/possible/id1677184070",
"spotify": "https://open.spotify.com/show/730YpdUSNlMyPQwNnyjp4k"
}
},
"pri-the-world": {
"id": "pri-the-world",
"title": "PRI's The World: Latest Edition",
"info": "Each weekday, host Marco Werman and his team of producers bring you the world's most interesting stories in an hour of radio that reminds us just how small our planet really is.",
"airtime": "MON-FRI 2pm-3pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-World-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.pri.org/programs/the-world",
"meta": {
"site": "news",
"source": "PRI"
},
"link": "/radio/program/pri-the-world",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/pris-the-world-latest-edition/id278196007?mt=2",
"tuneIn": "https://tunein.com/podcasts/News--Politics-Podcasts/PRIs-The-World-p24/",
"rss": "http://feeds.feedburner.com/pri/theworld"
}
},
"radiolab": {
"id": "radiolab",
"title": "Radiolab",
"info": "A two-time Peabody Award-winner, Radiolab is an investigation told through sounds and stories, and centered around one big idea. In the Radiolab world, information sounds like music and science and culture collide. Hosted by Jad Abumrad and Robert Krulwich, the show is designed for listeners who demand skepticism, but appreciate wonder. WNYC Studios is the producer of other leading podcasts including Freakonomics Radio, Death, Sex & Money, On the Media and many more.",
"airtime": "SUN 12am-1am, SAT 2pm-3pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/radiolab1400.png",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/radiolab/",
"meta": {
"site": "science",
"source": "WNYC"
},
"link": "/radio/program/radiolab",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/radiolab/id152249110?mt=2",
"tuneIn": "https://tunein.com/radio/RadioLab-p68032/",
"rss": "https://feeds.wnyc.org/radiolab"
}
},
"reveal": {
"id": "reveal",
"title": "Reveal",
"info": "Created by The Center for Investigative Reporting and PRX, Reveal is public radios first one-hour weekly radio show and podcast dedicated to investigative reporting. Credible, fact based and without a partisan agenda, Reveal combines the power and artistry of driveway moment storytelling with data-rich reporting on critically important issues. The result is stories that inform and inspire, arming our listeners with information to right injustices, hold the powerful accountable and improve lives.Reveal is hosted by Al Letson and showcases the award-winning work of CIR and newsrooms large and small across the nation. In a radio and podcast market crowded with choices, Reveal focuses on important and often surprising stories that illuminate the world for our listeners.",
"airtime": "SAT 4pm-5pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/reveal300px.png",
"officialWebsiteLink": "https://www.revealnews.org/episodes/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/reveal",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/reveal/id886009669",
"tuneIn": "https://tunein.com/radio/Reveal-p679597/",
"rss": "http://feeds.revealradio.org/revealpodcast"
}
},
"rightnowish": {
"id": "rightnowish",
"title": "Rightnowish",
"tagline": "Art is where you find it",
"info": "Rightnowish digs into life in the Bay Area right now… ish. Journalist Pendarvis Harshaw takes us to galleries painted on the sides of liquor stores in West Oakland. We'll dance in warehouses in the Bayview, make smoothies with kids in South Berkeley, and listen to classical music in a 1984 Cutlass Supreme in Richmond. Every week, Pen talks to movers and shakers about how the Bay Area shapes what they create, and how they shape the place we call home.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Rightnowish-Podcast-Tile-500x500-1.jpg",
"imageAlt": "KQED Rightnowish with Pendarvis Harshaw",
"officialWebsiteLink": "/podcasts/rightnowish",
"meta": {
"site": "arts",
"source": "kqed",
"order": 16
},
"link": "/podcasts/rightnowish",
"subscribe": {
"npr": "https://www.npr.org/podcasts/721590300/rightnowish",
"rss": "https://ww2.kqed.org/arts/programs/rightnowish/feed/podcast",
"apple": "https://podcasts.apple.com/us/podcast/rightnowish/id1482187648",
"stitcher": "https://www.stitcher.com/podcast/kqed/rightnowish",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkMxMjU5MTY3NDc4",
"spotify": "https://open.spotify.com/show/7kEJuafTzTVan7B78ttz1I"
}
},
"science-friday": {
"id": "science-friday",
"title": "Science Friday",
"info": "Science Friday is a weekly science talk show, broadcast live over public radio stations nationwide. Each week, the show focuses on science topics that are in the news and tries to bring an educated, balanced discussion to bear on the scientific issues at hand. Panels of expert guests join host Ira Flatow, a veteran science journalist, to discuss science and to take questions from listeners during the call-in portion of the program.",
"airtime": "FRI 11am-1pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Science-Friday-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/science-friday",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/science-friday",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=73329284&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Science-Friday-p394/",
"rss": "http://feeds.wnyc.org/science-friday"
}
},
"snap-judgment": {
"id": "snap-judgment",
"title": "Snap Judgment",
"tagline": "Real stories with killer beats",
"info": "The Snap Judgment radio show and podcast mixes real stories with killer beats to produce cinematic, dramatic radio. Snap's musical brand of storytelling dares listeners to see the world through the eyes of another. This is storytelling... with a BEAT!! Snap first aired on public radio stations nationwide in July 2010. Today, Snap Judgment airs on over 450 public radio stations and is brought to the airwaves by KQED & PRX.",
"airtime": "SAT 1pm-2pm, 9pm-10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/05/Snap-Judgment-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Snap Judgment",
"officialWebsiteLink": "https://snapjudgment.org",
"meta": {
"site": "arts",
"source": "kqed",
"order": 4
},
"link": "https://snapjudgment.org",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/snap-judgment/id283657561",
"npr": "https://www.npr.org/podcasts/449018144/snap-judgment",
"stitcher": "https://www.pandora.com/podcast/snap-judgment/PC:241?source=stitcher-sunset",
"spotify": "https://open.spotify.com/show/3Cct7ZWmxHNAtLgBTqjC5v",
"rss": "https://snap.feed.snapjudgment.org/"
}
},
"soldout": {
"id": "soldout",
"title": "SOLD OUT: Rethinking Housing in America",
"tagline": "A new future for housing",
"info": "Sold Out: Rethinking Housing in America",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Sold-Out-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Sold Out: Rethinking Housing in America",
"officialWebsiteLink": "/podcasts/soldout",
"meta": {
"site": "news",
"source": "kqed",
"order": 13
},
"link": "/podcasts/soldout",
"subscribe": {
"npr": "https://www.npr.org/podcasts/911586047/s-o-l-d-o-u-t-a-new-future-for-housing",
"apple": "https://podcasts.apple.com/us/podcast/introducing-sold-out-rethinking-housing-in-america/id1531354937",
"rss": "https://feeds.megaphone.fm/soldout",
"spotify": "https://open.spotify.com/show/38dTBSk2ISFoPiyYNoKn1X",
"stitcher": "https://www.stitcher.com/podcast/kqed/sold-out-rethinking-housing-in-america",
"tunein": "https://tunein.com/radio/SOLD-OUT-Rethinking-Housing-in-America-p1365871/"
}
},
"spooked": {
"id": "spooked",
"title": "Spooked",
"tagline": "True-life supernatural stories",
"info": "",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/10/Spooked-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Spooked",
"officialWebsiteLink": "https://spookedpodcast.org/",
"meta": {
"site": "news",
"source": "kqed",
"order": 7
},
"link": "https://spookedpodcast.org/",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/spooked/id1279361017",
"npr": "https://www.npr.org/podcasts/549547848/snap-judgment-presents-spooked",
"spotify": "https://open.spotify.com/show/76571Rfl3m7PLJQZKQIGCT",
"rss": "https://feeds.simplecast.com/TBotaapn"
}
},
"tech-nation": {
"id": "tech-nation",
"title": "Tech Nation Radio Podcast",
"info": "Tech Nation is a weekly public radio program, hosted by Dr. Moira Gunn. Founded in 1993, it has grown from a simple interview show to a multi-faceted production, featuring conversations with noted technology and science leaders, and a weekly science and technology-related commentary.",
"airtime": "FRI 10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Tech-Nation-Radio-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "http://technation.podomatic.com/",
"meta": {
"site": "science",
"source": "Tech Nation Media"
},
"link": "/radio/program/tech-nation",
"subscribe": {
"rss": "https://technation.podomatic.com/rss2.xml"
}
},
"ted-radio-hour": {
"id": "ted-radio-hour",
"title": "TED Radio Hour",
"info": "The TED Radio Hour is a journey through fascinating ideas, astonishing inventions, fresh approaches to old problems, and new ways to think and create.",
"airtime": "SUN 3pm-4pm, SAT 10pm-11pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/tedRadioHour.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/ted-radio-hour/?showDate=2018-06-22",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/ted-radio-hour",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/8vsS",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=523121474&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/TED-Radio-Hour-p418021/",
"rss": "https://feeds.npr.org/510298/podcast.xml"
}
},
"thebay": {
"id": "thebay",
"title": "The Bay",
"tagline": "Local news to keep you rooted",
"info": "Host Devin Katayama walks you through the biggest story of the day with reporters and newsmakers.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Bay-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Bay",
"officialWebsiteLink": "/podcasts/thebay",
"meta": {
"site": "radio",
"source": "kqed",
"order": 2
},
"link": "/podcasts/thebay",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-bay/id1350043452",
"amazon": "https://music.amazon.com/podcasts/d800ea4c-7a2c-42f2-b861-edaf78a5db0b/the-bay",
"npr": "https://www.npr.org/podcasts/586725995/the-bay",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-bay",
"spotify": "https://open.spotify.com/show/4BIKBKIujizLHlIlBNaAqQ",
"rss": "https://feeds.megaphone.fm/KQINC8259786327"
}
},
"thelatest": {
"id": "thelatest",
"title": "The Latest",
"tagline": "Trusted local news in real time",
"info": "",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/05/The-Latest-2025-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Latest",
"officialWebsiteLink": "/thelatest",
"meta": {
"site": "news",
"source": "kqed",
"order": 6
},
"link": "/thelatest",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-latest-from-kqed/id1197721799",
"npr": "https://www.npr.org/podcasts/1257949365/the-latest-from-k-q-e-d",
"spotify": "https://open.spotify.com/show/5KIIXMgM9GTi5AepwOYvIZ?si=bd3053fec7244dba",
"rss": "https://feeds.megaphone.fm/KQINC9137121918"
}
},
"theleap": {
"id": "theleap",
"title": "The Leap",
"tagline": "What if you closed your eyes, and jumped?",
"info": "Stories about people making dramatic, risky changes, told by award-winning public radio reporter Judy Campbell.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Leap-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Leap",
"officialWebsiteLink": "/podcasts/theleap",
"meta": {
"site": "news",
"source": "kqed",
"order": 17
},
"link": "/podcasts/theleap",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-leap/id1046668171",
"npr": "https://www.npr.org/podcasts/447248267/the-leap",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-leap",
"spotify": "https://open.spotify.com/show/3sSlVHHzU0ytLwuGs1SD1U",
"rss": "https://ww2.kqed.org/news/programs/the-leap/feed/podcast"
}
},
"the-moth-radio-hour": {
"id": "the-moth-radio-hour",
"title": "The Moth Radio Hour",
"info": "Since its launch in 1997, The Moth has presented thousands of true stories, told live and without notes, to standing-room-only crowds worldwide. Moth storytellers stand alone, under a spotlight, with only a microphone and a roomful of strangers. The storyteller and the audience embark on a high-wire act of shared experience which is both terrifying and exhilarating. Since 2008, The Moth podcast has featured many of our favorite stories told live on Moth stages around the country. For information on all of our programs and live events, visit themoth.org.",
"airtime": "SAT 8pm-9pm and SUN 11am-12pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/theMoth.jpg",
"officialWebsiteLink": "https://themoth.org/",
"meta": {
"site": "arts",
"source": "prx"
},
"link": "/radio/program/the-moth-radio-hour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/the-moth-podcast/id275699983?mt=2",
"tuneIn": "https://tunein.com/radio/The-Moth-p273888/",
"rss": "http://feeds.themoth.org/themothpodcast"
}
},
"the-new-yorker-radio-hour": {
"id": "the-new-yorker-radio-hour",
"title": "The New Yorker Radio Hour",
"info": "The New Yorker Radio Hour is a weekly program presented by the magazine's editor, David Remnick, and produced by WNYC Studios and The New Yorker. Each episode features a diverse mix of interviews, profiles, storytelling, and an occasional burst of humor inspired by the magazine, and shaped by its writers, artists, and editors. This isn't a radio version of a magazine, but something all its own, reflecting the rich possibilities of audio storytelling and conversation. Theme music for the show was composed and performed by Merrill Garbus of tUnE-YArDs.",
"airtime": "SAT 10am-11am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-New-Yorker-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/tnyradiohour",
"meta": {
"site": "arts",
"source": "WNYC"
},
"link": "/radio/program/the-new-yorker-radio-hour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/id1050430296",
"tuneIn": "https://tunein.com/podcasts/WNYC-Podcasts/New-Yorker-Radio-Hour-p803804/",
"rss": "https://feeds.feedburner.com/newyorkerradiohour"
}
},
"the-sam-sanders-show": {
"id": "the-sam-sanders-show",
"title": "The Sam Sanders Show",
"info": "One of public radio's most dynamic voices, Sam Sanders helped launch The NPR Politics Podcast and hosted NPR's hit show It's Been A Minute. Now, the award-winning host returns with something brand new, The Sam Sanders Show. Every week, Sam Sanders and friends dig into the culture that shapes our lives: what's driving the biggest trends, how artists really think, and even the memes you can't stop scrolling past. Sam is beloved for his way of unpacking the world and bringing you up close to fresh currents and engaging conversations. The Sam Sanders Show is smart, funny and always a good time.",
"airtime": "FRI 12-1pm AND SAT 11am-12pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/11/The-Sam-Sanders-Show-Podcast-Tile-400x400-1.jpg",
"officialWebsiteLink": "https://www.kcrw.com/shows/the-sam-sanders-show/latest",
"meta": {
"site": "arts",
"source": "KCRW"
},
"link": "https://www.kcrw.com/shows/the-sam-sanders-show/latest",
"subscribe": {
"rss": "https://feed.cdnstream1.com/zjb/feed/download/ac/28/59/ac28594c-e1d0-4231-8728-61865cdc80e8.xml"
}
},
"the-splendid-table": {
"id": "the-splendid-table",
"title": "The Splendid Table",
"info": "\u003cem>The Splendid Table\u003c/em> hosts our nation's conversations about cooking, sustainability and food culture.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Splendid-Table-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.splendidtable.org/",
"airtime": "SUN 10-11 pm",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/the-splendid-table"
},
"this-american-life": {
"id": "this-american-life",
"title": "This American Life",
"info": "This American Life is a weekly public radio show, heard by 2.2 million people on more than 500 stations. Another 2.5 million people download the weekly podcast. It is hosted by Ira Glass, produced in collaboration with Chicago Public Media, delivered to stations by PRX The Public Radio Exchange, and has won all of the major broadcasting awards.",
"airtime": "SAT 12pm-1pm, 7pm-8pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/thisAmericanLife.png",
"officialWebsiteLink": "https://www.thisamericanlife.org/",
"meta": {
"site": "news",
"source": "wbez"
},
"link": "/radio/program/this-american-life",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=201671138&at=11l79Y&ct=nprdirectory",
"rss": "https://www.thisamericanlife.org/podcast/rss.xml"
}
},
"tinydeskradio": {
"id": "tinydeskradio",
"title": "Tiny Desk Radio",
"info": "We're bringing the best of Tiny Desk to the airwaves, only on public radio.",
"airtime": "SUN 8pm and SAT 9pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/04/300x300-For-Member-Station-Logo-Tiny-Desk-Radio-@2x.png",
"officialWebsiteLink": "https://www.npr.org/series/g-s1-52030/tiny-desk-radio",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/tinydeskradio",
"subscribe": {
"rss": "https://feeds.npr.org/g-s1-52030/rss.xml"
}
},
"wait-wait-dont-tell-me": {
"id": "wait-wait-dont-tell-me",
"title": "Wait Wait... Don't Tell Me!",
"info": "Peter Sagal and Bill Kurtis host the weekly NPR News quiz show alongside some of the best and brightest news and entertainment personalities.",
"airtime": "SUN 10am-11am, SAT 11am-12pm, SAT 6pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Wait-Wait-Podcast-Tile-300x300-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/wait-wait-dont-tell-me/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/wait-wait-dont-tell-me",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/Xogv",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=121493804&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Wait-Wait-Dont-Tell-Me-p46/",
"rss": "https://feeds.npr.org/344098539/podcast.xml"
}
},
"weekend-edition-saturday": {
"id": "weekend-edition-saturday",
"title": "Weekend Edition Saturday",
"info": "Weekend Edition Saturday wraps up the week's news and offers a mix of analysis and features on a wide range of topics, including arts, sports, entertainment, and human interest stories. The two-hour program is hosted by NPR's Peabody Award-winning Scott Simon.",
"airtime": "SAT 5am-10am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Weekend-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/weekend-edition-saturday/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/weekend-edition-saturday"
},
"weekend-edition-sunday": {
"id": "weekend-edition-sunday",
"title": "Weekend Edition Sunday",
"info": "Weekend Edition Sunday features interviews with newsmakers, artists, scientists, politicians, musicians, writers, theologians and historians. The program has covered news events from Nelson Mandela's 1990 release from a South African prison to the capture of Saddam Hussein.",
"airtime": "SUN 5am-10am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Weekend-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/weekend-edition-sunday/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/weekend-edition-sunday"
}
},
"racesReducer": {},
"racesGenElectionReducer": {},
"racesGenElection2026Reducer": {},
"racesGenElection2026PresidentialReducer": {},
"radioSchedulesReducer": {},
"listsReducer": {
"posts/futureofyou?category=kqed-news": {
"isFetching": false,
"latestQuery": {
"from": 444,
"size": 12
},
"vitalsOnly": false,
"totalRequested": 12,
"isLoading": false,
"isLoadingMore": true,
"total": {
"value": 479,
"relation": "eq"
},
"items": [
"futureofyou_104578",
"futureofyou_104100",
"futureofyou_103654",
"futureofyou_103581",
"futureofyou_100556",
"futureofyou_100995",
"futureofyou_100084",
"futureofyou_94815",
"futureofyou_94302",
"futureofyou_94836",
"futureofyou_93348",
"futureofyou_64080"
],
"complete": true
}
},
"recallGuideReducer": {
"intros": {},
"policy": {},
"candidates": {}
},
"savedArticleReducer": {
"articles": [],
"status": {}
},
"newslettersReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"newsletters": {},
"isSubscribing": false,
"isUnsubscribing": false,
"subscribedNewsletters": {}
},
"termsReducer": {
"about": {
"name": "About",
"type": "terms",
"id": "about",
"slug": "about",
"link": "/about",
"taxonomy": "site"
},
"arts": {
"name": "Arts & Culture",
"grouping": [
"arts",
"pop",
"trulyca"
],
"description": "KQED Arts provides daily in-depth coverage of the Bay Area's music, art, film, performing arts, literature and arts news, as well as cultural commentary and criticism.",
"type": "terms",
"id": "arts",
"slug": "arts",
"link": "/arts",
"taxonomy": "site"
},
"artschool": {
"name": "Art School",
"parent": "arts",
"type": "terms",
"id": "artschool",
"slug": "artschool",
"link": "/artschool",
"taxonomy": "site"
},
"bayareabites": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"parent": "food",
"type": "terms",
"id": "bayareabites",
"slug": "bayareabites",
"link": "/food",
"taxonomy": "site"
},
"bayareahiphop": {
"name": "Bay Area Hiphop",
"type": "terms",
"id": "bayareahiphop",
"slug": "bayareahiphop",
"link": "/bayareahiphop",
"taxonomy": "site"
},
"campaign21": {
"name": "Campaign 21",
"type": "terms",
"id": "campaign21",
"slug": "campaign21",
"link": "/campaign21",
"taxonomy": "site"
},
"careers": {
"name": "Careers",
"type": "terms",
"id": "careers",
"slug": "careers",
"link": "/careers",
"taxonomy": "site"
},
"checkplease": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"parent": "food",
"type": "terms",
"id": "checkplease",
"slug": "checkplease",
"link": "/food",
"taxonomy": "site"
},
"education": {
"name": "Education",
"grouping": [
"education"
],
"type": "terms",
"id": "education",
"slug": "education",
"link": "/education",
"taxonomy": "site"
},
"elections": {
"name": "Elections",
"type": "terms",
"id": "elections",
"slug": "elections",
"link": "/elections",
"taxonomy": "site"
},
"events": {
"name": "Events",
"type": "terms",
"id": "events",
"slug": "events",
"link": "/events",
"taxonomy": "site"
},
"event": {
"name": "Event",
"alias": "events",
"type": "terms",
"id": "event",
"slug": "event",
"link": "/event",
"taxonomy": "site"
},
"filmschoolshorts": {
"name": "Film School Shorts",
"type": "terms",
"id": "filmschoolshorts",
"slug": "filmschoolshorts",
"link": "/filmschoolshorts",
"taxonomy": "site"
},
"food": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"type": "terms",
"id": "food",
"slug": "food",
"link": "/food",
"taxonomy": "site"
},
"forum": {
"name": "Forum",
"relatedContentQuery": "posts/forum?",
"parent": "news",
"type": "terms",
"id": "forum",
"slug": "forum",
"link": "/forum",
"taxonomy": "site"
},
"futureofyou": {
"name": "Future of You",
"grouping": [
"science",
"futureofyou"
],
"parent": "science",
"type": "terms",
"id": "futureofyou",
"slug": "futureofyou",
"link": "/futureofyou",
"taxonomy": "site"
},
"jpepinheart": {
"name": "KQED food",
"relatedContentQuery": "posts/food,bayareabites,checkplease",
"parent": "food",
"type": "terms",
"id": "jpepinheart",
"slug": "jpepinheart",
"link": "/food",
"taxonomy": "site"
},
"liveblog": {
"name": "Live Blog",
"type": "terms",
"id": "liveblog",
"slug": "liveblog",
"link": "/liveblog",
"taxonomy": "site"
},
"livetv": {
"name": "Live TV",
"parent": "tv",
"type": "terms",
"id": "livetv",
"slug": "livetv",
"link": "/livetv",
"taxonomy": "site"
},
"lowdown": {
"name": "The Lowdown",
"relatedContentQuery": "posts/lowdown?",
"parent": "news",
"type": "terms",
"id": "lowdown",
"slug": "lowdown",
"link": "/lowdown",
"taxonomy": "site"
},
"mindshift": {
"name": "Mindshift",
"parent": "news",
"description": "MindShift explores the future of education by highlighting the innovative – and sometimes counterintuitive – ways educators and parents are helping all children succeed.",
"type": "terms",
"id": "mindshift",
"slug": "mindshift",
"link": "/mindshift",
"taxonomy": "site"
},
"news": {
"name": "News",
"grouping": [
"news",
"forum"
],
"type": "terms",
"id": "news",
"slug": "news",
"link": "/news",
"taxonomy": "site"
},
"newsletters": {
"name": "newsletters",
"type": "terms",
"id": "newsletters",
"slug": "newsletters",
"link": "/newsletters",
"taxonomy": "site"
},
"perspectives": {
"name": "Perspectives",
"parent": "radio",
"type": "terms",
"id": "perspectives",
"slug": "perspectives",
"link": "/perspectives",
"taxonomy": "site"
},
"podcasts": {
"name": "Podcasts",
"type": "terms",
"id": "podcasts",
"slug": "podcasts",
"link": "/podcasts",
"taxonomy": "site"
},
"pop": {
"name": "Pop",
"parent": "arts",
"type": "terms",
"id": "pop",
"slug": "pop",
"link": "/pop",
"taxonomy": "site"
},
"pressroom": {
"name": "Pressroom",
"type": "terms",
"id": "pressroom",
"slug": "pressroom",
"link": "/pressroom",
"taxonomy": "site"
},
"quest": {
"name": "Quest",
"parent": "science",
"type": "terms",
"id": "quest",
"slug": "quest",
"link": "/quest",
"taxonomy": "site"
},
"radio": {
"name": "Radio",
"grouping": [
"forum",
"perspectives"
],
"description": "Listen to KQED Public Radio – home of Forum and The California Report – on 88.5 FM in San Francisco, 89.3 FM in Sacramento, 88.3 FM in Santa Rosa and 88.1 FM in Martinez.",
"type": "terms",
"id": "radio",
"slug": "radio",
"link": "/radio",
"taxonomy": "site"
},
"root": {
"name": "KQED",
"image": "https://ww2.kqed.org/app/uploads/2020/02/KQED-OG-Image@1x.png",
"imageWidth": 1200,
"imageHeight": 630,
"headData": {
"title": "KQED | News, Radio, Podcasts, TV | Public Media for Northern California",
"description": "KQED provides public radio, television, and independent reporting on issues that matter to the Bay Area. We’re the NPR and PBS member station for Northern California."
},
"type": "terms",
"id": "root",
"slug": "root",
"link": "/root",
"taxonomy": "site"
},
"science": {
"name": "Science",
"grouping": [
"science",
"futureofyou"
],
"description": "KQED Science brings you award-winning science and environment coverage from the Bay Area and beyond.",
"type": "terms",
"id": "science",
"slug": "science",
"link": "/science",
"taxonomy": "site"
},
"stateofhealth": {
"name": "State of Health",
"parent": "science",
"type": "terms",
"id": "stateofhealth",
"slug": "stateofhealth",
"link": "/stateofhealth",
"taxonomy": "site"
},
"support": {
"name": "Support",
"type": "terms",
"id": "support",
"slug": "support",
"link": "/support",
"taxonomy": "site"
},
"thedolist": {
"name": "The Do List",
"parent": "arts",
"type": "terms",
"id": "thedolist",
"slug": "thedolist",
"link": "/thedolist",
"taxonomy": "site"
},
"trulyca": {
"name": "Truly CA",
"grouping": [
"arts",
"pop",
"trulyca"
],
"parent": "arts",
"type": "terms",
"id": "trulyca",
"slug": "trulyca",
"link": "/trulyca",
"taxonomy": "site"
},
"tv": {
"name": "TV",
"type": "terms",
"id": "tv",
"slug": "tv",
"link": "/tv",
"taxonomy": "site"
},
"voterguide": {
"name": "Voter Guide",
"parent": "elections",
"alias": "elections",
"type": "terms",
"id": "voterguide",
"slug": "voterguide",
"link": "/voterguide",
"taxonomy": "site"
},
"guiaelectoral": {
"name": "Guia Electoral",
"parent": "elections",
"alias": "elections",
"type": "terms",
"id": "guiaelectoral",
"slug": "guiaelectoral",
"link": "/guiaelectoral",
"taxonomy": "site"
},
"futureofyou_category_kqed-news": {
"isLoading": true
},
"futureofyou_73": {
"type": "terms",
"id": "futureofyou_73",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "73",
"found": true
},
"relationships": {},
"featImg": null,
"name": "KQED News",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "KQED News Archives | KQED Arts",
"ogDescription": null
},
"ttid": 73,
"slug": "kqed-news",
"isLoading": false,
"link": "/futureofyou/category/kqed-news"
},
"source_futureofyou_94302": {
"type": "terms",
"id": "source_futureofyou_94302",
"meta": {
"override": true
},
"name": "Big Ideas",
"isLoading": false
},
"source_futureofyou_94836": {
"type": "terms",
"id": "source_futureofyou_94836",
"meta": {
"override": true
},
"name": "Mobile Health & Wearables",
"isLoading": false
},
"futureofyou_54": {
"type": "terms",
"id": "futureofyou_54",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "54",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Future of You",
"description": null,
"taxonomy": "program",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Future of You Archives | KQED Arts",
"ogDescription": null
},
"ttid": 54,
"slug": "future-of-you",
"isLoading": false,
"link": "/futureofyou/program/future-of-you"
},
"futureofyou_452": {
"type": "terms",
"id": "futureofyou_452",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "452",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Health Policy",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Health Policy Archives | KQED Arts",
"ogDescription": null
},
"ttid": 452,
"slug": "health-policy",
"isLoading": false,
"link": "/futureofyou/category/health-policy"
},
"futureofyou_1": {
"type": "terms",
"id": "futureofyou_1",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "1",
"found": true
},
"relationships": {},
"featImg": null,
"name": "KQED Future Of You",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "KQED Future Of You Archives | KQED Arts",
"ogDescription": null
},
"ttid": 1,
"slug": "future-of-you",
"isLoading": false,
"link": "/futureofyou/category/future-of-you"
},
"futureofyou_80": {
"type": "terms",
"id": "futureofyou_80",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "80",
"found": true
},
"relationships": {},
"featImg": null,
"name": "kqedscience",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "kqedscience Archives | KQED Arts",
"ogDescription": null
},
"ttid": 80,
"slug": "kqedscience",
"isLoading": false,
"link": "/futureofyou/tag/kqedscience"
},
"futureofyou_617": {
"type": "terms",
"id": "futureofyou_617",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "617",
"found": true
},
"relationships": {},
"featImg": null,
"name": "theranos",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "theranos Archives | KQED Arts",
"ogDescription": null
},
"ttid": 617,
"slug": "theranos",
"isLoading": false,
"link": "/futureofyou/tag/theranos"
},
"futureofyou_245": {
"type": "terms",
"id": "futureofyou_245",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "245",
"found": true
},
"relationships": {},
"featImg": null,
"name": "walgreens",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "walgreens Archives | KQED Arts",
"ogDescription": null
},
"ttid": 245,
"slug": "walgreens",
"isLoading": false,
"link": "/futureofyou/tag/walgreens"
},
"futureofyou_729": {
"type": "terms",
"id": "futureofyou_729",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "729",
"found": true
},
"relationships": {},
"featImg": null,
"name": "sweat",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "sweat Archives | KQED Arts",
"ogDescription": null
},
"ttid": 729,
"slug": "sweat",
"isLoading": false,
"link": "/futureofyou/tag/sweat"
},
"futureofyou_53": {
"type": "terms",
"id": "futureofyou_53",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "53",
"found": true
},
"relationships": {},
"featImg": null,
"name": "wearable devices",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "wearable devices Archives | KQED Arts",
"ogDescription": null
},
"ttid": 53,
"slug": "wearable-devices",
"isLoading": false,
"link": "/futureofyou/tag/wearable-devices"
},
"futureofyou_508": {
"type": "terms",
"id": "futureofyou_508",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "508",
"found": true
},
"relationships": {},
"featImg": null,
"name": "cyber security",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "cyber security Archives | KQED Arts",
"ogDescription": null
},
"ttid": 508,
"slug": "cyber-security",
"isLoading": false,
"link": "/futureofyou/tag/cyber-security"
},
"futureofyou_38": {
"type": "terms",
"id": "futureofyou_38",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "38",
"found": true
},
"relationships": {},
"featImg": null,
"name": "FDA",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "FDA Archives | KQED Arts",
"ogDescription": null
},
"ttid": 38,
"slug": "fda",
"isLoading": false,
"link": "/futureofyou/tag/fda"
},
"futureofyou_509": {
"type": "terms",
"id": "futureofyou_509",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "509",
"found": true
},
"relationships": {},
"featImg": null,
"name": "hacking",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "hacking Archives | KQED Arts",
"ogDescription": null
},
"ttid": 509,
"slug": "hacking",
"isLoading": false,
"link": "/futureofyou/tag/hacking"
},
"futureofyou_510": {
"type": "terms",
"id": "futureofyou_510",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "510",
"found": true
},
"relationships": {},
"featImg": null,
"name": "medical devices",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "medical devices Archives | KQED Arts",
"ogDescription": null
},
"ttid": 510,
"slug": "medical-devices",
"isLoading": false,
"link": "/futureofyou/tag/medical-devices"
},
"futureofyou_692": {
"type": "terms",
"id": "futureofyou_692",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "692",
"found": true
},
"relationships": {},
"featImg": null,
"name": "brain-training",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "brain-training Archives | KQED Arts",
"ogDescription": null
},
"ttid": 692,
"slug": "brain-training",
"isLoading": false,
"link": "/futureofyou/tag/brain-training"
},
"futureofyou_596": {
"type": "terms",
"id": "futureofyou_596",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "596",
"found": true
},
"relationships": {},
"featImg": null,
"name": "FTC",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "FTC Archives | KQED Arts",
"ogDescription": null
},
"ttid": 596,
"slug": "ftc",
"isLoading": false,
"link": "/futureofyou/tag/ftc"
},
"futureofyou_691": {
"type": "terms",
"id": "futureofyou_691",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "691",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Lumosity",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Lumosity Archives | KQED Arts",
"ogDescription": null
},
"ttid": 691,
"slug": "lumosity",
"isLoading": false,
"link": "/futureofyou/tag/lumosity"
},
"futureofyou_720": {
"type": "terms",
"id": "futureofyou_720",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "720",
"found": true
},
"relationships": {},
"featImg": null,
"name": "neuroplasticity",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "neuroplasticity Archives | KQED Arts",
"ogDescription": null
},
"ttid": 720,
"slug": "neuroplasticity",
"isLoading": false,
"link": "/futureofyou/tag/neuroplasticity"
},
"futureofyou_721": {
"type": "terms",
"id": "futureofyou_721",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "721",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Steve Berkowitz",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Steve Berkowitz Archives | KQED Arts",
"ogDescription": null
},
"ttid": 721,
"slug": "steve-berkowitz",
"isLoading": false,
"link": "/futureofyou/tag/steve-berkowitz"
},
"futureofyou_713": {
"type": "terms",
"id": "futureofyou_713",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "713",
"found": true
},
"relationships": {},
"featImg": null,
"name": "cancer moonshot",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "cancer moonshot Archives | KQED Arts",
"ogDescription": null
},
"ttid": 713,
"slug": "cancer-moonshot",
"isLoading": false,
"link": "/futureofyou/tag/cancer-moonshot"
},
"futureofyou_716": {
"type": "terms",
"id": "futureofyou_716",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "716",
"found": true
},
"relationships": {},
"featImg": null,
"name": "criticism",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "criticism Archives | KQED Arts",
"ogDescription": null
},
"ttid": 716,
"slug": "criticism",
"isLoading": false,
"link": "/futureofyou/tag/criticism"
},
"futureofyou_693": {
"type": "terms",
"id": "futureofyou_693",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "693",
"found": true
},
"relationships": {},
"featImg": null,
"name": "false advertising",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "false advertising Archives | KQED Arts",
"ogDescription": null
},
"ttid": 693,
"slug": "false-advertising",
"isLoading": false,
"link": "/futureofyou/tag/false-advertising"
},
"futureofyou_647": {
"type": "terms",
"id": "futureofyou_647",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "647",
"found": true
},
"relationships": {},
"featImg": null,
"name": "biotechnology",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "biotechnology Archives | KQED Arts",
"ogDescription": null
},
"ttid": 647,
"slug": "biotechnology",
"isLoading": false,
"link": "/futureofyou/tag/biotechnology"
},
"futureofyou_94": {
"type": "terms",
"id": "futureofyou_94",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "94",
"found": true
},
"relationships": {},
"featImg": null,
"name": "CRISPR",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "CRISPR Archives | KQED Arts",
"ogDescription": null
},
"ttid": 94,
"slug": "crispr",
"isLoading": false,
"link": "/futureofyou/tag/crispr"
},
"futureofyou_709": {
"type": "terms",
"id": "futureofyou_709",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "709",
"found": true
},
"relationships": {},
"featImg": null,
"name": "patent",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "patent Archives | KQED Arts",
"ogDescription": null
},
"ttid": 709,
"slug": "patent",
"isLoading": false,
"link": "/futureofyou/tag/patent"
},
"futureofyou_702": {
"type": "terms",
"id": "futureofyou_702",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "702",
"found": true
},
"relationships": {},
"featImg": null,
"name": "USPTO",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "USPTO Archives | KQED Arts",
"ogDescription": null
},
"ttid": 702,
"slug": "uspto",
"isLoading": false,
"link": "/futureofyou/tag/uspto"
},
"futureofyou_49": {
"type": "terms",
"id": "futureofyou_49",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "49",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Fitbit",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Fitbit Archives | KQED Arts",
"ogDescription": null
},
"ttid": 49,
"slug": "fitbit",
"isLoading": false,
"link": "/futureofyou/tag/fitbit"
},
"futureofyou_650": {
"type": "terms",
"id": "futureofyou_650",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "650",
"found": true
},
"relationships": {},
"featImg": null,
"name": "AIDS",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "AIDS Archives | KQED Arts",
"ogDescription": null
},
"ttid": 650,
"slug": "aids",
"isLoading": false,
"link": "/futureofyou/tag/aids"
},
"futureofyou_669": {
"type": "terms",
"id": "futureofyou_669",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "669",
"found": true
},
"relationships": {},
"featImg": null,
"name": "cure",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "cure Archives | KQED Arts",
"ogDescription": null
},
"ttid": 669,
"slug": "cure",
"isLoading": false,
"link": "/futureofyou/tag/cure"
},
"futureofyou_113": {
"type": "terms",
"id": "futureofyou_113",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "113",
"found": true
},
"relationships": {},
"featImg": null,
"name": "ucsf",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "ucsf Archives | KQED Arts",
"ogDescription": null
},
"ttid": 113,
"slug": "ucsf",
"isLoading": false,
"link": "/futureofyou/tag/ucsf"
}
},
"userPermissionsReducer": {
"wpLoggedIn": false
},
"eventsReducer": {},
"fssReducer": {},
"tvDailyScheduleReducer": {},
"tvWeeklyScheduleReducer": {},
"tvPrimetimeScheduleReducer": {},
"tvMonthlyScheduleReducer": {},
"userAccountReducer": {
"user": {
"email": null,
"emailStatus": "EMAIL_UNVALIDATED",
"loggedStatus": "LOGGED_OUT",
"loggingChecked": false,
"articles": [],
"firstName": null,
"lastName": null,
"phoneNumber": null,
"fetchingMembership": false,
"membershipError": false,
"memberships": [
{
"id": null,
"startDate": null,
"firstName": null,
"lastName": null,
"familyNumber": null,
"memberNumber": null,
"memberSince": null,
"expirationDate": null,
"pfsEligible": false,
"isSustaining": false,
"membershipLevel": "Prospect",
"membershipStatus": "Non Member",
"lastGiftDate": null,
"renewalDate": null,
"lastDonationAmount": null
}
]
},
"authModal": {
"isOpen": false,
"view": "LANDING_VIEW"
},
"error": null
},
"youthMediaReducer": {},
"checkPleaseReducer": {
"filterData": {
"region": {
"key": "Restaurant Region",
"filters": [
"Any Region"
]
},
"cuisine": {
"key": "Restaurant Cuisine",
"filters": [
"Any Cuisine"
]
}
},
"restaurantDataById": {},
"restaurantIdsSorted": [],
"error": null
},
"userAgentReducer": {
"userAgent": "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)",
"isBot": true
},
"requestOutcomesReducer": {
"notFound": []
},
"navPromosReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": true,
"promos": {
"news": {
"name": "2026 Voter Guide",
"link": "/voterguide",
"imageURL": "https://cdn.kqed.org/wp-content/uploads/2026/10/Nav-News-Nov2026ElectionCoverage@2x-7bd4aad4.png",
"description": "Get informed in minutes with our Voter Guide for California’s November 3 election."
},
"podcasts-radio": {},
"video-tv": {},
"events": {},
"support": {}
}
}
}